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Abstract
The symptoms of multiple sclerosis (MS), an immune-mediated, degenerative disease 
of the central nervous system (CNS), are thought to be due to demyelination and axonal 
damage leading to impairment of neurotransmission. In a mouse model of MS, chronic 
relapsing experimental allergic encephalomyelitis (CREAE), cannabinoid compounds 
have been shown to protect axons and improve disease severity. In this study, CREAE 
and rotation-mediated CNS aggregate cell cultures were used to examine the role of 
cannabinoid receptor 1 (CBjR) in endocannabinoid-mediated modulation of 
demyelination and neurodegeneration.
The aggregate cell culture system was developed and characterised in mouse to 
exploit CBiR knockout (CBiR-KO) animals. CREAE was induced in CBiR-KO mice 
and wildtype counterparts, and CNS aggregate cell cultures derived from the same 
mouse strains were demyelinated with interferon gamma. CREAE animals were 
assessed for functional deficit by clinical scoring and in an open field activity chamber. 
CREAE spinal cords and aggregate samples were assessed for myelin content and 
axonal damage by measurement of myelin basic protein and neurofilament. Axonal 
vulnerability was assessed using a monoclonal antibody (SMI-32) against a 
dephosphoiylated neurofilament epitope and caspase 3 expression and activation were 
measured to gauge cell death.
Neurofilament loss following demyelination was increased in CBjR-KO animals 
and cultures when compared with wildtypes while myelin levels did not differ between 
the two strains. This indicates that the presence of CBjR may be partially responsible 
for restricting damage to axons in inflammation, but has a less marked effect on 
myelination or remyelination. Neurofilament loss correlated with functional deficit,
suggesting that axonal or neuronal loss was responsible for neurodegeneration in 
CREAE. SMI-32 immunoreactivity was also increased, indicating axonal vulnerability 
or damage through alteration of neurofilament phosphorylation state. Increased 
activation of caspase 3 in knockout animals and cultures was evident, but not 
accompanied by increased procaspase 3 expression, signifying higher caspase activation 
rates. Caspases may therefore be involved in the death of neurons or axonal compromise 
in these two models.
Manipulation of the cannabinoid pathway by exogenous agonist-mediated CBiR 
activation or indirect upregulation of endogenous ligands could slow disease 
progression in demyelinating diseases such as multiple sclerosis, indicating a potential 
therapeutic benefit.
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1. Introduction
1.1. The Cellular Pathology of Multiple Sclerosis
Multiple sclerosis (MS) is a relapsing and often progressive neurodegenerative 
disorder predominantly affecting young adults, with an immune-mediated aetiology but 
potentially incorporating viral, bacterial and/or genetic triggers. With a prevalence of 
around 1 in 800 in the United Kingdom, the disease renders about 89% of patients 
unable to walk without assistance 25 years after onset. Two main forms of MS exist. 
60% of MS patients are diagnosed with relapsing remitting MS (RR-MS), with 
predominance in females of 2:1. This subtype is characterised by symptoms which 
develop over a period of several days, stabilise, and then typically improve over a 
period of a few weeks or months; the disease may progress in-between relapses, and 
eventually reach a stage of continuing decline without remission, termed secondary 
progressive MS. About 20% of people exhibit benign MS where following initial 
presentation, there is relatively little clinical disease activity. In contrast, the remaining 
20% of MS patients have a form known as primary progressive MS (PP-MS), 
characterised by a gradually progressive clinical course from diagnosis, and has a 
similar incidence in men and women as RR-MS (Bashir & Whitaker, 1999). 
Demyelinated areas in the central nervous system (CNS) termed lesions cause MS- 
associated deficit, with the symptoms and nature of deficit depending on lesion location 
in the CNS. The disease is diagnosed with the aid of magnetic resonance imaging (MRI) 
to identify and quantify lesions (Figure 1-1), a key feature of which being the 
demonstration of disseminated lesion development in space and time, cerebrospinal 
fluid (CSF) analysis to identify intrathecal immunoglobulin (Ig)-G production (termed 
oligoclonal banding -  Figure 1-2), as well as by clinical motor tests.
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Figure 1-1: Lesions in the brain in multiple sclerosis, a s  
visualised by m agnetic resonance imaging, ap p ear a s  light 
a re a s  on a darker background. Location of a  lesion in a brain 
structure d ictates w hether it is a “silent” lesion, or if it will 
elicit clinical sym ptom s. For instance, a lesion in the motor 
cortex can cau se  trem or or loss of m ovem ent function.
From: Multiple Sclerosis (Edited by Paty D.W., E bers G.C.; 
1997; Philidelphia, Pa. F.A. Davis)
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normal abnormal
Oligoclonal t  Oligoclonal
Bands < WKKm Bands
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CSF Plasma CSF Plasma
Figure 1-2: Oligoclonal bands p resen t in the cerebro-spinal fluid are 
a  diagnostic feature of multiple sclerosis. The p resen ce  of 
immunoglobulins usually only p resen t in the blood indicates a 
breach of the blood-brain barrier. The figure show s banding 
produced on a W estern blot gel stained with C om assie blue to 
visualise protein. Banding indicating blood-brain barrier breach 
occurs at the lower end of the gel. From: Multiple Sclerosis (Edited 
by Paty D.W., Ebers G.C.; 1997; Philidelphia, Pa. F.A. Davis)
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1.1.1. Invasion of the CNS in MS
A key early event in multiple sclerosis is the invasion of the CNS by activated 
leucocytes, T-cells and macrophages (Figure 1-3). This occurs in a multi-stage process. 
Firstly, the invading cell tethers to the vessel endothelium via selectin molecules. 
Facilitated by a reduction in blood flow via cytokine-mediated vasoconstriction, this 
slows down the cell in the bloodstream and causes it to roll along the endothelial cell 
wall. In the second stage, termed triggering, cytokines produced by the invading cell 
cause integrins and other strong adhesion molecules to be upregulated or activated on 
the epithelium and invading cell surface. Strong adhesion then occurs, accompanied by 
a flattening of the cell. Finally the cell is able to diapese probably directly through the 
endothelial cell wall, stimulated by chemotactic cytokines (Brown, 2001; Gran & 
Rostami, 2001; Greenwood et a l, 2003).
1.1.2. Pathophysiology of the MS lesion
It had generally been accepted that similar pathophysiological mechanisms lead 
to the symptoms of all types of MS. However, recent studies have demonstrated a 
degree of heterogeneity in pathological processes, with different processes bringing 
about similar symptoms. Such a divergence of distinct mechanism patterns may split 
patients into distinct subgroups based on the dominant subtype present in lesions in an 
individual (Lucchinetti et a l , 1996). In spite of this, there remains a large degree of 
similarity between pathological processes in MS patients.
Dual inflammatory responses are observed in the CNS. Innate immunity acting
through active microglia produces a focal and limited response to, for instance, an
invasive body; the adaptive immune response produces antigen-specific T-lymphocytes
to a more global and temporally extended attack (Lucchinetti et al., 2001). The most
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potent immunogens for the latter are present in myelin, with an autoimmune response 
consisting of recruited T- and B-cells priming resident and infiltrating macrophages to 
degrade myelin and secrete a range of damaging factors (Figure 1-4) (Gay & Esiri, 
1991; Van Noort & Amor, 1998; Wekerle,1997).
Inflammation of this type occurs in MS in focal demyelinating lesions or 
plaques, characterised as active (or inactive) by the presence (or absence) of 
autoimmune attack, macrophages containing myelin fragments and by activation 
markers. Perivascular cuffs formed at sites of invasion contain macrophages, 
lymphocytes, B cells and plasma cells; only macrophages and lymphocytes progress 
further into the parenchyma. The majority of the lymphocytes are T-cells, with both 
CD4+ (helper) and CD8+ (cytotoxic) cells being involved. The CD4+ cells are often 
further subdivided into proinflammatoiy (Thl) and anti-inflammatoiy (Th2); the 
proportions and activity of these cells may control overall lesion activity, although the 
distinction of activities is less clear cut in humans compared to their rodent counterparts 
(Markovic-Plese & McFarland, 2001).
The central pathophysiological event in MS is axonal conduction block, which 
worsens with disease course becoming irreversible. Axonal loss in the brain and spinal 
cord correlates with inflammation and demyelination (Trapp et a l , 1998). The potential 
mechanisms for this are numerous, and include cell-mediated cytotoxicity, damage via 
secreted effector molecules including tumour necrosis factor alpha (TNF-a), matrix 
metalloproteinases and reactive oxygen species, auto-antibodies and damage via 
glutamate release from microglia and activated leucocytes. Oligodendrocytes are highly 
sensitive to glutamate toxicity, with elevated glutamate levels in the CSF correlating 
with disease severity (Wemer et a l , 2001). A role for nitric oxide (NO) has been
21
° selectin 
o integrin
Perivascular
Cuffv receptor
Invading
monocyte
Figure 1-3: A model of invasion of the CNS by lymphocytes in inflammatory d isease
1 - Tethering/Rolling: Selectins slow down the lymphocyte in the blood flow.
2 - Activation: Endothelium chem okines activate the lymphocyte to re lease  pro- 
inflammatory cytokines and express integrins.
3 - Strong adhesion: Integrins adhere  to the endothelium; the lymphocytes flatten.
4 - Transmigration: Aided by p ro teases and directed by chem okines, the lymphocyte 
forces through the endothelial cell wall.
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Figure 1-4: Autoimmune Attack in Multiple Sclerosis
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proposed (Smith et a l, 2001), where sustained impulses in conducting axons produce 
intermittent conduction failure in MS patients. Increased NO at the site of inflammation 
may cause permanent deficit in conduction. Tissue plasminogen activator in excitotoxic 
lesions can damage neurons through disruption of axon-laminin interactions (Gveric et 
a l, 2001).
Whether the product or cause of axonal damage, the destruction of the myelin 
sheath is a hallmark of pathology in MS. Pro-enzymes in serum and plasma can, once 
activated, cause myelin sheath disruption even in the presence of serum/plasma 
proteinase inhibitors (Pescovitz et al., 1978). Lysis may occur through the formation of 
membrane attack complexes or by complement receptor-mediated opsonic phagocytosis 
(Silverman et al., 1984), and myelin can be phagocytosed by macrophages and 
polymorphonuclear leucocytes. Astrocytes have also been implicated through the 
presence of ingested myelin in chronic demyelinated MS plaques. Activated microglia 
and macrophages in the presence of an antibody can effect myelin uptake via receptor- 
mediated mechanisms in vitro (Prineas,1985), and T-cells can, via production of TNF-a 
and -p, be effective cytotoxic mediators . Finally the concept of “frustrated” 
phagocytosis may induce demyelination, where macrophages or microglia are unable to 
internalise myelin membrane, leading to discharge of lysosomal enzymes (Young & 
Zygas, 1987).
1.2. Experimental Allergic Encephalomyelitis: An in vivo model o f MS
Experimental allergic encephalomyelitis (EAE) is a demyelinating disease of the
CNS inducible in a number of inbred animal strains. It can take an acute or chronic,
potentially relapsing disease course, with inflammatory and sometimes demyelinating
lesions. The disease can be triggered following sensitisation with white matter or
24
purified myelin proteins such as myelin basic protein (MBP) or myelin oligodendrocyte 
glycoprotein (MOG) (Martin & McFarland,1997). This T-cell mediated autoimmune 
disease is used as a model of MS. It is worth noting that susceptibility to EAE varies 
greatly from strain to strain (Levine & Sowinski, 1973) and is reflective of the 
contribution of polymorphic genetic components. For example, ABH mice described 
below are highly susceptible to the disease, whereas the closely related ABL strain is 
not (Baker et a l , 1990).
EAE can be induced using a variety of sensitising antigens (Amor et a l , 1993; 
Amor et a l , 1994; Amor et a l , 1996; Morris-Downes et a l , 2002), but chronic 
relapsing EAE (CREAE) in the ABH mouse strain is most reproducibly induced by 
injecting the animal sub-cutaneously with syngeneic spinal cord homogenate in 
complete Freund’s adjuvant. The disease course is scored on a clinical scale of 1-5 
(Figure 2-3). Following significant weight loss, the acute attack that occurs around day 
15-17 is evident by the development of hind limb paralysis. This usually remits within
3-6 days, and is associated with weight gain. After a period of remission, a series of 
relapses occur, developing at around day 35-40 and at 2-3 week intervals thereafter. 
Each relapse is associated with a loss of weight and an increase in clinical score of at 
least 1 grade, but usually increasing to grade 4 -  complete hind limb paralysis. 
Increased residual clinical scores are evident during remission, and these accrue over a 
series of relapses, indicating a level of cumulative and permanent CNS damage (Baker 
et a l , 1990; Baker et a l 2000).
Injection of spinal cord and adjuvant acts as a trigger to set the stage for EAE 
development. Autoreactive T-cells, a normal and constant part of the mature T-cell 
repertoire, are then activated by the injected myelin antigen. These cells differentiate
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into primed T cells and circulate through tissues. This is facilitated by cell adhesion 
molecules on both T-cells (CD 11a and CD49d) and cerebrovascular endothelial cells 
(CD54 and CD 105) which are upregulated during CNS inflammation (Kalman et a l , 
1995; Lee & Benveniste, 1999). Activated T-cells are then able to migrate through the 
blood brain barrier (BBB) and also into the CNS parenchyma, where they activate 
resident perivascular and paranchymal and glial cells and attract further influx of 
monocytes and other T-cells via chemoattractant chemokines and cytokines (Leonard et 
a l , 1995; Ruddle etal., 1990).
1.2.1. Cellular infiltrates in EAE
Depending on the model, the spinal cord is a pathological focus for CNS cellular 
infiltrates, with lesions in the brain often being confined to the cerebellum (Baker et a l , 
1990). Infiltrate density is comparable during acute and relapse phases of the disease, 
and is mainly of a similar composition, with the exception of a more prevalent acute 
phase polymorphonuclear cell population (Allen et a l , 1993). Perivascular cuffs 
containing 30-50% T-lymphocytes, mostly CD4+, were observed, with further 
paranchymal infiltration of macrophages also occurring. There is extensive 
immunoglobulin deposition in the CNS lesions of relapsing animals, with lower 
paranchymal levels. In remission, the degree of infiltration falls with very few CD4+ T 
cells and active macrophages observed (Baker et al> 1990).
1.2.2. Neuronal damage in EAE
Axonal damage, neuronal death and demyelination in EAE and MS are likely to
occur through a number of routes. Again, the direct toxic effects of TNF-a and -p and
oxidative stress from T-cells and microglia which are likely to be responsible for
demyelination, as mentioned previously, are in direct proximity to the axon and may
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cause damage. Secondly, it has been found that sodium channel blockers such as 
phenytoin can protect neurons in culture (Lo et al., 2002). During EAE, mitochondrial 
function is impaired, reducing sodium/potassium adenosine triphosphatase (Na+/K+- 
ATPase) activity and causing axonal depolarisation (Sathomsumetee et a l, 2000). Also, 
loss of myelin reduced trophic support available to the axon (Bjartmar & Trapp, 2003). 
It is hypothesised that the resulting sodium ion (Na*) influx causes a reverse in the 
function of the sodium/calcium ion (Na+/Ca2+) exchange pump, leading to an increase in 
intracellular calcium levels (Carafoli, 1988). This may cause the activation of calcium- 
dependent proteolytic enzymes, such as calpain, and proteolysis of neurofilaments and 
other neuronal cytoskeletal components. Similarly, activation of calmodulin would 
cause upregulation of protein phosphatase 2B, dephosphoiylating and destabilising 
neurofilaments (Groth et al., 2003). Increased calcium at the presynaptic membrane 
would trigger excess neurotransmitter release, and excitotoxic effects on the post- 
synaptic cell. High levels of intracellular calcium can also trigger apoptosis via release 
of mitochondrial cytochrome c (Mattson, 2003). Nitric oxide, another potential agent of 
damage, has been found to act as a modulatory factor in the induction of the immune 
response. As such, different pathological environments induce NO to fulfil opposing 
roles as a degenerative or protective molecule (Willenborg et al., 1999). Contributing to 
degeneration, NO can be directly cytotoxic, or can act via peroxynitrite free-radical 
formation, causing oxidative damage to the BBB, myelin and axons (Hooper et al., 
2000). Nitric oxide also increases levels of intracellular cyclic guanidine 
monophosphate, activating T-cells and macrophages, leading to increased 
proinflammatory cytokine-induced toxicity, as well as the direct damage caused by 
these cell types (Sherman et al., 1992). In contradiction, it has been shown that NO
produced by NO synthase 2 (NOS-2 or iNOS), the inducible form of the enzyme, can 
inhibit T-cell proliferation, leukocyte adhesion/migration and down-regulate major 
histocompatibility complex (MHC) class II expression on macrophages, thereby 
inhibiting antigen presentation (Kahl et a l , 2003; Singh et a l , 2000). Owing to its small 
size, NO also has access to intramolecular sites, allowing diverse effects on key 
mechanistic molecules of the immune response, including ion channels, tyrosine kinase, 
phosphatases and transcription factors (Singh et a l , 2000). This presents a dichotomous 
role for NO-mediated protection in early disease and for later NO-mediated pathology.
1.2.3. Apoptosis in EAE
Most of the pathways described above will have an apoptotic final outcome. 
Oxidative stress combined with high intracellular Ca2+ concentrations leads to 
cytochrome c release from mitochondria, which is a vital part of the apoptosome, the 
caspase-9 based macromolecule responsible for a high degree of apoptotic end-point 
activity. Similarly, deoxyribonucleic acid (DNA) damage caused by free radicals or 
Ca -activated enzyme pathways leads to cytochrome c release via p53 upregulation. 
Loss of trophic support from damaged surrounding cells causes deregulation of cell- 
cycle signals and activation of the CD95 death receptor by TNF-a both leading directly 
to triggering of the caspase activation cascade, and ultimately to apoptosis (described in 
section 1.5.7) (Lossi & Merighi, 2003).
1.3. Rotation-mediated aggregate cell culture: An in vitro model of
demyelinative disease
Aggregation of dissociated embryonic cells was first performed in the late 1960s
by Moscana (Moscona,1965). Since that time, the system has been exploited
extensively for a wide variety of applications. Honegger and associates took up the
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system in the mid 1970s as a developmental model of myelination and remyelination 
(Honegger & Richelson, 1976).
1.3.1. Developmental characteristics
Methodology for the use of rat tissue involves mechanical dissociation of the rat 
telencephalon by sieving, and incubation at an optimal density under constant rotation. 
The cells in suspension spontaneously form 3-dimensional aggregated structures under 
constant rotation (Honegger & Richelson, 1976). Following a short period of time in 
vitro, differentiated neurons, astrocytes and oligodendrocytes are observed, arranged 
into a specific and highly reproducible structure (Trapp et al., 1979). In the rat, cells 
from foetal and early neonatal tissue yield viable aggregates. Developmental patterns of 
enzymatic activity varied with the age of starting tissue, with relatively undeveloped 
tissue yielding the highest levels of neuron specific enzymes (Honegger & Richelson, 
1976). Mitosis occurs, as confirmed by bromodeoxyuridine (BrdU) incorporation, and 
aggregates can be maintained for up to 48 days in culture (Copelman et al., 2000). 
Morphologically, synaptic contacts and myelinated axons appear with further 
maturation, but, while experimentally acceptable, myelin levels are lower than in 
organotypic cultures or in vivo (Trapp et a l , 1979). Synthesis, storage and release of 
neurotransmitters were confirmed by radiolabelling studies, indicating that the synapses 
present are electrically active (Honegger & Richelson, 1979).
1.3.2. Remyelination in the aggregate cell culture system
The CNS aggregate culture model has been extensively characterised for myelin
synthesis. It was found that commitment of myelination in vitro occurred after the same
period required in vivo, and was temporally coupled with the expression of 2’-3’-cyclic
nucleotide phosphohydrolase and cerebroside sulphotransferase, two myelin-specific
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enzymes (Sheppard et al., 1978). Furthermore, isoforms of MBP are differentially 
expressed in development, with exon 2-containing isoforms being expressed early on, 
and possibly playing a role in the onset of myelination (Kruger et al., 1999).
Further to the studies of myelination, the aggregate cell culture system has been 
used to study remyelination after a demyelinative insult in vitro. Myelinated axonal 
processes can be found in the intermediate shell of the aggregate (Trapp et a l, 1979). 
They are therefore accessible to exogenous factors added to the medium. Honegger et 
al. (1989) used the MOG-specific antibody 8-18-C5 to effectively demyelinate 
aggregate cultures (Honegger et al., 1989). Since then, other anti-MOG antibodies have 
shown a similar effect, along with the cytokines EFN-yand TNF-a, and IL-1 (3 (Loughlin 
et al., 1997). One line of study using this system has been to investigate the roles of 
macrophages in demyelination and remyelination (Copelman et a l, 2000; Copelman et 
a l, 2001; Loughlin et a l, 1997). The culture system is used to model a simplified 
demyelinating MS lesion, where it is thought that macrophages can have damaging or 
repairing effects dependent on the immediate microenvironment (Diemel et al., 1998). 
Supplementation of demyelinated cultures with peritoneal macrophages severely 
curtails their ability to remyelinate, while addition to an undamaged environment 
promotes myelinogenesis (Diemel et al. 2003). Another study investigated the role of 
macrophages in response to oxidative stress, where oxidative insult induced using 
menadione was significantly higher in macrophage-supplemented cultures (Bartnik et 
al, 2000).
1.3.3. Benefits of the aggregate system
The ability to add endogenous factors or other cell types (e.g. macrophages) to 
culture flasks and compare them with identical cultures from the same source is a major
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benefit of this system. A reproducible culture population can be seeded and treated in a 
highly flexible manner. The ability to maintain a relatively large volume of tissue in 
vitro for long periods of time allows temporal studies to be undertaken, sampling one 
culture flask at successive time points. The production of CNS specific structures and 
pharmacological systems by the aggregates makes possible the accurate assessment of a 
substance prior to whole animal studies, presenting a more humane method of animal 
testing. Finally, the aggregate culture allows development of cells in a three- 
dimensional context, more closely mimicking brain development than monolayer 
cultures.
1.4. Myelination and oligodendrocyte development
1.4.1. Myelination of the axon
With a few exceptions, myelination occurs only in vertebrates and can therefore be 
considered necessary for the evolution of higher nervous function. The process of 
myelination occurs in a highly reproducible manner, caudo-rostrally in the brain, and 
rostro-caudally in the spinal cord. Myelination in the mouse starts at around birth, and is 
complete by around 20 days postnatally in the spinal cord and 60 days postnatally in the 
brain (Bird et al., 1980; Siegrist et a l, 1981) and slightly later in the rat. The stage of 
differentiation can be identified by a group of molecular markers, as outlined in Figure 
1-5.
Initiation o f  myelination
Although in vitro uncompacted myelin-like structures can form in the absence of 
an axon (Sarlieve et al., 1983), in vivo, oligodendrocytes form myelin sheaths solely 
around axons. Proliferation of oligodendrocyte precursor cells (OPCs) appears to be
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dependent on axonal electrical activity (Barres & Raff, 1993), and oligodendrocyte 
numbers correlate closely with axonal numbers (Bume et al., 1996) suggesting direct 
and controlled glial-axonal signalling, although the precise nature of this signal has not 
yet been elucidated. Axonal diameter also plays a critical role, acting as a control of 
myelin thickness (Elder et al., 2001). However, axons are myelinated in intemodal 
sections, requiring a more spatially specific signal. Pharmacologically, the Na2+ channel 
blocker tetrodotoxin has been shown to block the initiation of myelination (Crespo et 
al., 1995), while a-scorpion toxin has the opposite effect (by slowing Na2+ channel 
activation, and thus repolarisation) (Demerens et al.t 1996). These findings again 
illustrate the importance of axonal activity for myelination.
Myelination begins with the extension of processes which, aided by astrocytic 
guidance (Meyer-Franke et a l, 1999), align with and adhere to the axon in an adhesion 
molecule-dependent process. The oligodendrocyte cell processes then form loose cups 
around an axonal segment. As the sheath envelops the axonal process, so one lip (the 
future inner tongue) becomes forced under the other lip. The lamellae develop by 
rotation of the inner tongue around the axon, and this is quickly followed by compaction 
(Figure 1-6). One oligodendrocyte may myelinate up to 40 segments (termed intemodal 
areas) on different axons in this way, creating a mesh of axons, myelinating 
oligodendrocytes and supportive astrocytes (Raine,1984).
Intemodal areas are flanked by nodes of Ranvier (noR), and are 150-200pm in 
length, with around 12nm between each layer (Butt & Ransom, 1989). Myelin thickness 
seems to be influenced by axon diameter, with thicker axons receiving thicker layers of 
myelin (Waxman & Sims, 1984). Following the spiralling of an axon by the sheet of 
myelin, the layers compact around the fibre, with the layers being assigned labels
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dependent on their intra- or extracellular orientation. The major dense line (MDL) is 
comprised of the intracellular cytoplasmic interface of the myelin, whereas the 
intraperiodic line (IPL) refers to the opposition of the external faces of the 
oligodendrocyte membrane (Figure 1-7) (Sjostrand, 1949). Separating the MDL and 
IPL is the lipid bilayer, containing the variety of myelin proteins (Figure 1-8).
The noR is an axonal membrane specialisation related to the saltatory 
conduction of action potentials down the axon. Prior to myelination, the axon 
membrane contains a low density of sodium channels, randomly distributed along its 
length. During myelination, the sodium channels become localised to the noR, with 
potassium channels concentrated in the juxtanode. This arrangement facilitates saltatory 
conduction by causing changes in membrane polarisation, and to regulating ion flow 
(Hildebrand et a l , 1993; Waxman & Black, 1995).
Molecular Aspects o f  Myelinogenesis
In the mouse, gene activation for transcription of myelin proteins occurs in the late pre­
natal period, when the switch from immature oligodendrocytes (expressing 
galactocerebrocide (GalC) and 2’-3’-cyclic nucleotide 3’-phosphodiesterase (CNP)) to 
mature oligodendrocytes (expressing MBP, proteolipid protein (PLP) and myelin 
associated glycoprotein (MAG)) occurs (Monge et a l, 1986). These molecules are 
transported by a variety of routes. MBP, which is required for myelin compaction by 
adhering to the cytoplasmic leaflet of the lipid bilayer, is likely to be non-specifically 
adhesive to organelle membranes. Therefore, MBP messenger ribonucleic acid (mRNA) 
is specifically transported to areas of myelination, where translation occurs (Colman et 
a l , 1982). In contrast, PLP is likely to be transported in vesicles, with proteins involved 
in such transport having been identified in oligodendrocytes (Allard et a l , 1998;
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Figure 1-6: the  morphological events surrounding the myelination of an 
axon. (A) Oligodendrocyte p ro cesses  begin to form a  sheet-like myelin 
structure upon axonal contact; (B) This sh ee t w raps around the axon until 
the two en d s meet; (C) O ne end ex tends further underneath  the  other, 
forming inner and outer tongues; (D) Myelin continues to encircle the axon, 
and the multi-layered structure com pacts by virtue of the electron-dense 
proteins in the  m em brane. After: Myelin, 2nd ed. (edited by Morell.P.; 1984; 
New York Plenum  Press).
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F igure  1-7: E lec tro n  m ic ro g ra p h s  sh o w in g  C N S  
m yelin. T h e  to p  p an e l s h o w s  partially  c o m p a c te d  
m yelin with th e  in n e r (sm all *) a n d  o u te r  ( la rg e  *) 
to n g u e s  (A - ax o n ); th e  low er p an e l sh o w s  
c o m p a c te d  m yelin , with th e  a rro w  ind icating  th e  
o u te r  to n g u e . From: Myelin, 2nd ed. (edited by Morell, 
P.; 1984; New York Plenum  P ress)
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Figure 1-8: Proteins of the myelin sheath.The main constituent glycoproteins of the myelin 
sheath are arranged so as to maximise interactions at the cytoplamsic interface and allow 
compaction to occur. Abbreviations: Cx32 - Connexin 32; MAG - Myelin Associated 
Glycoprotein; MBP - Myelin Basic Protein; PLP - Proteolipid Protein; MOG - Myelin/ 
oligodendrocyte glycoprotein. After: Myelin, 2nd ed. (edited by Morell,P.; 1984; New York 
Plenum Press)
Madison et a l, 1996; Madison et a l , 1999). As well as specific molecular 
transportation mechanisms, the activation of enzymes associated with lipid processing is 
closely temporally related to myelinogenesis. Myelination hits a peak rate at around 18 
days post-parturition in both the rat and mouse, as do the levels of a number of myelin- 
constituent processing factors (Lachepelle et al., 1994; Sarlieve et a l, 1974; Schulte & 
Stoffel, 1993; Schutgens et a l , 1985).
The formation of lipid and protein complexes in myelinogenesis is essential for 
the correct construction of myelin. Oligodendrocytes are rich in glycolipids, which have 
been shown to co-cluster with proteins, and form microdomains during transport from 
the Golgi apparatus. The presence of myelin vesicular protein in oligodendrocytes and 
in myelin strengthens the theory of lipid-protein microdomain complexes as a method 
of extending the specialised plasma membrane to form the sheath (Magyar et a l, 1997). 
From electron micrographs (see Figure 1-7), the myelin membrane appears to have 
layers of protein (dark lines) and lipid hydrocarbon chains (unstained lines) (Morell, 
Quarles, & Norton, 1994).
Each leaflet of the myelin lipid bilayer has a different molecular composition. 
Glycolipids are positioned on the extra-cellular face of the membrane, with the head 
groups protruding into the IPL; in contrast, the negatively charged amino-headed groups 
form the intracellular face. This differentiation is essential for correct myelin 
compaction. The most abundant proteins in the bilayer are MBP and PLP. It is thought 
that PLP stabilises the IPL, and, by interaction with acidic lipids in the opposite 
membrane, facilitates compaction of the major dense line (Stoffel et a l, 1997).
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1.4.2. Origin and fate of oligodendrocytes
Oligodendrocytes originate from neuroepithelial precursor cells in the 
developing CNS, mainly from the subventricular zone (SVZ) which is present 
throughout development and persists into later life in some mammals (Doetsch et al.,
1997). Precursor cells of the SVZ are often multipotent, but can also have a restricted 
lineage (Levison & Goldman, 1993), with the fate and survival of a given cell being 
influenced by the immediate microenvironment (Jensen & Raff, 1997). Migration, 
proliferation and differentiation of precursor cells is controlled by growth factors (such 
as platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF or FGF- 
2), insulin-like growth factor-1 (IGF-1), neurotrophin-3 (NT-3), glial growth factor 
(GGF), neuregulin), hormones (especially thyroid hormone) and neurotransmitters 
(Johe et al.y 1996). Like neurons, glial cells undergo apoptosis postnatally due to a lack 
of trophic support, with the death of each cell type being regulated by competition for 
limiting amounts of specific factors (Barres et al.y 1992; Levison & Goldman, 1993). 
Due to the multipotent effects of many growth factors, it is often difficult to elucidate 
their exact functions in vivo where two or more growth factors may act together to fine- 
tune a response (McMorris & McKinnon, 1996). The roles played by growth factors are 
outlined in Figure 1-5.
Hormones, neurotransmitters and Notch
Thyroid hormone has long been a candidate for the control of neural
development; hyper- or hypothyroidism during development severely increases the risk
of a child being bom with mental retardation (Eayers & Taylor, 1951). Thyroid
hormone exerts effects in three major areas through the active form of the hormone.
Firstly, it can act as a signal for generation of oligodendrocytes, and enhances the
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proliferation of committed precursors (Ahlgren et al., 1997). Secondly, thyroid hormone 
directly promotes differentiation of precursor cells, and thus regulates the numbers 
generated (Ben Hur et a l , 1998). Finally, it can directly stimulate myelin protein gene 
expression, including PLP and MBP (Tosic et a l , 1992).
Oligodendrocytes have been shown to cany receptors to known 
neurotransmitters, and voltage and ligand-gated ion channels have been identified in 
oligodendrocyte cell membrane. AMPA (dl-a-amino-3-hydroxy-5-methylisoxazole-4- 
propanoic acid), kainate, GABA-A (y-aminobutyrate-A), dopamine and opioid receptors 
have been identified on oligodendrocytes (Sontheimer et a l, 1989).
The Notch pathway is instrumental in priming oligodendrocyte development. 
Activation of the Notch 1 receptor by the ligand Jaggedl prevents differentiation of stem 
cells, and Jaggedl is down regulated in retinal ganglion cells in a manner that 
temporally parallels myelination (Givogri et a l, 2002). Axons are myelinated in the 
days following target innervation, leading to the hypothesis that axonal Jaggedl down 
regulation occurs in response to target innervation, and triggers the onset of myelination 
(Wang et a l, 1998). Therefore, the Notch pathway may play a role in keeping some 
stem and precursor cell populations elevated in adult tissues, forming a pool of 
progenitors which can be recruited for tissue repair and remyelination 
(Artavanistsakonas et al., 1995).
Early oligodendrocyte progenitors will migrate possibly large distances, to form 
a skeletal outline of the future white matter throughout the developing brain (Lachepelle 
et al., 1984; Levison & Goldman, 1993). This has to occur prior to maturation, as late 
progenitors have reduced migratory potential (Reynolds & Wilkin, 1991) and therefore,
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the environmental conditions have to be correct to prevent premature maturation (Wang 
e ta l , 1998).
Maturation is controlled by a variety of extracellular matrix molecules. For 
example, tenascin-C is found to be expressed at elevated levels in the junction of the 
retina and optic nerve, an area through which progenitors do not migrate 
(ffrenchConstant et a l , 1988). Modified (with the addition of polysialic acid or PSA) 
neural cell adhesion molecule (NCAM) has been identified in explant cultures, and PSA 
structures have been found to negatively modulate cell adhesion during development. In 
these cultures, removal of PSA-NCAM results in a complete blockade of 
oligodendrocyte progenitor migration (Durbec & Cremer, 2001).
1.4.3. Markers of mature myelin
Just as the stages of oligodendrocyte development can be characterised by a 
range of markers (as illustrated in Figure 1-5), the maturing oligodendrocytes can be 
followed during myelination. Glycolipids are early cell surface markers which remain 
present throughout oligodendrocyte maturity (Raff et a l, 1979), and include GalC and 
sulphogalactosylceramides (sulphatides).
The specific myelin proteins discussed previously are translated at various 
stages of oligodendrocyte maturation. CNP, MBP, PLP/DM20, MOG and MAG are all 
vital constituents of the compacted myelin sheath, and can be used to quantify the 
development of myelin (Figure 1-8).
Carbonic anhydrase II is the only one of the seven isoforms of carbonic 
anhydrase to be expressed in the CNS, and is present exclusively in glial cells. It can be 
used to differentiate between oligodendrocytes and other glial cell types as 
oligodendrocytes have a higher abundance of the enzyme (Ghandour et a l , 1980).
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1.4.4. Functions of myelin
Saltatory conduction o f  nerve impulses
The noR, where the axon is exposed to the extracellular space, maintain the 
velocity and integrity of salutatory conduction over distances. Na+ channels are 
anchored in place at the node by a network of filamentous molecules just below the 
surface (Lambert et al., 1997). These include ankyrin and spectrin, which also bind 
Na+/K+-ATPase molecules, as well as various cell adhesion molecules (Black et al.,
1990). The flanking paranodal regions, where the terminal loops of myelin can be 
found, are rich in potassium channels. The tight association of the terminal loops with 
the axolemma in the paranodal regions have been associated with paranodin (or caspr), 
a transmembrane glycoprotein unique to neural tissue (Einheber et al.t 1997). In the 
unmyelinated axon, a depolarisation in the axonal membrane causes current production 
that quickly attenuates, resulting in a loss of signal. After myelination, sodium channels 
are localised to the naked areas of axolemma -  the noR -  separated from localised 
potassium channels in the juxtanode. Insulation of the axon in the sheathed segments 
improves current flow along the axon. Once at the next noR, the localised sodium 
channels produce a further membrane depolarisation, leading to repropagation of the 
signal. It is these three events -  formation and maintenance of intemodal myelin 
segments, ion channel clustering and axonal insulation -  that comprise the primary role 
of the myelinating cell.
Role o f  oligodendrocytes in axonal development and maintenance
Oligodendrocytes play an important role in the development and maintenance of
functional axons. Axonal calibre has long been associated with conduction velocity,
with myelin thickness being closely controlled to provide an optimal conduction
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velocity for a given axonal diameter (Rushton, 1951). The mechanisms for this parallel 
axoglial development are mostly elusive. It has been shown that oligodendrocytes can 
regulate full axonal growth and development in the absence of myelin, as demonstrated 
using three transgenic mouse strains -  shiverer, jimpy and quaking (Sanchez et al.,
1996). Shiverer and jimpy mice have mutations in the MBP (Roach et al., 1983) and 
PLP (Philips, 1954) genes respectively, while quaking mice have an unknown mutation 
(Campagnoni, 1988), and all of them produce a dysmyelinating phenotype. In all three 
mutant strains, normal axonal development occurs in non-myelinated axons, an effect 
that is thought to be controlled by an oligodendrocyte derived factor. It has also been 
demonstrated that radial growth of axons is promoted by oligodendrocytes independent 
of myelination, by induction of neurofilament bundling. Reduced axonal calibre 
correlates with reduced neurofilament bundling and phosphorylation in non-myelinated 
areas.
Specific myelin proteins support axonal integrity. Although PLP knockout mice 
produce near-normal myelination, axonal integrity is compromised in these animals. 
Axonal swelling and widespread axonal degeneration occur, with the presence of 
spheroids -  membranous, mitochondria-rich inclusions (Griffiths et al., 1998). The 
location of spheroids at the distal paranode suggests an impairment of axonal transport. 
Transgenic mice with an extra autosomal copy of the PLP gene exhibited a phenotype 
characterised by severe hypomyelination, astrocytosis, seizures and premature death, 
indicating that genetic control of PLP expression is a critical determinant for 
oligodendrocyte differentiation and function (Readhead et a l , 1994). Individually the 
two isoforms of PLP (PLP and DM-20) had no effect on the jimpy phenotype, but when 
introduced together, a substantial increase in the number of myelinated axons was
observed, coupled with an increase in axonal integrity. This indicates vital and distinct 
roles for PLP and DM20 in axoglial interaction (Nadon et al., 1994).
Inhibition o f  axonal growth and regeneration by oligodendrocytes
The inhibition of regeneration in damaged or lesioned axons is a major problem 
following brain or spinal cord trauma or disease (Jackowski, 1995). Studies point to the 
ability of myelin-derived proteins to block the regrowth of axons. Late developing 
axons have been shown to be directed by oligodendrocyte associated neurite growth 
inhibitors (specifically NI-35 and NI-250) in the rat spinal cord (Schwab & Schnell,
1991), providing a guide for the development of new tracts. This positive 
developmental role becomes detrimental in the event of CNS damage. The potential for 
regeneration is limited in the CNS, in contrast to the peripheral nervous system (PNS) 
where NI-35 and NI-250 are expressed at far lower levels (Caroni & Schwab, 1988b). 
NI-35 and NI-250 are membrane-bound proteins which can be neutralised by the 
monoclonal antibody INI (Caroni & Schwab, 1988a). When applied in vivo following 
unilateral transection of the corticospinal tract in the rat brainstem (Thallmair et al.,
1998), INI produced sprouting of lesioned and intact fibres both above and below the 
lesion site, with rats demonstrating full recovery in sensory and motor tests. This study 
demonstrates that by altering the permissiveness of the glial environment, axonal 
regeneration can be stimulated, a finding supported by the spontaneous regeneration of 
lesioned CNS axons grafted into the PNS (Richardson et al., 1980), but not visa-versa 
(David & Aguayo, 1981). The myelin protein MAG mediates a second form of 
inhibition. This protein is inhibitory as opposed to non-permissive, causing growth cone 
collapse in vitro (Li et al., 1996). It has a soluble extracellular domain, which has been
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identified in vivo (Moller, 1996), and inhibits axonal regeneration in vitro (Tang et a l,
1997).
1.5. Innervation and neuronal development
1.5.1. Origins and differentiation
The hundreds of nerve cell phenotypes found in the adult vertebrate are 
descendants of a single population of embryonic ectodermal cells and the divergence is 
due to one of two proposed mechanisms: lineage (also known as intrinsic) and inductive 
(extrinsic) specification (Sulston & Horvitz, 1977). The lineage route involves 
asymmetric cell division where some cytoplasmic contents are divided unequally 
between daughter cells at mitosis. In the inductive route, cell division is equal and 
position-dependent cell-cell interactions define the phenotype. Most neuronal precursor 
division occurs by the inductive route, where daughter cells are conferred their fate from 
their position in the ectoderm. It is recognised, however, that invariant patterns of cell 
division can be due to highly reproducible cell-cell interactions, and that both lineage 
and inductive specification mechanisms can give rise to uniform lines of cells.
The number of neurons created during development is dependent on a group of 
cell cycle genes, (Schuurmans & Guillemot, 2002; Tzeng, 2003; Whitford et al., 2002), 
which regulate the production and segregation of neuroblasts, embryonic neuronal 
precursors. Interactions between neurons and glial cells control the number of 
oligodendrocytes produced, and ensure that there are enough myelinating and support 
cells for the number of neurons generated.
1.5.2. Migration
Early on in development, the neural tube develops by a folding up of the neural
ectoderm. Precursors in the neural tube have to migrate potentially large distances in
45
order to take their place in the embryonic CNS. Mitoses occur on the inner (ventricular) 
surface of the tube, migrating outwards between other cells to the outer (pial) surface. 
The ventricular face retains cells of mitotic potential, and becomes defmed as the 
ventricular germinal zone. In laminar brain regions such as the cerebral and cerebellar 
cortices, post-mitotic cells continue to migrate outwards to the more superficial levels in 
an “inside-out” manner (Angevine, Jr., 1970). In nuclear regions such as the 
hypothalamus, the “outside-in” proliferation occurs (Rakic, 1977). Other hotspots of 
neuronal proliferation exist, including the SVZ, which forms above the ventricular 
germinal zone. It is thought that post-mitotic neurons from both the ventricular and the 
sub-ventricular zones are guided by radially orientated glial cells, which extend from 
the ventricular to the pial surface (Rakic, 1972). The radial unit hypothesis, where 
discrete ventricular proliferative zones exist and their progeny migrate along a group of 
radial glial cells, has been shown to be a basis for the columnar organisation of the adult 
cortex (Rakic, 1988). Regional differences in cell division rate contribute to the 
increasingly complex folding of the neural tube, eventually creating primitive brain and 
spinal cord structures.
Some neurogenesis occurs in the mature mammalian CNS, as studied in the 
olfactory and hippocampal regions of the rodent brain (Altman, 1969; Lois & Alvarez- 
Buylla, 1993).
1.5.3. Initial innervation
Axonal growth from differentiated neurons occurs at the growth cone, an area 
containing the cellular machinery for manufacture of the extending axon -  
mitochondria, vesicles, microtubules and microfilaments. Axon guidance is handled by 
this leading-edge structure of the axon. Small outgrowths, or filopodia, dynamically
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branch out and retract according to the underlying substrate and in response to guidance 
cues (Letoumeau, 1981). Filopodia attachment, mediated via actin and myosin, is 
graded according to substrate -  the processes will have a stronger affinity for one 
substrate than another. A single filopodia can change the direction of axonal growth by 
adhesion to a preferable substrate -  relatively weak preferential differences can be 
crucial in this decision -  then the filopodia are swept backwards and to the side of the 
growth cone, pulling the axon in that direction (Bray, 1979). Glycolipid-containing 
vesicles in the growth cone undergo Ca2+-dependent fusion to the membrane in order to 
increase surface area for filopodia or axonal outgrowth. The tension produced through 
actin in an attached filopodia appears to initiate tubulin polymerisation and microtubule 
formation, thus axonal extension, indicating a functional link between actin and tubulin.
The polarity of the neuron is not attributed until late on in development at the 
point of axon outgrowth. All processes will start to grow at the same rate, with one 
accelerating and becoming the axon. It then develops unique biochemical and structural 
properties, as do the dendrites (Goslin & Banker, 1989). These include microtubule 
orientation -  in the axon the ‘positive’ end (where subunits are added) are at the 
growing tip, where as the dendrites have microtubules of each orientation (Black & 
Baas, 1989). This allows transport of ribosomes and Golgi body products into the 
dendrites, which are not present in the axon.
On arrival in the target tissue, stop signals allow the axon to slow or stop in 
order to find a target for synaptogenesis. Growth factors may be involved, with a drop 
in FGF concentration slowing axon advance (McFarlane et al., 1995), and the presence 
of neurotransmitters such as serotonin and dopamine eliciting a similar response
47
(Haydon et a l, 1984; McCobb et al., 1988). The growth cone changes shape from a 
consolidated mass with fine filopodia to an arborised, innervating structure.
1.5.4. Neurofilament construction/degradation
Neurofilaments (NFs) are the primary cytoskeletal component of the mature 
axon, extending along its length and providing structure and mechanical stability. 
Physiologically, protein subunits form protofilament polymers in a helical, rope-like 
structure, which in turn polymerise to form lOnm thick filaments. The three polypeptide 
subunits of NF, named NF-L, NF-M and NF-H after their low, medium and high 
molecular weights respectively, differentially construct these polymerised 
protofilaments. Carboxyl-tail cross-links between filaments contribute to regular 
spacing of filaments and ensure a high tensile strength in this unusually long structure. 
NFs are known to be anchored in the plasma membrane and the nuclear envelope, and 
also associate with cytoskeletal microtubules and actin filaments (Hoffman et al., 1987; 
Leterrier et a l, 1996). NFs are frequently modified by changes in their phosphorylation 
state, and are assembled and disassembled on this basis. Mammalian NF-H and NF-M 
have distinctive lys-ser-pro (KSP) motif repeats, with between 8 and 53 repeats in 
mouse and human NF-H, clustered in the crosslink-forming tail domains of the protein. 
Each of these can be phosphorylated twice, making this one of the most highly 
phosphorylated proteins in the CNS. NFs can also be less extensively phosphorylated in 
the amino-terminal head domain (Shetty et a l, 1993). NF deconstruction or degradation 
may result in aggregation of the protein, an event which has long been regarded as a 
marker of disease processes, and is increasingly thought to be directly responsible for 
CNS disease. In either case, the destruction of a vital member of the axonal cytoskeletal
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repertoire is a potential trigger for cell death, possibly by activation of the apoptotic 
pathway.
Neurofilament protein synthesis and transport
In a developmental situation, the neuronal cytoskeleton needs to accommodate 
behavioural and morphological transitions, from the early migratory target-seeking 
stage to the stable functioning neuron. Neuronal precursors express a range of 
intermediate filaments in addition to NFs, including nestin, vimentin, alpha-intemexin, 
and peripherin, the presence and phosphorylation states of which have been 
characterised by a group of monoclonal antibodies. Small regional and temporal 
variations occur, but there is a general pattern of intermediate filament expression. The 
swap from non-neurofilamentous intermediate filament to NF expression indicates a 
transition between the proliferative and differentiating stages of neuronal development 
with the prior group acting as a dynamic scaffold for NF assembly in vivo (Grant & 
Pant, 2000).
NF proteins are transported at 0.1-3mm per day, but unlike with other 
organelles, movement is interrupted by prolonged pauses with an estimated 90% of NF 
in transport being stationary at any one time (Roy et a l , 2000; Wang et a l, 2000). 
These studies also found that transport of NF can be in either an anterograde or 
retrograde direction. Transport mechanisms are likely to involve association with 
members of the kinesin and dynein families, but the exact transport proteins are 
unknown (Shah et a l , 2000). NF is thought to be transported in either small oligomers 
or as more complete filaments. Clearly, though, entire filaments need to be dissociated 
from the matrix prior to transport (Yabe et a l , 1999).
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Phosphorylation of NF plays a regulatory role in construction, and also may be 
involved in controlling association with motor proteins. Side-arm domains can be 
highly phosphorylated, and a correlation between the degree of phosphorylation and the 
speed of transport exists. In addition a high degree of phosphorylation on the side-arms 
leads to bundling of NF and thus decreased motility (Archer et al., 1994).
Neurofilament construction and phosphorylation
Following transport, NF subunits become highly phosphorylated, and therefore 
heavily cross-linked via the side-arm domains. Light and medium chain subunits are 
expressed first in development, with the heavy chain being expressed shortly after that 
in a mixture of partially phosphorylated and non-phosphorylated forms (Ackerley et al., 
2003). Phosphorylation occurs after transport in a gradient fashion along the axon in a 
proximal-to-distal direction, and continues into early postnatal life, correlating with 
synaptogenesis and myelination as a mature cytoskeleton is assembled (Szaro et al., 
1989; Willard & Simon, 1983). Indeed, myelination seems to provide a signal for 
further NF phosphorylation, with MAG being one putative signalling molecule (Yin et 
a l , 1998).
Assembly of the heteropolymeric filament relies on the correct phosphorylation 
of NF-L and -M  head domains, where phosphorylation of certain single serine residues 
can completely inhibit assembly of subunits, or may induce disassembly of constructed 
filaments (Sakaguchi e ta l , 1993).
It is thought that a highly sensitive stoichiometric balance regulates the calibre 
of a given axon (Sakaguchi et a l , 1993). Phosphorylation of the NF subunits 
contributes to the inter-filament spacing, but interactions with other components such as
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microtubules and actin filaments are essential for the construction of a dynamic 
cytoskeletal lattice (McQuarrie et al., 1986).
Phosphorylation effector molecules in this system fall into three categories -  
proline and non-proline directed NF-associated kinases, and phosphatases. The serine- 
55 residue of NF-L is the key, with phosphorylation of this site blocking assembly. This 
site is dephosphorylated on entering the axon by the non-proline directed kinase CK1, 
to allow NF construction (Nakamura et a l , 2000). Proline-directed kinases, especially 
of the cyclin-kinase and MAP-kinase families, are responsible for control of KSP-repeat 
phosphorylation, which occurs during and after construction. The repeat residues are 
usually stably phosphorylated during myelination and radial axonal growth as the 
mature cytoskeleton is established. This stability may, in part, be due to rendering NFs 
resistant to proteolytic digestion (Veeranna et a l, 1998). Phosphatases are involved in 
the more labile stages of axon outgrowth, with dephosphorylated NF more likely to 
disassemble and dissociate from other cytoskeletal components. This not only has 
implications in development, but also in plasticity, and potentially in learning and long­
term potentiation mechanisms (Hashimoto et a l , 2000).
1.5.5. Synaptogenesis
Properties of the pre-synaptic cell, post-synaptic cell and surrounding membrane 
need to change in order for synaptogenesis to take place. Structural specialisation at the 
pre-synapse and input from oligodendrocytes is also required. Synaptogenesis is 
regarded as a multi-step process at sites of axonal contact with dendrites, neuronal soma 
or other axons. Initial contact is followed by the establishment of stable sites of cell-cell 
contact, and subsequently by pre- and post-synaptic specialisation (Figure 1-9). 
Presynaptic differentiation involves the assembly of complex and elaborate
Figure 1-9:The molecular mechanisms of synaptogenesis
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macromolecular protein complexes which are rapidly assembled sequentially from 
cytosolic pools (Yamada & Miyamoto, 1995). As the neuron is a large and complex 
cell, unique molecular trafficking and sorting problems arise. Two subsets of synaptic 
vesicle proteins are transported from the Golgi apparatus in one of two “precursor” 
synaptic vesicle types. Maturation of the presynaptic apparatus occurs following 
recycling of synaptic vesicles with the plasma membrane. The vesicles are then filled 
with neurotransmitter and unregulated fusion and neurotransmitter release begins to 
occur, the role of which in synapse formation is unclear (Hannah et al., 1999). Some 
vesicle contents remain in the membrane, while some are released into the synaptic 
cleft, presumably to initiate or influence postsynaptic membrane specialisation. It is 
thought that channels, receptors and transporters are dynamically cycled between the 
synaptic membrane and the plasma membrane in vesicles (Roos & Kelly, 2000).
The post-synaptic membrane holds large, diverse molecular complexes 
constructed in-situ from individual elements, or using distinct classes of vesicular 
intermediates carrying limited repertoires of molecules. Receptors can be individually 
recruited to the membrane via signalling or activity dependent pathways (Sheng, 2001). 
It has been postulated that scaffold proteins cluster and stabilise receptors. Loss of one 
of these molecules does not perturb the lattice they form, suggesting that there is a 
degree of functional redundancy in the system (McGee et a l, 2001). Glial cells, 
particularly oligodendrocytes, play a vital role in neuronal maturation, as outlined in 
section 1.4.4.
1.5.6. Elimination of excess connections
Shortly after connections are made, the nerve cell population undergoes a period 
of cell death, eliminating half of the neurons in some sites, less in others (Hamburger &
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Oppenheim, 1982). This seemingly wasteful event has developed during evolution to 
generate accurate neuron numbers and to perfect axon guidance (Clarke, 1981), and is 
highly flexible allowing for rapid evolutionary changes in brain anatomy and function. 
Cell death occurs at this stage to eliminate neurons whose axons have failed to reach 
their target (Hamburger & Levi-Montalcini, 1949), to scale down neuronal numbers to 
match the number of targets (Cowan, 1973) and to eliminate connection errors (Rakic et 
al., 1986). The lack of electrical activity and competition for trophic factors are likely to 
determine the pattern of cell death.
1.5.7. The caspase pathway in neuronal cell death
The caspases are a growing family containing around 10 cysteine-dependent 
aspartate-specific proteases involved in the execution of the apoptotic cell death 
pathway (Philchenkov, 2003). This pathway plays an important role in the physiological 
development and homeostasis of brain cell numbers, but is also implicated in many 
CNS disease states (Bilsland & Harper, 2002). The caspases have been highly 
conserved throughout evolution, with mammalian caspase 1 (ICE) having been 
identified via the Caenorhabditis elegans homologue, ced-3 (Schwartz & Osborne, 
1994). The family contains a conserved active site composed of the pentapeptide 
QACXG, where X is variably R, Q or G in different isoforms. Caspases are synthesised 
as inactive proenzymes (zymogens) with an N-terminal peptide (prodomain), and 
usually one small subunit and one large subunit. In caspase 1 and 3, and possibly in 
other isoforms, the active enzyme is a hetero tetramer composed of two small and two 
large subunits. The caspase prodomains vary in length, with caspases 3, 6 and 7 having 
short prodomains compared to the other family members (Chang & Yang, 2000). The 
function of the prodomain in caspase 8 (and possibly caspase 10) is to directly link to
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the death receptors CD95 and TNF receptor 1 in the plasma membrane, and trigger the 
caspase activation cascade (Chinnaiyan et al., 1996). In the other caspases, the function 
of the prodomain is unclear. Caspases are cleaved at specific aspartate residues, leading 
to theories of sequential activation by other caspases in a hierarchical manner (Boatright 
& Salvesen, 2003). An initiator caspase (caspase 8) could activate an amplifier caspase 
(caspase 1), which in turn could activate machinery caspases (caspases 3 and 7) to 
cleave substrates. This model requires a factor or event to activate the caspases at the 
apex of the hierarchy, such as CD95 and TNF receptor 1 (Hengartner, 2000).
Caspase activation and induction o f  apoptosis
Activation of the caspases is effectively the trigger for the start of the apoptotic
process (Figure 1-10). Caspases appear to be cleaved via three main mechanisms -  by
an upstream caspase, by induced proximity activation or by association with a
regulatory subunit. In the first, activation by a previously activated caspase would
involve proteolytic cleavage of the zymogen between the prodomains (Fraser & Evan,
1996). These are separated by aspartate residues, suggesting that caspases could be
activated by “auto-cleavage” events. It is thought that this activation method is used
extensively to activate caspases 1, 6 and 7, which act as signal amplifiers contained
within a positive feedback loop (Budihardjo etal., 1999). This method, however, cannot
explain how the first caspase is activated. The second activation theory, which concerns
apex caspase activation, is termed induced proximity activation (Muzio et al., 1998).
Upon ligand binding, cell death receptors including CD95 and TNF receptor aggregate
to form membrane-bound complexes. Via adapter molecules, these then recruit and bind
a number of caspase 8 molecules, bringing them closer together (Chang et al., 2003b).
The concentration of zymogen molecules into a small space means that their combined
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O n
low intrinsic protease activity is sufficient to begin cleavage of the inactive caspase 8 
molecules, triggering the activation cascade. It is likely that other levels of control exist 
in vivo to regulate this activation pathway (Chang et al., 2003a). The third activation 
process is associated with caspase 9. Cleavage of pro-caspase 9 only produces a small 
increase in proteolytic activity and full activation only occurs via association with a 
regulatory subunit, Apaf-1, with the complex of these two molecules and possibly 
others constituting the true active form of caspase 9. The resulting complex enzyme, 
known as the apoptosome, exerts the effects of active caspase 9 (Li et al., 1997). 
Formation of the apoptosome relies on mitochondrial damage, as outlined below.
The regulation o f  apoptosis by Bcl-2 family
One important group of molecules involved in the caspase pathway are the B 
Cell Lymphoma (Bcl)-2 family of proteins (Burlacu, 2003). They have been divided 
into three structurally or functionally distinct groups, with group 1 being anti-apoptotic, 
and groups 2 and 3 displaying pro-apoptotic actions. These proteins can form active 
homodimers and inactive heterodimers with one another, where competitive binding 
regulates their activity. A higher concentration of group 1 proteins will bind pro- 
apoptotic group 2 and 3 proteins, neutralise them and exert an anti-apoptotic effect 
within the cell (Reed, 1997). The pro-apoptotic role of Bcl-2 group 2 and 3 proteins is 
focussed in the mitochondria. Housed inside the mitochondrion outer membrane is a 
cocktail of pro-apoptotic molecules, including cytochrome c. The release of cytochrome 
c enables it to join the apoptosome formed by caspase 9 furthering activation and 
increasing apoptosomal proteolytic activity (Li et al., 1997). There are several putative 
methods for Bcl-2 induced cytochrome c release from mitochondria. One pro-apoptotic
member Bc1-Xl has sequence homology with the pore-forming unit of diptheria toxin.
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Bcl-2 could induce conformational changes in the outer membrane by forming pores 
(Muchmore et a l, 1996). Secondly, it is known that several Bcl-2 proteins can bind to 
and regulate the activity of the voltage-dependent anion channel, a subunit of the 
mitochondrial permeability transition pore, which when opened, results in rapid loss of 
membrane potential and in mitochondrial swelling. Although this channel is too small to 
allow large molecules like cytochrome c to pass, significant Bcl-2 induced 
conformational change could reconfigure the channel proteins to form a larger pore 
(Shimizu et a l, 1999). Finally, Bcl-2 family members could induce rupture of the outer 
mitochondrial membrane, bypassing the need for a large-pore channel by allowing 
diffusion of molecules through tears in the bilayer. This would occur through control of 
mitochondrial homeostasis by Bcl-2 members, either directly or through intermediate 
proteins.
The protein substrates o f  caspases
To date, caspases have been found to cleave hundreds of potential substrates, a 
handful of which have vital structural or housekeeping roles within the cell, and are 
considered key substrates of caspases in apoptosis. Upon proteolysis, destruction of 
these substrates leads to a widespread shutdown of cellular functions, with chromatin 
condensation, changes in membrane permeability leading to cell shrinkage, and eventual 
phagocytosis (Eamshaw et a l, 1999).
1.6. Remyelination
1.6.1. Physiological remyelination
The CNS has an innate capacity to remyelinate following a demyelinative 
episode, but in these so-called “shadow plaques”, myelin takes the form of thin sheaths
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with a reduced intranodal length compared to development (Blakemore, 1974). One 
school of thought is that a recapitulation of events seen in development occurs, as 
developmental genes, such as MBP exon 2, become expressed in correlation with 
remyelination in MS (Capello et a l, 1997). The process is not identical to 
developmental myelination however, as thyroid hormone does not play a critical role 
(Franklin & Gilson, 1996) and other growth factors are also differentially expressed 
(Copelman et al., 2000). Another view is that the migratory and proliferative functions 
of OPCs are preserved in the remyelinating lesion, but that the microenvironment of the 
lesion is weighted against differentiation and remyelination. Studies indicate that 
recruitment of precursors occurs effectively (Carroll & Jennings, 1994; Franklin et a l ,
1997), but that the recruited cells do not differentiate, possibly due to inhibitory 
cytokines, chemokines and PSA-NCAM or Notch pathway protein expression 
(Franklin, 2002). Remyelinative potential decreases with age, an effect attributed to 
delayed growth factor expression and reduced capacity for OPC recruitment (Hinks & 
Franklin, 2000) and differentiation (Sim et a l, 2002).
Where it has been found to be effective, the consensus view of remyelination is 
based on this model of progenitor proliferation within, or migration to, the lesion site 
and differentiation into myelinating cells. Evidence has been presented for differentiated 
oligodendrocyte-derived remyelination, with MOG-positive cells found to produce new 
myelin sheaths in demyelinated MS plaques (Wolswijk, 2000). However, in 
experimental demyelination (Keirstead & Blakemore, 1997) and transplant studies 
(Crang et a l , 1998), this has not been observed leading to the conclusion that 
remyelination may also be carried out by adult progenitor cells (Scolding et a l , 1995).
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The signals thought to be required for remyelination are thus far limited to 
growth factors, the expression sequences of which have been elucidated from rodent 
models, which may differ from the human scenario (Copelman et al., 2001; Hinks & 
Franklin, 1999). Also, the potential reduction in remyelinative capacity with the age of 
animal has often not been duly taken into account (Hinks & Franklin, 2000). Perhaps 
more importantly, the pathology of an inflammatory disease is multifaceted and 
heterogeneous, involving a large number of growth factors, chemokines and cytokines 
(Baranzini et al., 2000). Links between remyelination and inflammation have been 
postulated, with TNF-a (Arnett et al., 2001) and IL-ip (Mason et a l, 2001), enhanced 
migration of OPCs (Tourbah et al., 1997), and expression of brain-derived neurotrophic 
factor (Kerschensteiner et a l, 1999) and ciliary neurotrophic factor (Linker et al., 2002) 
all thought to be beneficial in remyelination. In addition, the depletion of macrophages 
has been found to impair the remyelinative process (Kotter et a l, 2001).
1.6.2. Problems with remyelination in multiple sclerosis
Speculations as to the reason for a breakdown in the remyelinative repertoire of 
the CNS have been further confused by the identification of MS as a heterogeneous 
disease with distinct patterns of demyelination, as discussed in section 1.1 (Lucchinetti 
et a l, 2000). However, failures in several key areas combine to bring about 
remyelinative deficit.
In relapsing-remitting disease, an initial demyelinative attack may deplete OPC 
numbers in the lesion vicinity available for repair, followed by subsequent 
demyelinative episodes (Keirstead et a l, 1998). In addition, endogenous OPC migration 
is slow and covers only short distances, limiting repair capacity in large lesions 
(Blakemore et a l, 2000). This, however, is not thought to be the major rate-limiting step
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in remyelination, as OPCs are usually found in sufficient numbers in lesions. Axons are 
not receptive to remyelination following an episode in MS, due to the re-emergence of 
expression of PSA-NCAM (Chang et al., 2002). This molecule is expressed in 
development as an anti-myelinative factor, preventing interaction of the late OPC and 
the axon.
The astrogliosis accompanying the emergence of plaques in MS may be a 
stimulatory factor to OPCs, encouraging their proliferation and differentiation through 
the range of astrocyte-derived growth factors (Ridet et al., 1997). A failure of astrocytes 
to generate the correct signals in the MS plaque may lead to impairment of OPC 
recruitment. Astrocyte-derived neuregulin, a growth factor responsible for OPC 
differentiation, is found to be reduced in MS plaques (Viehover et al., 2001). Also, 
abnormal expression of jagged 1 by astrocytes in active lesions may be a negative 
regulatory factor for OPC differentiation, acting via the Notch receptor, an effect not 
observed in remyelinated lesions (John et al., 2002).
1.6.3. Experimental models of remyelination
Toxic demyelination
In this type of widely used model, a toxin such as lysolecithin or ethidium 
bromide is injected into the white matter of an experimental animal, causing myelin loss 
(Woodruff & Franklin, 1999b). The area and extent of demyelination is highly 
reproducible in these models. There is, however, some traumatic insult to the lesion area 
cause by the injection itself, and therefore localised blood brain barrier breach and 
inflammatory cell recruitment, independent of demyelination (Woodruff & Franklin, 
1999a). Cuprizone, a diet-administered copper chelator elicits complete and consistent 
demyelination in the corpus callosum and the superior cerebellar peduncle (Matsushima
& Morell, 2001). In preparation for transplant studies, demyelination by ethidium 
bromide injection can be combined with irradiation techniques to kill proliferating cells 
and prevent endogenous remyelination (Blakemore & Patterson, 1978). Irradiation 
damages astrocytes, however, so the astrocytic reaction to demyelination is altered. 
None of these models take into account the inflammatory aspects of demyelinative 
disease, as are seen in MS (Stangel & Hartung, 2002b).
Inflammatory demyelination
As previously discussed, EAE is a widely used and highly representative model 
of CNS inflammatory disease (Gold et al., 2000). Induced by the injection of myelin or 
CNS antigens, the disease can show signs similar to MS, with a relapsing-remitting 
disease course and accumulating movement deficit As it mimics many of the 
pathological features of inflammatory CNS diseases, EAE is considered an accurate 
model of demyelinative disease. Inflammatory disease can also be induced by injection 
of GalC antibodies plus complement (Woodruff & Franklin, 1999a), or by the 
implantation of a GalC-secreting hybridoma (Rosenbluth et al.9 1999). These models 
specifically damage oligodendrocytes, but again injection leaves a small traumatic 
lesion along the injection canal. Administration of an antibody against MOG has been 
found to augment demyelination in an acute EAE model of MS (Stefferl et al., 2000). 
Large confluent demyelinated plaques are produced (Linington et al., 1988), allowing 
the study of demyelination and potential repair mechanisms in the 
immunocompromised experimental environment of the EAE model (Iglesias et a l, 
2001).
62
Viral demyelination
Several virus-mediated models of demyelination exist. The Theiler’s murine 
encephalomyelitis virus (TMEV) persists within oligodendrocytes following injection, 
and gives rise to CNS inflammation and demyelination (Rodriguez et a l , 1983). 
Neurotrophic mouse hepatitis virus (MHV) and Semliki Forest virus (SFV) are also 
used in experimental investigations of remyelination (Mokhtarian et a l, 1999; Soilu- 
Hanninen et a l, 1994). The latter is thought to induce demyelination via molecular 
mimicry with MBP, where sufficient sequence homology or similarity between the viral 
and self peptides are able to induce autoimmune responses that lead to disease 
(Oldstone, 1987).
1.6.4. Promotion of endogenous remyelination
Growth Factors
Enhancing the inadequate endogenous remyelination system is an attractive
therapeutic target in MS. Growth factors play a large role in remyelination, and their
administration initially seems like a straightforward strategy. NGF has been found to be
protective against demyelination in EAE (Villoslada et a l, 2000), and neuregulin can
reduce damage to oligodendrocytes in EAE (Cannella et a l, 1998). FGF-2 gene therapy
ameliorates the course of EAE (Ruffini et a l, 2001), and injection of PDGF speeds up
recovery following toxin-mediated demyelination (Allamargot et a l, 2001). However,
growth factors have pleiotropic effects. IGF-1 enhanced remyelination in the acute
phase of EAE but this was transient, and was not observed when IGF-1 was injected in
the chronic phase (Cannella et a l, 2000). In addition, IGF-1 did not promote
remyelination following toxic insult (O'Leary et a l, 2002). A number of growth factors
are expressed sequentially in remyelination, and often one growth factor will modulate
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the activity or response of another (Copelman et a l , 2000). Therefore, administration of 
a single factor is probably not going to be sufficient for the long-term stability of 
remyelination; a complimentary group of factors may be required. It is worth bearing in 
mind that, even if growth factor repertoires sufficient for remyelination in rodents are 
elucidated, responses in human patients are likely to differ (Scolding et a l , 1995).
Intravenous immunoglobulins
Antibodies against spinal cord homogenate and specifically against MBP, have 
been made which have been found to promote remyelination in TMEV (Asakura & 
Rodriguez, 1998). All of these antibodies have an IgM isotype and the capacity to bind 
oligodendrocytes, but do not share epitope specificity. These antibodies also accelerate 
the rate of remyelination in chemically induced demyelination (Pavelko et a l , 1998) 
and in EAE (Miller et a l , 1997). The exact mechanism of action of these 
immunoglobulins is not yet known, but it is likely that they elicit an indirect, 
immunomodulatory effect, producing a permissive environment for remyelination, as 
opposed to acting via direct oligodendrocyte stimulation (Stangel & Hartung, 2002a).
Cell transplantation
Transplanting oligodendrocytes, precursors, Schwann cells, olfactory
ensheathing cells and stem cells into the CNS to promote remyelination has varied in
success (Blakemore, 1977; Franklin, 2003; Keirstead et a l, 1999; Lakatos et a l, 2003;
Targett et a l, 1996). The attempts which showed the most promising results often used
tissue from ethically sensitive sources. In addition, it is likely that the hostile lesion
environment which prevents remyelination by endogenous precursors will not permit
proliferation or differentiation of transplanted cells. Finally, lesions are disseminated
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throughout the CNS, and therefore it is likely that multi-site transplantation would be 
necessary.
i .  7. Cannabinoid signalling and neuroprotection
1.7.1. Cannabinoids in the physiological brain
Receptors
The isolation and purification of A9-tetrahydrocannabinol (A9-THC), the major 
psychoactive component of cannabis, was carried out and the structure elucidated in the 
1960s (Mechoulam & Gaoni, 1965). Synthetic analogues mimicking the effects of A9- 
THC were produced (Dewey, 1986), exposing the high stereoscopic specificity of the 
ligands (Mechoulam et al., 1980), and were used subsequently to identify the brain 
cannabinoid receptor, CBiR (Devane et a l, 1988). The receptor was then cloned 
(Matsuda et a l , 1990), and the anatomical distribution (Herkenham et a l , 1990) and 
neuropharmacology (Howlett, 1995) elucidated.
The cannabinoid receptor 2 (CB2R) was cloned from a human cell line some 
time after CBi (Munro et a l , 1993), and shares only partial homology. It is 
predominantly expressed in the periphery (Matsuda, 1997), especially on cells of the 
immune system, but has been reported in some CNS cell types (Facci et a l , 1995; 
Skaper et a l , 1996; Walter et al., 2003).
There is evidence from several pharmacological studies for a putative novel non- 
CBi non-CB2 CNS cannabinoid receptor, but one has not yet been identified or 
sequenced (Breivogel et al., 2001; Calignano et a l , 1998; Calignano et a l , 2001; Di, V 
et a l , 2000).
Caligano et al (1998, 2001) found that the endogenous fatty acid amide
palmitoylethanol induces antinociceptive effects that can be attenuated by antagonists
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acting at CB2R but not CBiR. The molecule has been shown not to have affinity for 
either CBiR or CB2R (Lambert et a l , 1999; Sheskin et al., 1997), leading to the 
proposition of a novel “CB2-like” receptor.
Di Marzo et al. (2000) and Breivogel et al. (2001) have demonstrated G-protein 
mediated second messenger pathway activity following administration of anandamide 
and WIN55-212-2 in tissue from the CBiR-KO mouse. These effects were not produced 
by other CBiR or CB2R agonists. Furthermore, it has been reported that the receptor 
stimulated by WIN55-212-2 may not signal via adenylate cyclase, unlike that occurring 
with CBjR and CB2R (Monory et a l , 2002).
Agonists and activating agents
Following identification of A9-THC, synthetic agents were produced with
generally high binding affinity for the cannabinoid receptors, and have been recently
officially classified into four groups -  classical and non-classical cannabinoids,
aminoalkylindoles and eicosanoids. Classical cannabinoids have a tri-cyclic structure
and a benzopyran moiety, examples of which include the natural extracts of cannabis
(Howlett, 2002). Non-classical cannabinoids include bi- and tri-cyclic analogues of
classical cannabinoids, lacking the pyran ring structure (Howlett, 2002). Examples
include CP55-940, which was instrumental in the discoveiy of CBiR (Devane et a l ,
1988). Aminoalkylindoles are a group of molecules not structurally derived from THC
(Pacheco et al., 1991), and include WIN55-212-2, a highly studied molecule shown to
produce many of the effects of THC (Compton et a l, 1992). Finally, eicosanoids
include the endogenous cannabinoid agonists anandamide and 2-arachidonoyl glycerol
(2-AG). Anandamide (arachidonoyl ethanoamide) is produced at synapses, and in
macrophages and other leukocytes (Felder et al., 1996). 2-AG has a binding affinity
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similar to anandamide and was first isolated from the canine gut (Mechoulam et al.,
1995). Fatty acid amide hydrolase is thought to be the principle enzyme responsible for 
the breakdown of anandamide and 2-AG, and as such plays a key role in the 
endocannabinoid signalling pathway (Di, V et al., 1999). Other putative 
endocannabinoid compounds have been reported.
Endocannabinoid signalling
Depolarisation-induced suppression of inhibition (DSI) describes the 
phenomenon of transient suppression of inhibitory GABAergic cellular events by brief 
depolarisation of the cell. It was first described by Marty in cerebellar Purkinje cells 
(Glitsch et al., 1996), and by Alger in hippocampal pyramidal neurons (Alger et al.,
1996). DSI demonstrates that a post-synaptic signalling event can alter pre-synaptic 
neurotransmitter release, requiring a retrograde synaptic messenger. In the 
hippocampus, DSI only applies to GABAergic inhibitory neurons. In the cerebellum on 
the other hand, glutamatergic neurons can also be affected, resulting in depolarisation- 
induced suppression of excitation (DSE) (Wilson & Nicoll, 2001).
Studies carried out to investigate the role of CBiR at the synapse found that
CBiR agonists blocked DSI and DSE, and that antagonists reverse this effect. DSI is
missing in the hippocampus of CBiR KO mice (Yoshida et a l , 2002). Both
hippocampal and cerebellar neurons produce enzymes required for endocannabinoid
synthesis and degradation, and the retrograde suppression of synapses and formation of
endocannabinoids are calcium dependent. CBiR is located in the pre-synaptic
membrane of hippocampal pyramidal synapses, and on both inhibitory and excitatory
inputs to cerebellar neurons (Ohno-Shosaku et a l, 2002). It has also been found that
CBiR activation can downregulate cyclic adenosine monophosphate production by
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interaction with adenylate cyclase, indicating control via this second messenger 
pathway.
The mechanism of signalling can be divided into post- and pre-synaptic events 
(Figure 1-11). In the post-synaptic cell, neurotransmitter-receptor interactions cause 
depolarisation, thus opening calcium channels, allowing influx, at the same time as a 
separate glutamate pathway induces cannabinoid synthesis via metabotropic glutamate 
receptor 1. The cleavage of N-arachidonoylphosphatidylethanolamine (NAPE) by 
phospholipase D (PLD) liberates the active cannabinoid, anandamide, which crosses the 
synapse in a retrograde fashion and activates CBjR on the pre-synaptic membrane. This 
G-protein coupled receptor then inhibits Ca2+ influx into the pre-synaptic cell via direct 
interaction between the Gpy subunit and the calcium channel, with no second messenger 
involvement. The drop in calcium influx leads to a reduced probability of vesicle fusion, 
and therefore a reduction in neurotransmitter release (Maejima et a l , 2001).
1.7.2. Cannabinoids in EAE and MS
Anecdotal evidence for the use of cannabinoids as a treatment for the symptoms
of multiple sclerosis is long-standing, but has more recently been backed up by pre-
clinical and clinical data. A large proportion of that evidence has come from rodent
EAE models of inflammatory disease, suggesting that cannabinoid compounds may
have efficacy for symptom relief. Studies using purified A9-THC (Lyman et al., 1989)
and subsequently the more stable A8-THC (Wirguin et a l , 1994) demonstrated an
improvement in the signs of treated rats and guinea pigs. Recent, more detailed studies
have shown that cannabinoids may control spasticity and tremor, and potentially act as
neuroprotective agents (discussed in Section 1.7.3). The non-psychotropic cannabinoid
dexanabinol (HU211, an NMDA-receptor antagonist) inhibited the acute course of EAE
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in the Lewis rat, significantly reducing clinical score (Achiron et al., 2000). This 
seemed to be due to a reduction in CNS infiltrates as assessed by histology; however, 
having little efficacy at the cannabinoid receptors, these effects are clearly not via the 
CBIR. Cannabinoid receptor activation using the synthetic agonist WIN 55,212-2, the 
active constituent of cannabis, A9-tetrahydrocannabinol, the anandamide analogue 
methanandamide and the CB2-selective agonist JWH-133all produced a significant 
reduction of tremor and spasticity in the ABH mouse chronic relapsing EAE model 
(Baker et a l 2000). CB1 and CB2 antagonists exacerbated the signs, suggesting 
involvement of the endocannabinoid system in symptom control. Further investigation 
into enhancement of the endocannabinoid pathways in EAE showed that anandamide 
reuptake and hydrolysis inhibitors ameliorate spasticity, an effect reversed by 
cannabinoid receptor 1 and 2 antagonists (indicating cross reactivity of antagonists 
between CB1 and 2). Blocking G protein-coupled phosphodiesterase activity 
downstream of the CB1 and 2 receptors exacerbated spasticity and tremor. The same 
study also identified that endocannabinoid levels are increased in spastic CREAE mice 
but not in non-spastic immunised animals, suggesting that endocannabinoids increase in 
an attempt to compensate for the spastic deficit. This finding was followed up and 
confirmed by the same group (Baker et al., 2001). Cannabinoid receptor levels have 
been found to be elevated in striatal and cortical neurons in the Lewis rat EAE model, 
postulated to be a compensatory mechanism for motor dysfunction (Berrendero et al., 
2001).
Numerous clinical trials of cannabinoid compounds have been carried out in 
recent years, investigating the potential for symptom control in humans. A9-THC was 
first assessed in single patient or small scale trials in the 1980s and 1990s (Clifford,
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1983; Martyn et a l , 1995; Meinck et al., 1989; Petro & Ellenberger, Jr., 1981; 
Ungerleider et a l , 1987), with varied patient responses. Larger scale trials have tested a 
range of compounds administered via several routes. Oral administration of A9-THC 
and cannabis sativa plant extract on patients (n=16) who presented with severe 
spasticity found no beneficial effects (Killestein et a l , 2002). Both substances were 
deemed safe for further trial, but neither reduced spasticity, and both worsened the 
patient’s global impression. A second study using orally administered cannabis extract 
found an improvement in spasm frequency (n=57; p<0.05), and a tendency towards an 
increase in mobility (Vaney et a l , 2004). Spasticity as assessed by the Ashworth scale, 
tremor, sleep disturbance and bladder control were not improved. One of the largest 
studies to date has been the CAMS study, investigating the use of orally administered 
cannabis extract and A9-THC on 667 established MS patients with muscle spasticity 
(Zajicek et a l , 2003). This study found no improvement in spasticity (again assessed by 
the Ashworth scale), but some improvement in secondary outcome measures were 
observed, including improved mobility and a more positive perception of symptoms.
The sublingual spray may provide an alternative route of administration, 
potentially allowing higher cannabinoid bioavailability, avoiding the high 1st pass 
metabolism and long-term body-fat storage of ingested cannabinoids. Wade et al (Wade 
et a l, 2003) found that A9-THC, cannabidiol or a combination of the two could bring 
about improvements in relief of pain and muscle spasms, and an improvement in 
bladder control and spasticity in a small cohort (n=20). An unpublished phase III 
clinical trial with larger groups of patients also using the sublingual route of 
administration found improvements in neuropathic pain (p<0.05; n=66), sleep
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disturbance (p<0.05; n=70), and a reduction in spasticity (p<0.01; n=160). Carried out 
by GW pharmaceuticals, these results have yet to be subjected to peer-review.
While there are clearly potential benefits from cannabinoid compounds in MS, it 
would appear that trials so far have not uncovered definite therapeutic avenues. Studies 
have tended to be poorly performed with little attention paid to the pharmacokinetics of 
cannabinoid compounds, revealing the insensitivity of outcome measures employed. 
Changes to the administration route, characterisation of inferred novel receptors and of 
the endocannabinoid system as a whole, and development of new agonists may help to 
elucidate strong clinical targets.
1.7.3. Evidence for cannabinoid-mediated neuroprotection
The evidence for cannabinoid-mediated neuroprotection comes from a wide 
range of experimental models both in vitro and in vivo. Evidence has been found for 
protection mediated via cannabinoid receptors against excitotoxic and ischaemic insult 
and via non-receptor mediated pathways for excitotoxic, ischaemic, oxidative and 
traumatic damage.
Excitotoxic damage via glutamate release and calcium influx has been studied 
the most extensively. Two in vitro studies, from Shen and Thayer (Shen & Thayer,
1998) and Abood et al (Abood et al., 2001) agree that damage can be attenuated by 
application of WIN55212-2, a cannabinoid receptor agonist and A9-THC, the active 
form of cannabis, respectively. Furthermore, the effect is attributed to activation of the 
CBiR, as SR141716A, a CBiR antagonist, can block protection. Protection is most 
likely afforded through CBiR-linked inhibition of synaptic glutamate release, since 
concomitant addition of agonist and extracellular glutamate results in neuronal damage. 
A third excitotoxic study by Hansen et al (Hansen et al., 2002) found that antagonism of
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Figure 1-11: Endogenous cannabinoid signalling at a glutamateric synapse. (A) Action-potential medaited glutam ate release from the presynaptic mem brane activates 
postsynaptic glutam ate receptors to  depolarise the cell. (B) Among the receptors activated is MGluR 1, which upregulates phospholipase D activity. In turn, PLD processes 
NAPE, liberating anandam ide which crosses the synapse in a retrograde manner. Activation of presynaptic CB1 receptors closes calcium channels and halts synaptic vesicle 
fusing and glutam ate release.This retrograde synaptic negative feedback mechanism may be implicated in excitotoxic damage.
the CBjR elicited reduced neuronal cell death, and that CBiR agonists had no effects. 
The disparity between this and previous studies was put down to substantial differences 
between models, with the Hansen model being N-methyl-D-aspartate (NMDA) specific. 
Finally, a study by Hampson et al (Hampson et a l, 1998) looked at excitotoxic and 
oxidative damage, and concluded that cannabidiol and A9-THC can be neuroprotective, 
but that the effect is not mediated via cannabinoid receptors. A second study into the 
effect of cannabinoids in oxidative stress (Marsicano et al., 2002) examined protection 
by a range of classical and non-classical cannabinoid and non-cannabinoid compounds. 
These were split into three groups, based on their structure and binding profiles. Results 
from these studies suggest that presence of a phenolic ring structure is sufficient to 
protect against non-receptor mediated oxidative stress (Marsicano et al., 2002).
Protection from ischaemic insult has been studied in vivo, in the four-vessel 
transient occlusion and the middle cerebral artery permanent occlusion models 
(Nagayama et al., 1999), and in vitro in hypoxic cerebellar cortical neuron cultures 
(Sinor et a l, 2000). The in vivo studies both confirm that WIN55212-2 can protect brain 
tissue against ischemic injury via receptor-mediated mechanisms. The authors 
concluded that the effect could be due to cannabinoid receptor-mediated G-protein 
coupled reduction of flux through Ca2+ channels, or via second messenger pathways, 
such as cyclic adenosine monophosphate and phospholipase A2-cyclooxygenase.
A model of closed head trauma showed that 2-AG reduced oedema (intracranial 
swelling) significantly in the damaged hemisphere, and that recovery from the injury 
was transiently expediated. Infarct volume and hippocampal cell death were also 
attenuated. Again, this effect appeared to be receptor mediated (Panikashvili et a l, 
2001). Increased levels of endocannabinoids have also been reported in head trauma
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models following injury, indicating a potential autoprotective mechanism (Hansen et 
al.y 2001).
Finally two parallel studies using an novel MRI methodology found that two 
compounds -  A9-THC and anandamide protect brain tissue via different routes (van der 
Stelt et a l.y  2001b; van der Stelt et a l.y  2001a). Both studies used the Na+/K+-ATPase 
inhibitor oubain to induce acute insult to the striatum, followed by longitudinal (7 days 
duration from insult) MRI analysis to record recovery. A9-THC was found to protect 
striatal neurons from insult for 7 days, mediated by CBjR. Conversely, anandamide 
protected neurons in the early stage (up to 24 hours after insult) via non-receptor 
mediated routes. This was reversed in the late stage (7 days after insult) when 
SR141716A abolished neuroprotective properties. The authors speculate that the early 
protective effect could be due to the affinity of anandamide for other molecular targets, 
including the serotonin, NMDA and vanilloid receptors (van der Stelt et a l.y  2001b; van 
der Stelt et a l.y  2001a).
1.7.4. Cannabinoid receptor-1 knockout mouse characteristics and 
traits
Two mutant mouse strains with disrupted CBiR gene (the CBiR KO mouse) 
have been engineered and used in studies since 1999, one on the CD1 mouse 
background (Ledent et a l.y  1999) and one on the C57BL/6 mouse background (Zimmer 
et a l.y  1999). These strains allow for the investigation of the role of CBi on axonal and 
neuronal loss in CREAE.
Behavioural Traits
CBjR-KO mice on the CD1 strain background have been shown to have a mild
increase in locomotor activity when newly exposed to an open field, and exhibit
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increased exploratory behaviour, compared with wildtypes (WT) (Ledent et a l, 1999). 
Both of these effects are transient, as the mice become quickly habituated and may be 
due to changes in short term memory. Conversely, some studies have shown that CBjR- 
KO on the C57BL/6 background are hypoactive in the open field (Zimmer et a l, 1999). 
However, we have found that there is no difference in locomotor activity between 
wildtype and knockout mice on the ABH background.
Developmental differences and mortality
Although CBjR knockout mice have no gross anatomical or functional deficits 
at birth (Zimmer et a l, 1999), both hetero- and homozygous knockout animals are 
under-represented at birth when compared to wildtype. This indicates the death of pre- 
or early post-natal pups, possibly due to a deficit in embryo implantation mechanisms. 
General life expectancy has been reported to be lower in the knockout animals, with % 
survival changing from approx. 95% in wildtypes to 70% in knockouts after 24 weeks 
(Zimmer et a l, 1999). It has been found that antagonist administration reduces the 
probability of blastocyst development in the preimplantation mouse embryo and 
administration of anandamide promotes blastocyst implantation in vitro at 14nM, but 
inhibits it at higher concentrations (Paria et a l, 2001). Cannabinoid antagonist 
administration also inhibits suckling in new-bom pups, potentially leading to death 
(Fride et a l, 2001). These effects are likely to be strain dependent, since animals bred 
on the C57BL/6J background are susceptible, while those backcrossed on to the ABH 
background show no evidence of changes in postnatal survival compared to knockout 
mice on the CD1 background (D.Baker, personal communication).
75
1.8. Aims
Exogenous cannabinoids have been reported as being neuroprotective through 
CBjR in a range of neuropathological conditions, including immune-mediated EAE 
models. In view of this, the aims of this project were to assess the degree of axonal and 
myelin pathology in an animal lacking the receptor during EAE in vivo and IFN-y 
mediated demyelination in the aggregate cell culture model.
To assess the CBiR knockout mouse, the aggregate cell culture system was 
modified to use tissue from the mouse telencephalon. Enzyme-linked immunosorbent 
assays (ELISAs) for NF and MBP were set up to assess axonal loss, demyelination and 
neuron damage/compromise in both systems, and the activation of caspase 3 was 
investigated as a harbinger of cell death. Clinical assessment of EAE by score and 
weight loss correlated with functional impairment in an activity chamber.
Modification of endogenous cannabinoid pathways is a preferable route to 
therapy for demyelinating inflammatory conditions, as, while effective, administered 
cannabinoids are unpredictable in their dosing attributes, and elicit numerous 
undesirable side-effects. This study aims to shed light on the endogenous pathway as a 
therapeutic target by investigating pathology in the absence of that system.
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Materials and Methods
All chemicals were from Sigma-Aldrich Co. Ltd., Poole, UK, unless otherwise stated.
2.1. M ouse Aggregate Cell Culture System  
2.1.1. Media
Mechanical dissociation and subsequent washes/centrifugation were carried out 
in D1 solution (Honegger, 1985), containing 138mM NaCl, 5.4mM KC1, 0.17mM 
Na2HPC>4, 0.22mM KH2PO4, 5.55mM D-glucose, 58.43mM sucrose, 5mg/l phenol red 
(Gibco BRL Life Technologies Ltd, Paisley, UK). Aggregates were cultured in serum- 
free high glucose Dulbecco’s modified Eagle’s medium (DMEM) without sodium 
pyruvate (Gibco), supplemented with 0.8jiM bovine insulin and other trace hormones, 
vitamins and elements. The above media was supplemented with lOOU/ml penicillin 
and lOOpg/ml streptomycin antibiotics (Gibco).
2.1.2. Preparation of foetal mouse telencephalon
Foetuses were removed from outbred BK1 (B&K Universal, Grimston, UK), 
inbred C57BL/6 (B&K Universal) and inbred ABH mice (in-house stock) at 16-19 days 
after gestation, and placed separately in sterile, ice-cold D1 solution. New bom pups of 
0, 1 and 2 days post-parturition were decapitated and the heads placed in ice-cold D1 
solution. The telencephalon of these foetal/new bom mice were dissected out and placed 
in 50ml centrifuge tubes (Philip Harris Scientific, Ashby-de-la-Zouch, UK) containing 
ice-cold sterile D1 solution.
2.1.3. Mechanical dissociation and seeding of telencephalon cells
After washing twice by replacing the D1 solution in each tube and allowing the 
material to settle under gravity, brain tissue was dissociated by sieving through a nylon 
mesh with 200pm pores (Nybolt, Zurich, Switzerland) submerged in D1 solution, using
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a sterile 5ml pipette outside the sieve to gently break up tissue (see Figure 2.1). The 
suspension was then poured through a nylon mesh sieve with 115pm pores (Nybolt) 
under gravity. Tissue of each foetal age was sieved separately. The filtrates were made 
up to 50ml with D1 solution, and centrifuged in a Sorvall RT6000B centrifuge (Dupont 
Ltd, Stevenage, UK) at 300g for fifteen minutes at 4°C with no brake. After discarding 
the supernatant, the pelleted cells were thoroughly re-suspended in D1 solution. A 
sample was diluted in 0.1% trypan blue/phosphate-buffered saline (PBS; 1.84mM 
KH2P04, lOmM K2HPO4.3 H2O, 154mM NaCl2, pH 7.2-7.4) to enable counting of 
viable cells by trypan blue exclusion, following which the suspension was re- 
centrifuged. The remaining pellet was re-suspended in the appropriate volume of 
DMEM to produce a cell suspension of 107 viable cells per ml, and 4ml of this 
suspension was seeded into 25ml capped DeLong flasks (Aimer Products, Enfield, UK) 
to give a total of 4xl07 cells per flask. The cells were incubated at 37°C in a humid 10% 
CC>2/90% O2 atmosphere (Heraeus incubator; Philip Harris Scientific, Ashby-de-la- 
Zouch, UK) under constant rotation (Kuhner Shaker; Philip Harris). The rotation speed 
was increased from 68rpm to 80rpm over the first week of incubation to ensure optimal 
cell aggregation. The day of seeding is termed Day in vitro (DIV) zero.
2.1.4. Culture Maintenance
On DIV2, the aggregates were transferred to 50ml DeLong flasks (Aimer) 
containing 4ml of pre-warmed DMEM, bringing the total volume in each flask to 8ml. 
On DIV5, 8, 11, 14 and then every other day, 5ml of complete DMEM was replaced in 
each flask with pre-warmed DMEM.
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Figure 2-1: Setting up the agg regate  cell culture. F oetuses a re  rem oved from the 
m other at em bryonic day 16-18 under sterile conditions. The telencephalon is 
d issected  out by removal of the cerebellum , and  m echanically dissociated by sieving. 
Cells a re  seed ed  and incubated under constant rotation, forming ag g reg ates  over the 
following 2 days.
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2.1.5. Demyelinating treatment of aggregate cultures
Aggregate cultures were treated with the cytokines IFN-y and TNF-a, and the 
anti-MOG antibodies 8-18C5 and Z12.
Cytokine treatment: Stock solutions of cytokine were prepared by dilution in sterile 
PBS, aliquoted to avoid repeated freeze-thaw cycles and stored at -20°C. Murine 
recombinant IFN-y (23ng/ml or 200U/ml; Chemicon International Ltd., Harrow, UK) or 
TNF-a (20ng/ml or 500U/ml; Chemicon) were added to pre-warmed culture medium. 
Cultures were then maintained as normal, substituting medium for cytokine- 
supplemented medium, on DIV 21 and 23. Flasks were then flushed of cytokine by 
washing with fresh prewarmed medium three times on DIV 25. Control flasks were also 
subjected to triple washing.
Antibody Treatment: Stock solutions of antibody were prepared by dilution in sterile 
PBS, aliquoted to avoid repeated freeze-thaw cycles and stored at -20°C. An IgGi 
mouse monoclonal antibody derived from clone 8-18C5 (Linington et al., 1984) or the 
IgG2a mouse monoclonal antibody, Z12 (Piddlesden et a l, 1993) were added to pre- 
warmed culture medium in the presence of complement (guinea pig serum; Serotec Ltd, 
Oxford, UK). Cultures were then fed as normal, substituting medium for antibody and 
complement-supplemented medium, on DIV 21 and 23. Flasks were flushed of antibody 
and complement by washing as described above. When using antibodies to demyelinate, 
the addition of complement is necessary to successfully demyelinate aggregate cultures, 
providing the need for a second set of control flasks, containing complement only.
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2.1.6. Aggregates from rat tissue
For verification of the new mouse tissue method, comparison with rat aggregates was 
necessary. The protocol for establishing an aggregate culture from rat tissue was as for 
the mouse culture, with the exception that embryonic day 16 Sprague-Dawley rat 
foetuses were used as a tissue source.
2.1.7. BrdU incorporation
Harvested aggregates were transferred directly into a 6-well cell culture plate (VWR 
International, Lutterworth, UK) into 2ml of pre-warmed medium containing 10pM
BrdU. This was incubated under constant rotation at 37°C for 4 hours. Following BrdU
incorporation, aggregates were fixed for 10 minutes in 4% paraformaldehyde and 
washed in PBS. Aggregates were subsequently stored in PBS containing 0.01% sodium 
azide as a preservative.
2.1.8. Sampling of cultures
Samples of aggregates were harvested at desired time points through the culture 
period for biochemical, molecular biological or morphological analysis. Harvesting 
regimens varied according to experimental design, and care was taken not to over 
sample, to maintain aggregate microenvironment homeostasis.
Sampling aggregates fo r  biochemical analyses:
The flask was gently agitated to ensure even distribution of aggregates, and a 
volume of medium with aggregates was transferred to a conical 10ml polypropylene 
tube (Fisher Scientific UK, Loughborough, UK) on ice. The aggregates were allowed to 
settle, the medium aspirated away, and the pellet was washed twice in 10ml of
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barbitone buffer (63mM Sodium Barbital, 1 ImM Barbital, 1.2mM EDTA). Most of the 
barbitone buffer was removed, and the aggregates were transferred to a 1.5ml microfuge 
tube (VWR), where the remaining buffer was removed, and the sample frozen at minus 
70°C.
Sampling aggregates fo r  mRNA analysis:
Sampling was performed as above, with extra care being taken to minimise 
RNA degradation, involving the use of ribonuclease (RNase)-free tubes and PBS.
Sampling aggregates fo r  analysis by confocal microscopy:
Sampling was performed as for biochemical analyses, with the addition of a 
fixation step. After removal of remaining barbitone buffer, the aggregates were fixed for 
10 minutes in 500j l l 1 of 4%-paraformaldehyde. Following 2 washes with 10ml Barbitone 
buffer, the samples were stored in 200jil of PBS containing 0.01% sodium azide as a 
preservative.
Sampling aggregates fo r  immunocytochemical analysis:
Aggregates were harvested and washed as for biochemical analysis. They were 
then treated with 200|il of 2% dispase in PBS at 37°C for 20 minutes while being 
agitated in order to disaggregate the cells. The remaining cell suspension was affixed to 
a microscope slide using a cytocentrifuge (Thermo Shandon UK, Runcorn, Cheshire, 
UK) at 600rpm for 5 minutes. After 10 minutes drying time the slides were placed in 
boxes with care taken not to disturb the cells, and frozen at -20°C.
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2,2, Measurement o f total protein concentration
The total protein concentration of aggregate homogenates was assessed using 
the Folin phenol method (Lowry et al., 1951), which is based on a two-step colour 
reaction. In an alkali solution copper associates with protein and subsequently reduces 
the Folin reagent to form a blue coloured product. To maximise the colour resulting 
from the reduction, 0.4M sodium hydroxide is present to neutralise any acid released on 
addition of the Folin’s solution and sodium carbonate is added to buffer the reagents to 
an optimal pH of 10. The optical density, read at 750nm, is proportional to the copper- 
bound protein.
Aggregates were homogenised in 500pl of homogenisation buffer (Barbitone
buffer, as previously described, supplemented with 2 0 pg/ml leupeptin, 2 0 pg/ml
pepstatin A, 200pg/ml benzoylarginine methyl ester (BAME), 200pg/ml tosylarginine
methyl ester (TAME), 200jxg/ml trypsin inhibitor, 200pg/ml tosylphenylalanyl
chloromethane (TPCK), 200jig/ml aprotinin and 4mM ethyl glycol tetraacetic acid
(EGTA)). This was done using a high-intensity ultrasonic processor (Jencons Scientific
Ltd, Leighton Buzzard, UK). An aliquot of each sample was then diluted to 1 in 26
using 0.05M NaOH, and standard concentrations of BSA (bovine serum albumin) were
prepared (0, 5, 10, 15, 20 and 30pg/ml) in a volume of 150jxl. Samples and standards
were assayed in duplicate. 50|il of each diluted sample was placed in a 10ml conical
tube (Fisher) with 100|il distilled water. 50|il of 0.4M NaOH was added to each tube
(standards and samples), followed by 1ml of freshly prepared solution X (2% Na2C0 3 ,
0.02% K2 Tartrate in 0.1M NaOH added to 1% Q 1SO4.5 H2O in a ratio of 99:1). All
tubes were vortexed, and left for 15 minutes. lOOjxl of Folin and Ciocalteu’s reagent
(diluted 1:1 with water; VWR) was added to each tube. After vortex mixing the tubes,
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they were incubated in the dark for a further 30 minutes. The absorbance of each sample 
at 750nm was read on an Ultraspec 2000 spectrophotometer (Amersham Pharmacia 
Biotech UK Ltd., Little Chalfont, UK), and the generation of a linear standard curve 
allowed conversion of optical density to pg of protein per sample.
2.3. Measurement o f myelin basic protein and neurofilament content 
by ELISA
MBP content correlates with the extent of myelination in the CNS as assessed by 
electron microscopy (Shine et al., 1992). MBP content had previously been assessed 
using a radioimmunoassay (RIA) technique, using potentially dangerous radioactive 
chemicals. This was replaced by a novel sandwich-type ELISA for MBP.
2.3.1. Measuring MBP by ELISA
Sample and standard preparation:
Aggregates sampled for biochemical analysis were homogenised as for the 
measurement of total protein, and then diluted to 1 in 2.5 in diluent solution (0.2% BSA, 
0.5% Tween-20 in barbitone buffer). An MBP concentration of lOOOng/ml was 
prepared from isolated human MBP and this was serially diluted 6 times in diluent to 
produce a standard curve. The final standard concentration was zero, using diluent alone 
to control for background activity. For reproducibility between assays, batches of 
standards were prepared and frozen for use in multiple assays.
ELISA protocol
Coat antibody (rat anti-MBP 36-50, Serotec) was diluted to 1:2000 in coating 
buffer (lOOmM Na2HPC>4 adjusted to pH 9.0 with lOOmM Na^PCU), and lOOpl was 
added to each well of a 96-well Nunc Maxisorp plate (VWR). The plate was then
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incubated overnight at 4°C. After bringing the plate to room temperature, non-specific 
binding was blocked by incubation with 200|il of 1% BSA in barbitone buffer to each 
well for 1 hour at room temperature. Following blocking, the plate was washed once 
using barbitone buffer with 0.5% Tween-20 (PBS-T) and then incubated with samples 
and standards for 2 hours at room temperature under gentle agitation. After washing 4 
times as above, the detect antibody (polyclonal rabbit anti-MBP; Chemicon) was diluted 
to 1:1000, lOOpl was added to each well, and the plate incubated at room temperature 
under gentle agitation for 1 hour. Following a further 4 washes, horseradish peroxidase 
(HRP)-conjugated anti rabbit antibody (Amersham) was diluted to 1:1000 in diluent as 
previously, and 100jxl was added to each well. The plate was incubated for 1 hour at 
room temperature under gentle agitation. Tetramethylbenzadine (TMB) substrate (R and 
D systems UK Ltd., Abingdon, UK) was removed from refrigeration and prepared in a 
light-excluded 50ml centrifuge tube to allow it to rise to room temperature. Following 4 
final washes, 100pl of substrate was added to each well, and the colorimetric reaction 
observed for 5-10 minutes before being stopped with 1M phosphoric acid. The plate 
was read on a dedicated photometer (Anthos Labtec Instruments, Salzburg, Austria) at 
450nm wavelength, using 620nm wavelength as a reference measurement.
Analysis o f  MBP ELISA results
Using Microsoft Excel, an equation representing the standard curve was 
determined, and used to predict the concentration of MBP in each sample from the 
optical density reading. This figure was then divided by the total protein for that sample, 
as determined by the Folin phenol method (see Section 2.2), to give the concentration of 
MBP per mg of total protein. In this way differences in sample concentration caused by 
non-identical sample sizes were normalised, allowing direct comparison of samples.
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2.3.2. Measuring neurofilament by ELISA
Samples were prepared as for the MBP ELISA and diluted to 1 in 5 with diluent. 
Standards were prepared from recombinant NF H (Affiniti Research Products, Exeter, 
UK) by serially diluting 6 times in diluent solution from a stock of 250ng/ml. The final 
standard was zero, using diluent alone. The protocol and analysis for the ELISA 
(Petzold et al.y 2003) was the same as for MBP. The antibodies used were as follows: 
coat antibody -  SMI35 (Stemberger Monoclonals Inc, Lutherville, USA) at ; detect 
antibody -  rabbit anti-NF 200; HRP-linked antibody -  HRP-conjugated anti-rabbit 
(Amersham). All antibodies were diluted to 1:1000. SMI-32 and SMI-35 reactive NF is 
termed NFHSM,3S or NFHSMm accordingly.
2.4. Measurement o f MBP by radioimmunoassay
The radioimmunoassay (RIA) is a limited reagent assay which provides a 
quantative measure of ligand using a specific antibody exhibiting high affinity for that 
ligand. By binding a fixed concentration of antibody to a fixed concentration of 
radiolabelled ligand in the presence of an unknown quantity of unlabelled ligand, 
labelled and unlabelled ligand compete for antibody binding(Kruger et al., 1999).
2.4.1. Radiolabelling MBP
125Iodine (125I) was used to radiolabel purified human MBP (supplied by 
N.Groome, Oxford Brookes University, Oxford, UK) using Iodogen iodination reagents 
(Peirce and Warriner UK Ltd., Chester, UK). Iodine needs to be in its oxidised reactive 
form to be successfully substituted into aromatic ring structures such as tyrosine, a step 
which is facilitated by use of these reagents. Iodogen Iodinating Reagent 
(tetrachlorodiphenylglycouril) was coated on to glass pyrex tubes (Bibby Sterilin Ltd, 
Stone, UK) by addition to the tube and evaporation overnight in a fume hood.
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IOjllI purified human MBP (1 mg/ml in 0.05M sodium phosphate buffer, pH7) 
was added to an iodogen coated tube containing lOpl of sodium phosphate buffer, pH 7, 
followed by 5pi of sodium 125I (approx. 18.5 MBq) in dilute sodium hydroxide, pH 7- 
11, to provide a final concentration of around 74MBq/20|il. The tube was incubated for 
30 minutes at room temperature. The iodination reaction was stopped by adding 0.5ml 
of 1M sodium phosphate buffer containing tyrosine (1 mg/ml) and lmg of blue dextran 
to the reaction vessel. The contents were then pipetted on to a PD10 column containing 
Sephadex G-25 M (Amersham) in order to desalt and separate labelled from non­
labelled fractions. The dextran blue-stained fraction containing iodinated MBP was
collected in a plastic screw-top phial and stored at 4°C in a lead container until required.
The success of iodination was estimated by activity counting using the LKB-Wallac 
1275 mini gamma counter (EG & G Wallac, Milton Keynes, UK).
2.4.2. Measurement of sample MBP
Buffer for the RIA (0.05M sodium phosphate, pH7, 1.2% w/v sodium chloride, 
0.5mg/ml calf thymus histones type II-S, 0.05% hexadecyltrimethyl ammonium 
bromide (CTMB)) was prepared and used to suitably dilute aggregate homogenate 
samples. A 50|xl aliquot of diluted sample was added to gamma-counter compatible 
tubes in duplicate. Stock 125I-labelled MBP was diluted in RIA buffer to give 
approximately 20,000cpm per 50|il, and this amount was added to each tube. A non­
specific binding (NSB) tube containing 50pl 125I-MBP and 50(il RIA buffer (to 
determine the percentage counts in the absence of antibody) and a total (T) tube
17^containing 50|il I-MBP alone (to measure total radioactive counts) were also prepared 
in duplicate. Each tube was vortex mixed and incubated overnight at 4°C to enable
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components to reach a binding equilibrium. Separation of bound and free ligand was 
accomplished by using the Sac-Cel method (IDSLtd, Tyne and Wear, UK): a cellulose- 
linked secondary antibody raised against the IgG type of the primary anti-MBP 
antibody was added. This binds to 125I-MBP and can then be removed by centrifugation 
(2 minutes, 18°C, lOOOg). The supernatant was then discarded and the 125I radioactivity 
(cpm) retained in the bound fraction within the pelleted cellulose was counted.
2.5. Immunocytochemical analysis of aggregates
Immunocytochemical staining of prepared slides (see Section 2.1.8) was carried
out to assess the types and morphology of cells within the aggregate. The prepared
slides were fixed in ice-cold methanol for 5 minutes at -20°C. After washing with PBS,
non-specific binding was blocked by incubation for 30 minutes with normal goat serum
(Vector Laboratories Inc., Burlingame, USA) diluted to 1 in 40 with PBS. Following 3
five-minute washes with PBS, 75|xl of the relevant primary antibody was applied (see
Table 2-1) and incubated for 1 hour at room temperature. Following a further 3 five-
minute washes, the relevant biotinylated secondary antibody was applied to the slide at
a 1 in 200 dilution, and incubated for 1 hour at room temperature. After 3 five-minute
washes, the sensitivity of the staining was augmented by using the Vectastain Elite
ABC kit (Vector Laboratories Inc., Burlingome, USA) avadin-biotin system. The
reagents were applied as per the manufacturers instructions, and slides were incubated
for 1 hour at room temperature. Following 3 final PBS washes, the slides were placed in
PBS with 2% 3,3'-diaminobenzidine tetrahydrochloride (DAB) and 5pM H2O2 for 5
minutes in order to develop colouration. Slides were then washed under running tap
water, and counterstained in freshly filtered haemotoxylin for 30 seconds, followed by a
5-minute wash under running tap water. Dehydration of the stained slides was carried
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out by immersion in 90% ethanol (VWR), then two immersions in 100% ethanol 
(VWR), followed by two immersions in 100% xylene (VWR), each for 45 seconds. 
Slides were mounted using Distrene 80:plasticiser.xylene (DPX) medium and allowed 
to dry overnight before viewing.
2.6. Histochemistry o f spinal cord transverse sections
8(im paraffin-wax spinal cord sections fixed in 4% paraformaldehyde were cut (Bright 
Instruments, Huntingdon, UK) from ABH mice (in-house stock), and mounted on to 
poly-lysine coated microscope slides (VWR). Sections were provided by AstraZeneca 
Sweden.
2.6.1. Luxol fast blue staining for myelin
Sections were incubated in Luxol fast blue solution (Salthouse, 1964) (Luxol fast blue 
1% w/v in ethanol with 2% acetic acid) overnight at 37°C, rinsed in 95% ethanol and 
then distilled water. Staining was differentiated by immersion in 0.05% lithium 
carbonate, followed by 70% alcohol and water washes, and slides were counterstained 
in eosin and cresyl violet (0.25% cresyl violet, 0.1% acetic acid) before dehydration and 
mounting with a coverslip.
2.6.2. Bielschowsky’s silver stain
Following hydration, slides were placed in preheated 20% silver nitrate solution at 37°C 
for 15 minutes. After three washes in distilled water, slides were placed in ammoniacal 
silver solution for 10 minutes at 37°C, and then in developer solution (5% 
formaldehyde, 20% absolute alcohol in distilled water) until the stain had developed 
appropriately (1-5 minutes) (Yamamoto & Hirano, 1986). Slides were toned in 0.1%
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gold chloride for 2 minutes, and fixed in 5% sodium thiosulphate for 2 minutes. 
Sections were mounted in DPX (VWR).
2.7, Aggregate analysis by confocal microscopy
Immunofluorescent staining of whole aggregates and subsequent analysis by 
confocal microscopy was performed to allow identification of cell types and their spatial 
organisation within the aggregates. Aggregates were fixed and stored as described in 
Section 2.1.8. The free-floating whole aggregates were then stained by incubation 
overnight at 4°C with 50pl of a relevant primary antibody (see Table 2-1). After 
washing three times with PBS, the relevant fluorochrome-conjugated secondary 
antibody was applied, and aggregates incubated overnight at 4°C. Where double 
staining was required, aggregates were incubated overnight with a second primary 
antibody with a different IgG subtype, followed by three washes with PBS, and a final 
overnight incubation with directly conjugated secondary antibodies against those IgG 
subtypes. After immunolabelling, 3-10 aggregates were placed on a glass microscope 
slide (VWR) followed by a drop of glycerol containing 22mM 1,4- 
diazobicyclo[2,2,2]octane (to reduce fluorochrome fading). A glass cover slip was then 
placed on top of the aggregates, squashing them slightly, and sealed with clear nail 
varnish. Aggregates were analysed on a Zeiss 410 inverted scanning confocal 
microscope (Zeiss UK Ltd, Welwyn Garden City, UK) with three separate excitation 
lasers, and images were prepared using Adobe Photoshop 7.0.
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Cell type Primary Source
Pluripotent oligodendrocyte 
precursor; perinatal and late 
OG progenitor; adult OG 
precursor.
Rabbit anti-PDGF-a receptor; 
1:1000
RandD
Systems
Perinatal and late OG 
progenitor; Adult OG 
precursor.
Rabbit anti-NG-2; 1:1000 Gift(G.Wolswijk)
Late OG progenitor; Adult 
OG precursor. Mouse monoclonal 04 (tissue culture supernatant); 1:2
Gift
(G.Wolswijk)
Oligodendrocyte cell body 
and myelin IgG3 Mouse anti- Galactocerebrocide C; 1:4
Chemicon
Myelin Rabbit anti-myelin basic protein; 
1:200
Chemicon
Neuron IgGl mouse anti-neurofilament; 
1:500
Sigma
Dividing cells IgM mouse anti-BrdU; 1:100 CymbusBiotchnology
Vulnerable or compromised 
subset neurons Mouse IgGl anti-dephosphorylated neurofilament (SMI-32); 1:1000
Stemberger
Oligodendrocyte Cell Body Rabbit anti-carbonic anhydrase II; 
1:1000
Gift
(G.Wolswijk)
Table 2-1: Primaiy antibodies for immunocytochemistry and fluorescent confocal 
microscopy
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Antibody Source
rabbit-Cy3 conjugate; 1:400 Donkey Research Diagnostics Inc
mouse IgGl-CY5 conjugate Goat Southern Biotechnology
mouse IgGl-TRITC conjugate; 1:500 Goat Serotec
mouse IgG2a-FITC conjugate 1:500 Goat Cymbus Biotechnology
mouse IgG3-FITC conjugate 1:100 Goat Serotec
mouse IgM-TRITC conjugate 1:100 Goat TAG Inc
rabbit IgG-TRITC conjugate; 1:500 Goat Sigma
rat IgG-TRITC conjugate; 1:500 Goat Seralab
goat- FITC conjugate; 1:100 Rabbit Sigma
rat IgG-FITC conjugate; 1:100 Rabbit Sigma
mouse IgGl-FITC conjugate; 1:100 Sheep Serotec
Table 2-2: Secondary antibodies for confocal microscopy analysis
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2.8. Extraction o f Total RNA from aggregates
Total RNA was extracted from aggregate samples using a modified version of 
the Chomczynski and Sacchi procedure (Chomczynski & Sacchi, 1987). Guanadine 
thiocyanate and guanadine hydrochloride were used to disrupt cell membranes, 
including nucleoprotein complexes, allowing RNA to be released into solution and 
purified free of protein. These compounds, along with p-mercaptoethanol and sodium 
acetate also serve to inactivate RNases released from cell membrane-bound organelles 
on disruption. Purification by phenolxhloroform extraction separates RNA from 
contaminating DNA and proteins, which can then be alcohol precipitated.
2.8.1. Cell disruption and RNA extraction/precipitation
Isolation was performed on ice to slow the rate of RNase activity and RNase
free equipment was used and gloves worn throughout. Aggregates in RNase-free 1.5ml
Eppendorf tubes were thawed on ice. In an extraction hood, 750|il of filter-sterilised
guanidine thiocyanate (4.215M guanidine thiocyanate, 25mM sodium citrate pH7,0.5%
N-lauroyl sarcosine, 0.1M p-mercaptoethanol, 12.5ml dipyrocarbonate (DEPC)-treated
water) was added to each tube, and aggregates triturated by passing through a 23-gauge
needle several times. After transferring to a 2ml lock-cap Eppendorf tube, RNA was
extracted by sequentially adding 75pl of sodium acetate (2M sodium acetate, 2M glacial
acetic acid, pH 4), 750pl of saturated phenol containing 1 mg/ml hydroxyquinoline
(Gibco), and 150|ll of chloroform:isoamyl alcohol (24:1), with each tube being inverted
to mix the contents between additions. The samples were then thoroughly vortex-mixed,
incubated on ice for 15 minutes, and centrifuged at 8000g for 15 minutes at 4°C. The
remaining lysate consisted of an aqueous upper phase containing RNA, and an organic
lower phase containing DNA and proteins. The aqueous phase was transferred to a fresh
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1.5ml Eppendorf tube and RNA was precipitated by mixing with 750jil of isopropanol, 
followed by an overnight incubation at -20°C.
Following incubation, samples were centrifuged as above to pellet the RNA, and 
the supernatant carefully removed and discarded. The pellet was resolubilised in 750jil 
of filter-sterilised guanidine hydrochloride (6M guanidine hydrochloride, 0.1M sodium 
acetate pH 5, 5mM dithiothreitol, 5.1ml DEPC-treated water), gently vortexed, and 
incubated on ice for 15 minutes. A 375pl aliquot of absolute ethanol was used to 
reprecipitate the RNA, again during an overnight incubation at -20°C.
Following centrifugation, the supernatant was removed and discarded, and the 
pellet was resuspended in 375pl of 70% ethanol. Samples were further dehydrated by 
vortexing and resuspending in 80% and then 100% ethanol. Samples were air-dried in a 
sterile environment to remove remaining ethanol, and the pellets resuspended in 40pl of 
RNase-free water before heating to 60°C for 10 minutes. After freeze-thawing the 
sample, the RNA was quantified by spectrophotometric analysis.
2.8.2. Spectrophotometric determination of RNA concentration and 
purity
To determine the concentration of RNA in each sample, the samples were 
suitably diluted, and measured at 260nm (UV wavelength) on an Ultrospec 2000 
spectrophotometer (Amersham). An optical density of 1 corresponds to 40pg of RNA in 
lml, so the concentration in pg/ml was calculated (i.e. RNA conc. = OD at 260nm x 40 
x dilution factor). Also, by measuring the 280nm wavelength OD, a ratio was obtained 
to estimate the purity of RNA extracted, with ratio values close to 2 indicating little 
contamination by DNA, protein or an extraction agent.
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2,9, Reverse-transcription of extracted RNA
RNA extracted from aggregates was reverse transcribed into single-stranded 
DNA for analysis by the polymerase chain reaction method. Using retroviral reverse 
transcriptase, incubation of messenger RNA with oligo d(T) primers and free 
deoxyribonucleoside triphosphates (dNTPs) under the correct conditions allows the 
retroviral enzyme to reverse transcribe single-stranded DNA from the extracted RNA. 
Again, extreme care was exercised in the handling of RNA, as contamination with 
RNases would produce degradation.
A 3pg aliquot of total RNA was placed in a RNase free 1.5ml Eppendorf tube 
with 40 units of recombinant RNase inhibitor (Promega Biosciences Inc., Southampton, 
UK) and made up to 13.5pi with DEPC-treated water. Oligo d(T) primers (0.5ng) were 
added to each tube, and samples were incubated at 70°C for 10 minutes to allow 
annealing of the primer to the poly-A tail of the RNA. These were transferred directly to 
ice to prevent the formation of secondary structures in the RNA, and 3 pi of 0.1M 
dithiothreitol, 40 units of RNase inhibitor, 1.5pl o f lOmM dNTPs, 600 units of Malarey 
murine leukaemia virus (MMLV) reverse transcriptase (Promega), and 6pl of 5 x 
reverse transcription buffer (50mM Tris (hydroxymethyl) aminomethane (Tris)-HCl pH
8.3, 7mM MgCb, 40mM KC1, 0.1 mg/ml BSA, 0.01% NP-40; Promega) were added. 
The samples were then incubated with this mixture for 1 hour 20 minutes at 37°C to 
allow primer extension and complimentary DNA (cDNA) production. This was 
followed by MMLV reverse transcriptase denaturation with a 10 minute incubation at 
70°C. After transferring directly to ice, the samples were made up to 150pl with DEPC- 
treated water, and the mRNAxDNA hybrids were denatured at 100°C for 5 minutes. 
Samples were then cooled on ice and stored at -20°C.
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2.10. Amplification of CBiR cDNA by Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a technique for amplifying areas of 
DNA using complimentary fragments of DNA flanking the region of interest (primers). 
Primer design requires knowledge of the DNA sequence of a gene. Following DNA 
denaturation, primers anneal to the single-stranded DNA (ssDNA) at specific 
temperatures related to their basic structure. The temperature is then changed to allow 
activation of a heat-tolerant DNA polymerase that extends the primer in a 5’ to 3’ 
direction using surplus free dNTPs. A third temperature change denatures the DNA 
strands and the cycle can repeat, allowing the number of cycles to determine the degree 
of DNA amplification. The amplification is exponential up to a point then plateaus out, 
with DNA polymerase being the limiting factor. Taq DNA polymerase (from Thermus 
aquaticus bacteria) is heat stable, and therefore ideal for this application. It requires the 
presence of free magnesium ions to function, with the magnesium acting as a cofactor.
2.10.1.Primer design
Primers for the mouse CBi receptor were designed using the Lasergene software 
from DNAstar Inc. (Madison, USA) and the National Centre for Biotechnology 
Information (NCBI) nucleotide database (http://www.ncbi.nlm.nih.gov). The primers 
used for CBjR (accession number: NM007726) in the mouse were as follows:
Forward: 5’-CAT CAT CAC AGA TTT CTA TGT AC-3’
Reverse: 5’-GAG GTG CCA GGA GGG AAC C-3’
PCR conditions for these primers were optimised by altering the magnesium chloride 
concentration for the reactions, and then by changing primer extension time and cycle 
number so that a single clear band was visible in each lane. The cycle number used was 
still in the linear phase of exponential duplication.
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2.10.2.PCR protocol
A 5jxl aliquot of each RT product was loaded into a sterile PCR reaction tube 
(Perkin-Elmer Applied Biosystems, Norwalk, USA; 8 tubes per strip) with 200mM 
dNTPs, 1.25mM MgCl2, 1 x PCR Buffer (200mM Tris-HCl pH 8.4, 500mM KC1; 
Invitrogen Ltd, Paisley, UK), ImM forward and reverse primers (Qiagen Ltd., Crawley, 
UK), 2.5 units of Taq DNA polymerase (Invitrogen), in a final volume of 50|il. The 
tube strips were loaded into a Geneamp PCR System 9700 (Perkin-Elmer), caps applied 
to each tube strip, and incubated under thermal cycling conditions for 40 cycles at an 
optimum annealing temperature of 55°C. Following incubation, products were stored at 
4°C.
2.10.3.Analysis of PCR products by 1% agarose gel electrophoresis
Separation of the 366bp DNA fragment was performed on a 1% agarose gel, and 
visualised under ultra-violet light using ethidium bromide. The sizes of PCR products 
were determined by comparison with a DNA ladder. Agarose in Tris-boric acid-EGTA 
(TBE) buffer (Gibco) with 0.5pg/ml ethidium bromide was prepared and loaded into a 
gel box with well-forming comb, and allowed to set for 45 minutes. Once set, the combs 
and barriers were removed, and the gel was mounted in an electrophoresis box and 
covered by TBE buffer (Gibco) containing 0.5 fig/ml ethidium bromide. Samples and a 
100 base pair DNA ladder (Promega) were prepared by diluting 5 pi of PCR 
product/ladder with 5pi of dH20  and 2pl of 6x orange G dye. Samples were loaded into 
separate wells, flanked by wells containing DNA ladder, and the gel was run at 110V/ 
0.05 amps for 1 hour 30 minutes. After running, the gel was destained in dH20  under 
agitation for 15 minutes, photographed using dedicated CoolSnapPro-cf monochrome
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camera and analysed using the GelPro image analysis package (Media Cybernetics, 
Berkshire, UK).
2.11, Measurement o f active and total caspase 3 by Western blotting
Western blotting is a technique for quantifying specific protein levels in a given 
sample. The technique entails running the protein in a sample through a gel under high 
electric current to separate protein by molecular weight -  smaller proteins will travel 
further than large proteins in a given time. These are then transferred on to a membrane 
and probed with antibodies raised against the protein of interest. Bands on an 
autoradiograph can then be quantified using computer techniques.
A 40jig aliquot (20-3 Opl) of protein was diluted in running buffer (2% sodium
docecyl sulphate [SDS], 10% Glycerol, 2.5% P-mercaptoethanol, 125mM Tris-HCL pH
6.8, 0.02% bromophenol blue), denatured at 100°C and loaded on to 5% stack, 12%
resolve gels (Biorad, Hemel Hempstead, UK), which were placed in a Biorad Mini-
Protean 3 gel-running box. Any empty wells were topped up with sample buffer prior to
the addition of running buffer (0.25M Tris base, 1.92M Glycine, 1% SDS) to the
chamber. The gel was then run under 180 volts for ~45 minutes until the bromophenol
blue dye-front had reached the bottom of the gel. Following removal of the gel, it was
equilibrated in transfer buffer (0.25M Tris base, 1.92M Glycine, 20% Methanol) along
with Immobilon P polyvinylidene fluoride blotting membrane (Millipore,
Massachusetts, USA). Mini Protean 3 fibre pads and 3mm blotting paper were also
soaked in transfer buffer. The transfer sandwich was constructed according to the
manufacturer’s instructions, and loaded into a transfer block. This was then immersed in
transfer buffer in the Mini Protean 3 chamber and proteins transferred to the membrane
using 22v current overnight at 4°C. Following removal of the membrane and one 10
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minute wash in Tris-buffered saline and Tween-20 (T-TBS; 0.01M Tris-HCL, 0.15M 
sodium chloride, 0.05% tween-20; Sigma Aldrich), non-specific binding sites were 
blocked using 5% Marvel fat-free milk (Premier International Foods (UK) Ltd, Lines, 
UK) dissolved in T-TBS. After another single 10 minute wash in T-TBS, primary rabbit 
antibody specific for caspase 3 (Santa Cruz Biotechnology, California, USA) was 
diluted to 1:1000 in 5% Marvel in T-TBS and incubated with the membrane for 2 hours 
at room temperature. The membrane was washed 3 times for 10 minutes in T-TBS, 
followed by incubation with goat antibody specific for rabbit IgG (secondary antibody) 
diluted to 1:1000 (Santa Cruz) for 1 hour at room temperature. Three further 10 minute 
T-TBS washes were followed by incubation with ECL reagents (Amersham) for 1 
minute according to the manufacturers instructions. The blot was then visualised using 
ECL x-ray film (Amersham), with exposures for 1, 5 and 20 minutes. Film was 
developed and fixed in Kodak reagents, and analysed using the GelPro software 
package.
2,12. Induction of EAE
ABH mice (in-house stock) were injected subcutaneously in the flank on day 0 and 7 
with 0.3ml of an emulsion of lyophilized spinal cord homogenate (SCH) reconstituted 
in PBS, and mycobacterium-supplemented Freund’s incomplete adjuvant (BD 
Biosciences Ltd, Oxford, UK). Each animal received 1 mg of SCH and 60 pg 
Mycobacterium (Mycobacterium tuberculosis H37Ra, butyricum ( 4 : 1 )  per injection) 
(Baker etal., 1990).
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2.13. Assessment o f functional deficit in EAE
2.13.1. Clinical scoring of mice
Mice with EAE were scored from day 11 onwards on a clinical scale of one to five, as 
illustrated in Figure 2-2, and photographed in Figure 4-2. Diagnostic criteria are as 
follows: 1 -  loss of muscular tone in the tail; 2 -  impaired righting reflex when the 
animal is turned on to its back; 3 -  partial hind limb paralysis, with one limb affected; 4 
-  complete hind limb paralysis, with both limbs affected; 5 -  moribund and unable to 
move. In order to more effectively facilitate use of the ranking with statistical analyses, 
neurological signs of a lower severity than typically observed for a defined grade were 
scored 0.5 lower. Therefore, animals in remission have tail movement and tone, but the 
tail is also limp, so is scored as a 0.5. Animals which are slowly able to right themselves 
following inversion are scored 1.5, and animals showing a small degree of partial limb 
paralysis are scored 2.5. Bilaterally paralysed animals showing only minor hind limb 
movement are scored as 3.5. Accompanying these clinical signs, weight loss occurs 1-2 
days prior to onset of disease, and is an accurate predictor of changes in disease, with 
animals regaining weight prior to recovery in remission.
2.13.2. Movement in an open-field activity chamber
Mice were placed in a 27 x 27 cm open-field activity chamber (Med Associates, 
Georgia, VT, USA) at varying stages of disease severity and movement around the 
chamber was recorded over a five-minute period. Total distance moved was recorded 
via computer, and data analysed using the SigmaStat V.2 (Jandel Scientific, San 
Rapheal, USA).
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0 - Normal
(1) -  R em ission1 - Limp Tail
2 - Impaired 
Righting R eflex
3 - Partial 
Paralysis
4 - Hind Limb 
Paralysis
5 - Moribund
Figure 2-2:The clinical scoring criteria in relapsing-remitting EAE. Signs 
become more severe as the disease course progresses, and are 
accompanied by weight loss prior to acute attack or relapse onset, and 
weight gain prior to remission.
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2.14, Statistical evaluation
Data was analysed with the GraphPad Prism computer package (GraphPad Software, 
San Diego, USA). Datasets were compared with either one or two-way analysis of 
variants (ANOVA) with 95% confidence limits, and errors calculated as the standard 
error of the mean (SEM). P-values were taken as proof of significance with the 
following nomenclature: * - p<0.01; ** - p<0.005; *** - p<0.001. N-numbers were 11 
and above for the spinal cord analyses, and 15 and above for the aggregate analyses. 
Individual n-numbers are given in each results chapter.
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3. Characterisation of a mouse aggregate cell
culture system
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3.1. Introduction
The aggregate cell culture system was developed using rat tissue, and has been 
extensively characterised and used to investigate myelination and remyelination, as well 
as growth and differentiation of cells over time (Almazan et al., 1985; Honegger et al., 
1979; Honegger & Lenoir, 1980), developmental expression of opiates (Lenoir et al., 
1983; Lenoir et al., 1984), neurotransmitters and growth factors (Honegger & Guentert 
Lauber, 1983; Honegger & Lenoir, 1982), adhesion molecule expression (Jorgensen et 
al., 1984), viral infection (Pulliam et a l, 1984) and toxicological studies (Honegger & 
Werffeli, 1988), amongst others. The volume of tissue that can be cultured, relative ease 
of technique, lack of exogenous supportive factors, three dimensional arrangement and 
flexibility of experimental variables makes the system ideal for examining cell types in 
conjunction with others. This environment models the in vivo situation more closely 
than a monolayer culture, allowing the interactions between cells to be examined. This 
is one reason why myelination, a process which intrinsically links nerves and 
oligodendrocytes, has been extensively studied using the aggregate system. Advances in 
gene knockout technologies in mice have presented an invaluable tool with which to 
elucidate the effects of a single factor on a system. A combination of the aggregate cell 
culture with gene knockout technology would provide a methodology with which to 
examine in detail processes such as myelination and neurogenesis, and the cellular 
interactions they represent.
The mouse strains employed in these studies were chosen for specific strain- 
dependent properties. BK1 mice are outbred, and mate reliably giving consistently large 
litter sizes. This means that a high number of flasks can be set up for each experiment. 
C57BL/6 mice are an inbred strain commonly used as the background strain for
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knockout mice. As this work was done with a view to using knockout animals, it was 
important that tissue from the background strain formed viable aggregates. However, 
C57BL/6 mice are relatively resistant to EAE induction (Levine & Sowinski, 1973), 
except where MOG is the immunogen (Slavin et a l , 1998). Therefore, ABH mice were 
tested for aggregate cell culture suitability, as CREAE can be effectively induced in 
these animals, as described previously. This was done with a view to backcrossing a 
gene deletion on to the ABH background strain.
3.2. Results
3.2.1. Aggregate molecular and cellular characteristics
The n-numbers used for all statistical evaluations in Section 3.2 were at least 
n=15 flasks. When examined under the light microscope, aggregates from mouse tissue 
were smaller than published data on rat aggregates, being 150-200|im in diameter, 
compared to 360-400pm in the rat (Figure 3-1). Variation in aggregate size was evident 
in the earlier stages of development, but was considerably reduced by 14 DIV. 
Aggregates had a spherical gross structure which remained intact for the duration of the 
42 day culture period.
The morphology of the aggregates was similar to that of aggregates from rat
tissue. As can be seen from Figures 3-2 and 3-3, an astrocytic shell surrounds an
intermediate layer of neuronal processes, myelin and oligodendrocyte cell bodies.
Neuronal cell bodies can be found in the core of the aggregate. Expression of markers
for early and late oligodendrocyte progenitors occurred in concordance with the in vivo
situation, as well as with rat aggregate development (Figure 3-4). NG2-positive cells, an
early progenitor marker, appear to be present in greater numbers at DIV 5 than 04-
positive late progenitors. The early progenitors persist until DIV 14, apparently
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reducing in numbers between DIV 14 and 21, whereas late progenitor numbers remain 
high until at least DIV 21. These progenitors have a morphology similar to that seen in 
rat aggregates. NG2-positive cells are round with few processes; 04-positive cells have 
a similar rounded shape, but often have more complex morphology with higher numbers 
of processes. Expression of 04 and NG2 and a third marker, PDGF-a, variably overlap 
at different stages of progenitor maturation. Simultaneous immunostaining for these 
three markers enables identification of progenitors in different stages of the lineage (see 
Figure 1-8). As can be seen from Figure 3-5, early and late progenitors dominate until 
DIV8, after which more pre-myelinating oligodendrocytes are seen. In conjunction with 
Figure 3-4, this indicates the progressive nature of oligodendrocyte development in 
vitro in the presence of other cell types.
3.2.2. Development of an ELISA for myelin basic protein
Whilst performing the first biochemical studies on mouse tissue aggregates 
using an RIA to measure MBP, it became clear that a less time consuming and safer 
technique was required to efficiently analyse aggregate myelin content, as the RIA took 
a minimum of 48 hours to complete. An ELISA was developed for MBP employing a 
two-antibody sandwich around the antigen. Three candidate capture antibodies (which 
is bound to the plastic surface of an ELISA plate in order to capture the antigen) were 
identified and tested for sensitivity (Figure 3-6). These antibodies were all monoclonal 
and sourced from readily available clones. They were coated on to a ELISA plate at a 
concentration of 1:1000 (see methods for a detailed description) and exposed to 
doubling dilutions of MBP. It was found that clone 12 was the most sensitive to MBP, 
detecting levels of around 7ng/ml above background. Clones 22 and 14 were sensitive 
to around 50ng/ml. Following selection of the coat antibody, the concentration of coat,
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detector and reporter antibodies were optimised by varying the concentration of each 
individually (Figure 3-7). Taking into account background and sensitivity, it was found 
that the optimum concentration for all three antibodies was 1:1000.
A comparison of three chromogenic substrates, 2,2’-azino-bis (3-ethylbenz- 
thiazoline) 6-sulfonic acid (ABTS), TMB and orthophenylenediamine (OPD) was 
undertaken to establish the most suitable for use in the assay (Figure 3-8a). OPD was 
found to produce a highly chromogenic and very rapid reaction producing saturated 
results and was therefore discarded. TMB was found to be more sensitive than ABTS, 
producing a well-paced reaction. Two proteins were tested for efficacy at blocking non­
specific binding on the ELISA plate -  bovine serum albumin and histones. Both have 
been used in past methodologies, and as can be seen from Figure 3-8b, there is a 
negligible difference between the two. BSA was chosen over histones due to being 
readily available and more cost effective.
To verify that colour production was due to the presence of antigen and not 
cross-reaction between components, experiments were conducted omitting pertinent 
components of the ELISA, with the aim of getting no colour production. For example, 
to test that the coat and detect antibodies did not cross-react, one ELISA was performed 
with no antigen present. Cross-reaction between coat, detect and report antibodies, the 
plastic plate, the BSA blocking agent and the TMB chromogenic substrate were all 
negative (Figure 3-9a). A comparison was carried out between the ELISA and RIA 
techniques to verify that the results were comparable between the two (Figure 3-9b). 
Samples in which MBP had previously been quantified using the RIA were retested
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Figure 3-1: M ouse ag g reg a tes  after 21 days in vitro form the 
characteristic sp h ere  morphology, at around 200pm  in diameter. 
A ggregates from rat tissue averaged  around 340pm  in diameter. Shown 
a t (A) 5x (B) 30x and (C) 20x magnifications.
109
I ’.1 $  * *■’- ' 'Mir- j M ' ' 1'. .
y f  JSm
R t f  - *
■ S . , .  r r
■B 'H  J mJ I
Figure 3-2 - Im m unofluorescent labelling and confocal microscopical analysis of agg regates 
highlighting morphology and cellular arrangem ent.
(A) The interm ediate layer of axonal p ro cesses  interspersed with oligodendrocyte cell bodies. 
Neurofilament (axons - green) and carbonic anhydrase (oligodendrocyte cell bodies - red); 
magnification x30;
(B) - The sam e interm ediate axonal layer, with the outer astrocytic shell. Neurofilament (axons - 
green) and glial fibrillary acid protein (astrocytes - red); magnification x30;
(C) - Axonal p ro cesses  and myelin in an  aggregate  are  indicated by yellow double staining. 
Neurofilament (axons - green) and myelin basic protein (myelin - red); magnification x40
(D) - Neuronal nuclei. Hu (neuronal cell bodies - green); magnification x30.
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Figure 3-3: G eneral 3-D cellular organisation of an  aggregate. A shell 
comprising mostly astrocytes surrounds an  interm ediate layer containing 
myelinated axons and  oligodendrocytes cell bodies. The aggregate  core 
com prises mostly neuronal cell bodies.
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Figure 3-4: Confocal staining of NG2 (top) and 0 4  (bottom), m arkers for early and late oligodendrocyte progenitors respectively, over developm ent of the 
agg regates from wildtype anim als. NG2-positive cells ap p ear first, with 04-positive cells being less abundant in the first instance. Both su b se ts  persist to DIV 21.
Figure 3.5: Confocal microscopy of early oligodendrocyte cell m arkers confirms the p resence of 
oligodendrocyte progenitor and precursor cells in the agg regate  cell culture. All progenitor 
subtypes ap p ear to persist in lower num bers throughout the cell culture period, but are  most 
abundan t in the first 14 days in w'fro.
Dual or triple staining indicates subtypes of progenitor cell, a s  described below and indicated 
by num bered arrows Red - NG2; G reen - 0 4 : Blue - PDGF«-R.
1 - Purple: early (perinatal) oligodendrocyte progenitor
2 - White: late oligodendrocyte progenitor
3 - Yellow: Premyelinating oligodendrocyte
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Primary (capture) antibodies in MBP ELISA
B ackground
Clone 12 (MAB 386 Chem icon) 
C lone 22 (MCA 686 Serotec) 
Clone 14 (MCA 408 Sero tec)
1.3-
1.2 -
1.0 -
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Figure 3.6: Com paring th ree  m onoclonal cand ida te  an tibodies for an tigen  cap tu re  
in an  MBP ELISA. P la tes w ere coa ted  with capture antibody at a  diulution of 1:1000 
and  exposed  to differing concentrations of MBP. D etect and  report an tibod ies w ere 
also  applied a t 1:1000 prior to chrom ogenic su b stra te  reaction to determ ine the 
m ost sensitive coat antibody with the lowest background reactivity at th e se  
concentrations. C lone 12 w as u sed  in su b seq u en t ELISAs, a s  it yielded a  high 
level of sensitivity without proportionally-increased background.
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Coat Ab concentration
Background 
with 250ng/ml MBP1.25
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Dilution of coat antibody (1 in x)
D etect Ab concentration2 .00-1
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Dilution of detection antibody (1 in x)
R ep o rte r Ab Concentration2 .00-1
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Dilution of reporter antibody (1 in x)
Figure 3.7: Optimisation of antibody dilutions for the MBP ELISA.
ELISA antibodies w ere applied at varying dilutions (1:4000 to 
1:31) and tes ted  for optimum sensitivity with minimal background.
All o ther an tibodies w ere applied at 1:1000, and  the antigen,
purified hum an MBP, w as used  a t 250ng/ml. In all ca se s ,
antibodies w ere found to be optimally sensitve  a t a  dilution of
1:1000 115
Comparison of 3 chrom ogenic substrates
OPD
TMB3.0-
ABTS
2.5-
00
2.0 -
Q.o
1.0 -
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0.0
100 100010
Myelin basic protein (ng/mg total protein)
Figure 3 .8a - 3 colour-producing peroxidase reactive su b s tra te s  w ere 
tested  for suitability and  sensitivity in the ELISA. A standard  test ELISA 
w as used , with an tibodies a t 1:1000, and  varied concentrations of 
antigen (purified hum an MBP). T h ese  chem icals vary in the intensity 
of colour p roduced  over a five m inute period. TMB w as found to be  
the m ost suitable, producing a wide-ranging near-stra ight curve which 
did not sa tu ra te  quickly.
Comparison of blocking agents1.50-,
Histones1.25-
> >  1.00-
^  0.75-
Q.
°  0.50-
0.25-
0.00
100010 100
Myelin basic protein (ng/mg total protein)
Figure 3.8b - Bovine serum  album in and  h istones w ere com pared  for 
blocking of non-specific binding over a range of MBP dilutions. T he 
standard  te s t ELISA w as used , with antibodies a t 1:1000. S tandard  curves 
w ere similar, and  BSA w as ch o sen  a s  the blocking protein due to 
availability and low cost.
Test of ELISA components for cross-reactivity
1.75-1
1.50-
1.25-
V)c 0 TJ
.8  0.75-
Q.
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1.00 -
0.25-
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Figure 3 .9a - R eagen t cross reactivity may produce false-positive resu lts in ELISA. 
C ross reactivity betw een ELISA antibodies w as tes ted  by omitting a com ponen t ea ch  
time. For exam ple, to te s t for cross-reactivity betw een the coa t and  d e tec t 
antibodies, no antigen w as applied. The a s sa y  w as then  run a s  norm al an d  optical 
density  produced w as com pared with background. None of the com ponen ts  w ere 
found to be c ro ss  reactive.
Comparison: Radioimmunoassay and ELISA for m easures 
of myelin basic protein
] ELISA 
I RIA
14 21 28 35
Time (Days in vitro)
Figure 3.9b - Aliquots from a group of sam ples w ere m easu red  with both 
the ELISA and R adioim m unoassay1 techn iques to te s t for in ter-assay  
reproducibility. MBP values obtained w ere not significantly different 
betw een  the two techniques indicating that the ELISA provides a reliable 
quantification of MBP. The ELISA results also have sm aller errors. 
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Comparison: Three standard curves for myelin basic protein
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Figure 3.10 - T hree a s s a y s  w ere perform ed at different tim es to te s t the 
reproducibility of the MBP ELISA. S tandard  curves (MBP concentrations of 
3 .5 to 1000 ng/ml) w ere not found to be significantly different betw een 
tests. Even so, internal control sam ples w ere u sed  in future a s s a y s  which 
used  m ore than o n e  plate, to en su re  interplate comparability.
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using the ELISA, and no significant differences were found. Finally, three separate 
standard curves were run to test inter-assay reproducibility. All three experiments were 
performed using the same methodology but on different days, and as can be seen in 
Figure 3-10, they produced highly comparable standard curves, verifying 
reproducibility between assays.
3.2.3. Quantification of myelination and neurofilament accumulation
The ELISA for MBP was used, along with another in-house ELISA for NF (Petzold et 
al., 2003) to characterise the development of mouse aggregates in terms of myelin 
accumulation and neuronal process growth. The C57BL/6 mouse strain is an inbred 
strain commonly used as the background in genetically modified mouse lineages. The 
use of inbred animals limits the biological variation that can occur in outbred 
populations. Initially, aggregates from BK1 and C57BL/6 animals were evaluated for 
MBP and NF content over the time-course of the culture. It was found that, while there 
were no significant differences in NF accumulation (Figure 3-11), the BK1 mice had 
significantly lower MBP levels at each time point. Following this, the C57BL/6 and 
ABH inbred strains were compared. ABH mice were found to accumulate significantly 
higher levels of myelin and NF in vitro (Figure 3-12), and were used in all subsequent 
experiments. With the intention of examining knockout mouse models for myelination 
and neuronal development, experiments were carried out to optimise the foetal 
dissection age. Pups were taken at embryonic day 16 and 18 (El6 and E l8), at postnatal 
day 0 (shortly following parturition; P0), PI and P2. As can be seen in Figure 3-13, 
MBP levels rose steadily in aggregates from E16 and E18 pups, with each expressing 
similar levels. Aggregates from pups dissected at P0 had high initial levels of myelin, 
which fell over the culture period. Foetal brain tissue dissected at postnatal
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Myelination in aggregates from BK1 and C57BL/6 mouse strains
*★*
14 21 28 35 42
Time (Days in Vitro)
Neurofilam ent accum ulation in a g g re g a te s  from  BK1 and 
C57BL/6 m o u se  strains
Time (Days in Vitro)
Figure 3-11: Myelination (A) and Neurofilament accum ulation (B) w as 
m easured  in ag g reg ates  from BK1 and C57BL/6 mice by ELISA for myelin 
basic protein and neurofilam ent H respectively. A higher d eg ree  of 
myelination w as observed  in the C57BL/6 strain, although neurofilam ent 
levels differed less. Outbred BK1 m ice w ere ch o sen  due to their high litter 
production, and inbred C57BL/6 mice are  the background strain from 
which m any g ene knockout anim als are eng ineered . Error bars rep resen t 
SEM, and significances w ere evaluate by one-w ay ANOVA.
* - P <0.05  * * *  - p<0.001
Myelination in C57BL/6 and ABH mice
] C57BL6 
I ABH
14 21 28 35 42
Time (d ay s in vitro)
N eurofilam ent accum ulation  in C57BL/6 an d  ABH m ice
B
Tim e (d ay s in vitro)
Figure 3-12: Myelination (A) and Neurofilam ent accum ulation (B) in 
ag g reg a tes  from the C57BL/6 and ABH m ouse strains a s  
m easured  by ELISA for myelin basic protein and neurofilam ent H 
respectively. ABH mice accum ulate more myelin and neurofilam ent 
over the culture period than C57BL/6 m ice so  ABH mice w ere used 
in su b seq u en t experim ents. Each strain is inbred, with an  inherent 
lack of genetic variation betw een anim als. C57BL/6 is com m only 
used a s  a background strain in genetically modified anim al 
lineages, w hereas a w ell-characterised form of crEAE can be 
induced in the ABH mice.
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Myelination in tissue taken from differing foetal a g es  
of ABH anim als
A MBP d Z D  D issected at E16
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x
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D issected at PO
35
Neurofilament accumulation in tissue taken from differing 
foetal a g es  of ABH animals
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Figure 3-13: Myelination (A) and Neurofilam ent accum ulation (B) in 
ag g reg a tes  from ABH m ouse tissue d issec ted  at varying foetal a g e s  
a s  m easured  by ELISA for myelin basic protein and neurofilam ent H 
respectively. T issue from pups taken a t E16-E18 (1-3 days prior to 
birth) m yelinate and accum ulate neurofilam ent effectively; tissu e  from 
new born pups (PO) lose both m arkers over the culture period.
E16-18 pups w ere used for all su b seq u en t culture experim ents.
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Myelination in 3 separate cultures using tissue from ABH animals
B 17-i
—  16 c 
1
o 15 
CL
3O 14-
05
- i  1305
3.
c05
E3w=
2o05
12 -
1 1 -
10 -
9-
21 28  
Time (Days in Vitro)
N eurofilam ent accum ulation  in 3 s e p a ra te  ex p e rim en ts  
using tissu e  from  ABH an im als
NF
I
14 21
Time (Days in vitro)
Figure 3-14: Myelination (A) and Neurofilament accum ulation (B) w as 
m easu red  in ag g reg a tes  from three sep a ra te  ABH m ouse cultures by 
ELISA for myelin basic protein and neurofilam ent H respectively. No 
significant d ifferences w ere found, indicating that the culture 
preparation technique w as reproducible, and that cultures developed  
on a similar time frame. 123
day 1 or 2 did not form viable aggregates, with cells adhering to the wall of the flask. 
NF levels in aggregates from tissue dissected at E16 accumulated quickly, with a 
sustained peak from DIV 35 persisting until the end of the culture period (DIV 42). El 8 
mice formed aggregates which accumulated NF more slowly, with a lower but 
acceptable peak level. Aggregates from tissue dissected at PO had high NF levels at DIV 
14, which fell rapidly thereafter, in tandem with MBP levels. It was decided that mice 
of ages El 6, El 7 and El 8 would be used for future culture experiments to maximise the 
tissue yield from one set of time-matings.
Finally, reproducibility of the levels of myelination and NF accumulation in 
vitro was examined in three successive cultures using tissue from ABH mice. As can be 
seen if Figure 3-14, it was found that levels of both MBP and NF were similar in all 
three experiments.
3.3. Discussion
The morphology of aggregates from mouse telencephalon tissue was similar in 
arrangement to aggregates from rat tissue, suggesting that cell-cell recognition, 
interaction, migration and differentiation patterns observed in rat aggregates are 
conserved in mouse (Trapp et al.t 1979). The predominantly astrocytic shell surrounds a 
layer made up mostly of myelinated neuronal processes which could be likened to the 
interposition of astrocytes between blood vessels and axons in vivo. However, 
astrocytes are also found dispersed throughout the aggregate, providing support, both 
‘passively* in nutrient provision, debris phagocytosis and chemical/ionic buffering, and 
‘active’ in neuronal survival and possibly synapse formation. The astrocytic layer may 
also play a more mechanically protective role to the fragile processes within, as 
aggregate collision with other aggregates is inevitable. Neuronal cell bodies are
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concentrated in the centre of the aggregate in a position least vulnerable to chemical or 
mechanical damage. Astrocytes have been found radiating inwards from the shell, 
providing support for the neuronal cells bodies at the centre (personal communication, 
L.Diemel). Retrograde axonal transport may be responsible for some nutrient provision 
to the soma. The temporal pattern of myelination in mouse aggregates is similar to that 
of rat aggregates, which in turn has been likened to myelination in vivo (Kruger et a l, 
1999; Matthieu et al., 1978), confirming the mouse aggregate system as being a relevant 
model for studying developmental myelination. A reduction in myelin levels observed 
after around 30 DIV in the first rat aggregate experiments (Matthieu et a l, 1978) was 
not mirrored in this system, or in preceding experiments with rat tissue (Copelman et 
a l, 2001; Kruger et a l, 1999; Loughlin et a l, 1997), making it possible to carry out 
valid experiments with culture periods of six weeks. This improved longevity of culture 
may be influenced by a reduction in the time period between termination of the mother 
and getting cells into culture, meaning that more viable cells were seeded. By confocal 
microscopy, oligodendrocyte progenitors follow a similar developmental pattern to 
those in rat aggregates (Diemel et al 2003). Markers for NG2 and PDGF-a receptor 
appearing early on in the culture period, followed by 04, galactocerebrocide and MBP- 
positive cells as maturation and differentiation take place. Oligodendrocyte progenitor 
cell markers persist throughout the culture period. This provides a potential pool of 
replacement oligodendrocytes following demyelinative insult (Nait-Oumesmar et a l, 
1999). As these progenitors are situated in the intermediate aggregate layer alongside 
neuronal processes, and in direct proximity to both astrocytes and neuronal cell bodies, 
they have access to chemical cues from these cells which may control development or 
differentiation.
MBP and NF levels appeared to be lower in the initial cultures from BK1 out- 
bred animals, increasing in the C57BL/6 inbred mice and highest in ABH inbred 
animals. This could be attributed to inter-species variation. It also could be due to 
improvement in dissection techniques over the first months of culture work. The amount 
of time it took to seed one culture, from termination of the mother to seeding, was 
reduced dramatically by the time ABH mice were being used. However, culture MBP 
and NF levels were found to be highly reproducible in ABH cultures, suggesting that an 
optimum dissection technique and time had been reached by this point. Despite 
aggregates from mouse tissue being smaller than their rat counterparts, MBP levels are 
comparable between the two, suggesting that there are similar numbers of smaller 
myelinated fibres in the mouse culture, as opposed to less myelinated processes. The 
size of a comparable neuron and its dendritic arbour is greater in rat than in mouse 
(Purves & Lichtman, 1985), supporting this hypothesis. The age of foetal dissection is a 
crucial variable controlling effective aggregate formation and development. For 
example, myelination in cultures using postnatal tissue fell over the culture period as 
aggregates shrank and disintegrated. This is likely to be due to changes which occur at 
birth, as foetal pups taken the day before birth form viable aggregates. Birth may be a 
trigger for large-scale differentiation of oligodendrocytes and myelination; 
differentiated cells may not be as well equipped as progenitors for survival after 
mechanical dissociation. Differentiation may also elicit changes in cell-cell recognition 
or interaction, so that cells form weaker bonds and therefore non-viable aggregates. NF 
levels in cultures from E16 mice are markedly higher than those in cultures from E l8 
mice, despite the fact that they have very similar levels of MBP. Again, it is possible 
that a higher proportion of undifferentiated neural precursors in the E l6 animals at
dissection may confer survival, and thus higher NF accumulation, with dissociation 
causing death of differentiated neurons. The same MBP levels indicate that there are 
more unmyelinated axon-like processes in cultures from E16 animals, or that MBP is 
present in a form not associated with myelin at higher levels in E16 cultures.
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4. Evidence for cannabinoid mediated 
neuroprotection in vivo
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4.1. Introduction
EAE is an inflammatoiy demyelinating disease of the CNS inducible in a variety 
of species. CREAE in the ABH mouse has been found to be a representative model of 
multiple sclerosis (Baker et al., 1990). Animals have a relapsing-remitting time-course 
of paralysis, with worsening residual functional deficit over the course of the disease. 
The events of blood brain barrier dysfunction, cellular infiltration demyelination and 
axonal loss are similar to that occurring in multiple sclerosis and are most evident in the 
spinal cord. This means that a few strategic lesions can cause a relatively high 
functional deficit, enabling accurate disease scoring using a scale of well-defined 
clinical signs in addition to stereotypical weight change fluctuations. The CBjR-KO 
mouse, originally on the EAE-resistant CD1 mouse background (Ledent et al., 1999) 
was bred on to the ABH background by back-crossing to enable induction of CREAE 
and study the role of the cannabinoid system in this model (Brooks et a l , 2002). For 
these studies, spinal cords were removed from adult CBiR-KO and ABH wildtype mice 
either during the acute attack, first, second, third or fourth remission for assessment of 
the accumulation of axonal dysfunction. The CBjR-KO mouse accumulates 
neurological deficits that rapidly reach unacceptable severity limits following the first 
relapse of disease where there is chronic paralysis, so data for the second, third and 
fourth remissions is confined to wildtype animals. Spinal cord tissue was homogenised 
and tested for MBP, NFHSMI35 and NFHSMI32. SMI-35 and -32 are monoclonal 
antibodies against phosphorylated and dephosphorylated NF respectively (Stemberger 
& Stemberger, 1983). Phosphorylated NFs are stable in the developed neuron, with 
dephosphorylated NF representing a damaged subset of NFs, compromising the 
cytoskeletal structure (Howland & Alii, 1986; Meller et a l , 1993; Trapp et a l, 1998).
As there is no standard against which to compare dephosphorylated NF, and as it 
represents a subset of NFHSM135, it is presented as a ratio over NFHSMD5. Finally, 
caspase 3 is investigated as a potential death effector mechanism of function loss in 
EAE (Ahmed et al., 2002). Total and cleaved (activated) caspase 3 were quantified by 
Western blotting and computer analysis.
4.2. Results
4.2.1. Clinical and pathological features of EAE in wildtype and 
CBjR knockout animals
The n-numbers used for statistical analyses in Section 4.2.1 were all 11 or 
above, except for remission 2 and 3 spinal cords, where the n=5 and 6, respectively. To 
confirm lack of the CBi receptor in knockout animals, PCR for reverse-transcribed 
CBiR mRNA was carried out As can be seen in Figure 4-1, there is no receptor 
expressed in the knockout mice, or in cultures derived from them. Lack of the receptor 
was also functionally tested using WIN55-212-2, a cannabinoid agonist (20mg/kg 
intraperitoneal injection in dimethyl sulphoxide:Cremophor:PBS (1:1:18)) and failed to 
induce significant catalepsy, visually assessed hypomotility or hypothermia. The 
relapsing-remitting disease course is associated with increasing functional deficit over a 
series of relapses in CREAE (Figure 4-2). These are associated with hind-limb 
paralysis, as illustrated photographically in Figure 4-3. It was found that, when initiating 
EAE in CBiR-KO mice, the disease onset and acute attack proceeded in a similar 
manner to the wildtype, with a peak clinical score of around 4. Following this however, 
the almost-complete recovery associated with the disease in wildtype animals did not 
usually occur. Instead, a residual deficit represented by a score of around 2.5 was 
observed in the first remission period (Figure 4-4). Following the second attack,
knockout animals exhibited chronic limb paralysis that reached unacceptable severity 
limits and demanded euthanasia. In an open-field activity monitor, motor function 
impairment can be quantified by measuring the distance an animal travels in a given 
amount of time. In wildtype animals, movement is reduced with each successive disease 
state (Figure 4-5). A more severe deficit was observed in knockout animals, with deficit 
following the first attack being equivalent to that following four paralytic attacks in the 
wildtype mouse. Immunostaining for MBP in the spinal cord shows progressive loss 
over the course of the disease (Figure 4-6). Accompanying immunostaining for NF 
shows a marked lack of neuronal somata and processes, indicating that NF loss and 
demyelination are parallel processes.
4.2.2. Demyelination and loss of neurofilament in EAE
Myelin levels as quantified by ELISA for MBP showed a trend towards 
demyelination over the course of the disease (Figure 4-7). In wildtypes, there was no 
significant (p<0.01) difference between control, acute attack and 1st remission animals, 
but a trend was evident signifying demyelination. By the third remission, a highly 
significant (p<0.001) drop in MBP levels was observed, with no change in the MBP 
levels following that. Knockout animals did not have significantly different MBP levels 
at any disease stage, but again there was a trend towards demyelination at each point. 
NF levels, as quantified by ELISA, also showed reduction over the disease period. In 
wildtype mice, the trend was towards loss of NF over the disease course, culminating in 
a highly significant loss in fourth remission animals. Samples from remission 2 and 3 
agreed with this trend, but errors were larger in these samples. Knockout levels were
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A - Aggregate cell culture
CB1 R eceptor Knockout Wildtype
GAPDH
B - ABH m ice
W ildtype 1 Knockout 1 W ildtype 2 Knockout 2
GAPDH
Figure 4-1: PCR for cannabinoid receptor 1 gene (Cnr1) mRNA confirms that this 
receptor is not exp ressed  in knockout animals, but is p resen t in their wildtype 
counterparts. (A) T issue from the aggregate cell culture (B) Spinal cord tissue  from ABH 
mice. The lower panel in both (A) and (B) show s the mRNA expression of GAPDH, a 
housekeeping protein, to validate equal RNA loading onto the gel.
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Clinical course of d isease in CREAE in the Biozzi ABH mouse
5
Acute First 
Attack
Second Third 
Rem ission Rem ission Rem ission
Fourth
Rem ission
4
3
2
1
Wildtype
Knockout
0
0 10 20 30 50 60 7 0 8040 90
Days after immunisation
Figure 4.2 - G raph illustrating the clinical cou rse  of d ise a se  in biozzi ABH 
mice with chronic relapsing EAE. T he g reen  line rep resen ts  the course in 
a wildtype m ouse, the  red in a  CB1-R knockout m ouse. W ildtype mice 
have a  relapsing-rem itting d isea se  co u rse  with a  step-w ise increase  in 
functional deficit with each  rem ission. Spinal cords w ere taken  from mice 
without d is e a s e  (control), and  in the acute, first rem ission second , third 
and  fourth rem ission s tag e s  of d isea se  (fourth rem ission is clinically 
equivalen t to a  chronic d is e a se  state). Knockout m ice often survive until 
th e  first re lapse , from which they do not remit and  either die or a re  
term inated. Therefore, it is not possib le  to sam ple from knockout mice 
following the  first re lapse.
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Figure 4.3: Photographs of the s tag es  of d isea se  in CREAE in ABH mice. 
Following injection of 1mg of spinal cord hom ogenate in Freund’s adjuvant on day 
0 and 7, anim als developed a relapsing-remitting d isease  course. Each attack and 
relapse is characterised  by tail and hind limb paralysis, indicated by white arrows. 
This is not seen  in rem issions, but by remission 4, chronic paresis and hind limb 
paralysis has often becom e perm anent.
A - Normal, p re-d isease  control B - Paralysis in acute attack
C - Recovery in remission 1 D - Paralysis in re lapse  1
E and F - Perm anent paresis in remission 4
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1st remission clinical score deficit in CB knockout mice
4.5-,
ABH Wildtype 
CB1R Knockout
4.0-
3.5-
3.0-
2.5-
2 .0 -
1.5-
1. 0 -
0.5-
0.0
10.0 12.5 15.0 17.5 20.0 22.5 25.0 27.5 30.0 32.5 35.0
Time after immunisation (days)
Figure 4.4: Increased  clinical score deficit is observed  following the acu te  
CREAE attack in knockout mice com pared with wildtypes. Following injection of 
1mg of spinal cord hom ogenate  in F reund’s adjuvant on day 0 and 7, anim als 
developed  a relapsing-rem itting d ise a se  cou rse .T he  co u rse  of clincal d isea se  
a s  a s s e s s e d  by scoring differs betw een wildtype and  knockout anim als over the 
first re lapse. Knockout anim als accum ulate  more clinical deficit after the  first 
acu te  attack.
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CE^R KO mice rapidly accumulate immobility during CREAE 
demonstrated in an open-field activity cham ber
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Remission 1 Remission 4 Control Remission 1Control
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Figure 4.5: Motility deficit in crEAE increases with w orsening d ise a se  condition. 
This is illustrated using an open-field activity cham ber, w here the d istance 
travelled by a m ouse in 5 m inutes is recorded. The d istan ce  travelled by 
wildtype mice is reduced in each  su cessiv e  d isea se  state , with each  symbol 
representing  m ovem ent in one individual animal. The deficit observed  in 
CB1R-KO anim als, however, w orsens more quickly. Fourth rem ission wildtype 
mice are  com parable with first remission knockout m ice in this test, illustrating 
the increased  functional deficit in CB1R-null anim als.
* - p<0.05; ** - p<0.0005; *** - p<0.00001
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No d is e a s e  R em ission  1 R em ission  4
Figure 4.6: Staining of decalcified wax sections for myelin (colour) and neurofilament (greyscale) illustrating progressive loss of each  
from the spinal cord over the course  of EAE. Luxol fast staining for myelin show s early degradation around peripheral regions a t 
remission 1 (B), and m arked loss by remission 4 (C). A similar pattern is observed with axonal p ro cesses  (D and E), a s  stained with the 
Bielschowsky silver stain method.
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Myelin basic protein expression in spinal cords from 
C B ^  KO and wildtype CREAE mice
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Figure 4.7: Significant dem yelination (A) and N eurofilam ent loss (B) in spinal cords 
from mice with cr-EAE over the tim ecourse of the d ise a se  a s  m easu red  by ELISA. 
Demyelination is not significantly different betw een wildtypes and knockouts, but 
loss of NfHSMI35 is increased  in CB1R KO mice, indicating that the CB1R is 
neuroprotective in the demyelinative sta te . * - p<0.05; ** - p<0.01; *** - p<0.001
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significantly lower at all disease stages than in their wildtype counterparts, and fell by 
around 33% by remission 1, compared to 20% drop in wildtypes over the same period.
4.2.3. Increase in the NFHSMB2:NFHSMI35 ratio in EAE
SMI-32 reactive NF is considered to be damaged or compromised due to 
dephosphorylation, and can be measured by ELISA. In wildtype animals, it was found 
that levels of NFHSMI32 normalised over total protein increased from control in the acute 
phase, and then fell to near baseline levels during remission 1, remaining so into 
remission 2 (Figure 4-8). Levels increased in subsequent remissions so that by the 
fourth remission, levels were 8 times that of control. In control CBiR KO mice, prior to 
disease induction, NFHSMD2 levels were elevated over wildtype controls. Levels 
increased proportionally to wildtypes in the acute phase and fell in remission. When 
NFHSMI32 was presented as a ratio to NFHSML}5, these trends held true, but the 
differences between wildtype and knockout animals were accentuated.
4.2.4. Differentially Increased Caspase 3 levels in wildtype and CBjR- 
KO animals with EAE
Analysis of caspase 3 by Western blotting allowed quantification of the total and 
active isoforms of the protein, by virtue of the polyclonal antibody used (Figure 4-9). 
Total caspase 3 expression, normalised over actin expression, was at negligible levels in 
control wildtype animals (Figure 4-10). During the acute attack, these levels rose 
sharply to as much as 45 times the control level, and fell slightly to around 30 times 
control in remission 1. Levels rose again in remission 4 to around those observed in the 
acute attack. Total caspase 3 levels in knockout control animals were similar to those in 
wildtype controls. The levels rose in the acute phase, but remained significantly lower 
than their wildtype counterparts. In the first remission, levels of total caspase did not
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Figure 4.8:(A) - NfHSMI'32 in spinal cord from CREAE anim als a s  
m easured  by ELISA. E xpressed  a s  a  proportion of total protein. (B) - 
Levels of NfHSMI' 35 ex p ressed  a s  a proportion of total protein. (C) - Ratio 
of NfHSMI32 to NfHSMI35 levels. In wildtype anim als, a rise in the acu te  
phase , is followed by a drop in NfHSMI'32 in the first rem ission and 
su b seq u en t accum ulation. CB tR KO mice have a higher d eg ree  of
NfHSM'32 p rjor to d isea se  induction, and have higher levels in the two 
tested  d isea se  s tag es . * - p<0.05; ** - p<0.01; *** - p<0.001
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Figure 4.9 - R epresentative W estern blots showing c a sp a se  3 
expression in spinal cord hom ogenates from (A) knockout and 
(B) wildtype anim als in CREAE. Animals w ere term inated a t the relavent 
d isease  stag e  and the spinal cord hom ogenised for W estern blot analysis. 
Sam ples w ere also probed for actin to dem onstrate equal sam ple loading on 
the gel. Blots w ere quantified using com puter analysis, the result of which 
are shown in Figure 4.10.
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significantly change from those seen in the acute attack. Levels of active caspase 3 were 
measured by quantifying smaller cleaved caspase 3 moieties using western blotting and 
computer aided densitometry techniques. In wildtype animals, a similar pattern to total 
caspase 3 expression was seen. Very low levels in control animals increased 
dramatically in the acute phase of disease, falling in the first remission and rising again 
by the fourth remission. In contrast to total caspase 3, the active subunits occurred at 
significantly (p<0.05/0.01) higher levels in knockouts than in wildtype animals.
Expressions of the active caspase 3 measurements as a percentage of total 
caspase 3 clarifies the significant difference between the levels of active caspase 3 in 
wildtype and knockout animals, being higher in knockout animals at each disease point.
4.3. Discussion
Neuronal damage in autoimmune disease is likely to be caused through a variety 
of mechanisms and pathways, via glutamate toxicity (Pitt et al., 2000; Smith et al., 
2000b), oxidative damage (Liu et al., 2003) and cytokines, including TNF-a (Kollias & 
Kontoyiannis, 2002) and IL1 (Huitinga et al., 2000). Evidence has been presented 
which shows that CBiR knockout mice have a more severe disease course in EAE. 
Following an initial acute paralysis phase, recovery does not occur as effectively as it 
does in their wildtype counterparts and CBjR knockout mice show increased movement 
deficit. Histology and quantification of nerve proteins show loss of neurofilament and 
myelin basic protein from immunostained spinal cord sections and accelerated 
emergence of transacted axons and axonal end-bulbs associated with pathology. These 
findings may indicate that the CBi receptor confers neuroprotective properties in the 
mouse CNS.
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Quantitative measures of NF content in the spinal cord shows that NF levels are 
reduced in the CBiR knockout mouse prior to disease induction. Although this could 
represent slow, underlying neurodegeneration in these mice this may also reflect brain 
and CNS modelling events during development. This suggests that the cannabinoid 
system may play an important role in developmental neural plasticity. Cannabinoid 
receptors appear early in foetal mouse development, and at atypical locations compared 
to postnatal distribution (Femandez-Ruiz et al., 1999). They are found on neurite 
growth cones, influencing migration and motility (Zhou & Song, 2001), and have been 
shown to modulate synapse formation in vitro (Kim & Thayer, 2001), as well as 
modulation of neurotransmitter production (Femandez-Ruiz et a l , 1999). Alternatively, 
endogenous cannabinoids could prevent inherent neurodegeneration that occurs during 
brain modelling during development. Although recent studies have reported that 
cannabinoids can induce apoptosis in vitro, (Galve-Roperh et al., 2000; Sarker et al., 
2000) these studies were conducted with high doses of synthetic cannabinoid 
compounds, producing a pharmacokinetic environment that may be different from the 
developing brain. Galve-Roperh et al (2000) reported apoptosis induction by 
cannabinoid compounds in tumourous tissue, but with ‘no significant neurotoxic 
effects’. One study reported protection via CBi against vanilloid-receptor mediated 
apoptosis (Maccarrone et al., 2000). The diversity of the results produced in such 
studies may be a consequence of the numerous intracellular signalling pathways by 
which cannabinoid compounds act, and the developmental stage of the cell on which 
they are acting. This complexity, coupled with the limitations of cell culture techniques, 
may partly explain the published differences between in vitro studies and the findings 
stated here.
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It is evident that the inflammatory insult in wildtype mice causes accumulating 
axonal pathology. This has recently been demonstrated in another mouse strain (SWXJ 
(H-2q,s), where the histological axon content inversely correlated with the number of 
relapses (Wujek et a l, 2002). Counting of axons indicated that 10-20% of nerve loss 
was clinically silent, residual paresis was evident with >30% axonal loss. Chronic 
paralysis in MS was associated with a loss of 68% of axons (Bjartmar et al., 2000). The 
results of this study using the quantitative ELISA technique show close parallels with 
histological counting of axons in sections. Whilst lesions can occur along the entire 
neuraxis (Baker et al., 1990), there may be regional variations as shown by differences 
in cervical and lumbar cord axonal loss in CREAE (Wujek et a l, 2002). Analysis of the 
whole cord will average this regional effect. The use of this ELISA is significantly 
faster than labour-intensive counting, and provides an estimate of axonal content in the 
whole cord.
Knockout mice lose more NF than wildtypes with each successive disease stage, 
indicating that inflammatory insult elicits a greater neuropathological effect on mice 
lacking the receptor. This demonstrates the neuroprotective effects of endogenous CBi 
receptor activation. CBiR agonism has been shown to protect against a range of insults 
in vivo and in vitro, including ischemia (Nagayama et a l, 1999), hypoxia (Sinor et a l, 
2000), excitotoxicity (Shen & Thayer, 1998) and oxidative damage (Marsicano et a l, 
2002). Indeed, the latter two have been implicated in EAE pathology (Espejo et al., 
2002; Pitt et a l, 2000), and can occur as a result of microglial activation. Excesses of 
glutamate and TNF-a are directly toxic to neurons and oligodendrocytes and can also 
lead to production of reactive oxygen and nitrogen species. Whether the excitotoxic 
effects of glutamate or the oxidative stress caused by reactive species is the primary
pathological agent is as yet unknown. It is interesting to note that the increased damage 
to neurons in knockout mice does not appear to be due to primary demyelination, as 
MBP loss is not significantly different between knockouts and wildtypes. This indicates 
that the degree of neuronal loss is not necessarily dependent on the degree of 
demyelination in EAE.
The vulnerability of a neuron to damage can be assessed by the ratio of 
dephosphorylated NF to phosphorylated NF, as measured by the SMI-32 and SMI-35 
antibodies, respectively (Petzold et a l, 2003). The SMI32:35 ratio is increased in acute 
phase EAE in wildtype animals, and then falls in remission. This indicates a transient 
dephosphorylation during the active disease stage, making the neuron unstable and 
vulnerable to degradation. The effect is reversed in the first remission, in a pattern 
mirroring that of inflammatory-cell infiltration into the CNS. Accumulation of 
dephosphorylated NF occurs over subsequent remissions, with levels being high by 
remission four, indicating a high number of vulnerable or damaged neurons. The 
possibility of dephosphorylation being linked to infiltrating cellular entities is illustrated 
by the ability of macrophages and microglia to produce kinases and related molecules. 
Alternatively, infiltrating leucocytes may stimulate resident CNS cells to produce these 
molecules. In CBjR knockout animals, the SMI32:35 ratio follows the same pattern as 
the wildtypes, but levels are higher after disease development This indicates that, while 
dephosphorylated NF is not a physiological feature of the knockout mouse, lack of the 
receptor may confer greater vulnerability of axonal processes in the pathological state. 
This, however, is dependant on the notion of dephosphorylated neurofilament as a 
marker of axonal injury. As can be seen from the model of NF phosphorylation in 
Figure 4-11 (after (Grant & Pant, 2000)) changes in calcium influx, growth factor
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Figure 4.11: MAP Kinase (ERK1/2) c a scad e  hypothesis of neurofilament protein 
phosphorylation. Activation of CE^R can potentially lead to effects on growth factor 
receptors, calcium channels and s tress  factors, all of which may m odulate neurofilament 
phosphorylation through the protein kinase pathw ays indicated. After Grand and Pant, 2000 
(Journal of Neurocytology 29. 843-872)
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receptor activation and stress factors could all contribute to NF phosphorylation by 
various intracellular pathways. CBiR activation has been shown to modulate these 
processes (Takahashi & Linden, 2000; Williams et al., 2003), and is therefore a 
candidate molecule for regulating NF stability. This also provides a mechanism 
whereby cannabinoid receptor activation protects neurons against dephosphorylation, 
and therefore vulnerability. Alternatively, phosphorylation of NF is associated with 
stabilising the molecule in CNS development, and there is evidence to suggest that in 
neuronal repair, a similar situation is encountered (Hall & Yao, 2000). Rebuilding or 
appending to NFs would require the transport of further NF polymers from the soma, 
increasing the level of non-phosphorylated NF epitopes. So, in addition to being a 
marker of damage, antibodies to non-phosphorylated NF epitopes may indicate repair.
Caspase 3 is a ubiquitous cell-death effector molecule, responsible at least in 
part for apoptotic cell death. In wildtype mice, levels of both total and active caspase 3 
rose during disease, indicating that apoptotic cell death is a factor in EAE. Increased 
total caspase 3, the benign precursor isoform, indicates that expression is upregulated. 
Increased active caspase 3 indicates an increase in the rate of processing of precursor to 
active caspase 3. It is possible, however, that the caspase increases observed are a result 
of glial, as well as of neuronal, cell death. This could be due to death receptor-activated 
processing of upstream caspases, indicating an upregulation of other caspase molecules. 
Alternatively, more active caspase 3 could be due to a higher incidence of mitochondrial 
membrane breach related to Bel-family member activity, contributing to higher levels of 
apoptosomal activity via cytochrome c incorporation. Thirdly, inhibition or down- 
regulation of the inhibitor of apoptosis molecules (LAPs), possibly due to the release of
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smac/DIABOLO from compromised mitochondria, may contribute to this effect 
(Gottlieb, 2000).
Wildtype mice have higher levels of total caspase 3 than knockout mice, but 
have lower levels of active caspase 3. This finding could simply reflect the fact that 
more of the pool of total caspase 3 is being cleaved in the knockout animals, leaving 
less total and producing more active caspase 3. It is possible that endogenous activation 
of the CBiR inhibits apoptosis. In vitro studies on cortical neurons show that CBiR 
agonists can elicit the opposite effect, and induce apoptosis (Campbell, 2001). However, 
as mentioned previously in this chapter, high doses of synthetic cannabinoid agonists 
were used in these experiments that may not accurately reflect the in vivo physiology, 
and are used in a context that may be very different from the post-mitotic neural 
environment of the adult CNS.
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5. Evidence for cannabinoid mediated 
neuroprotection in vitro
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5.1. Introduction
The aggregate cell culture system, a 3D multiceliular system representative of 
the CNS physiology, has been used in numerous studies investigating demyelination 
and remyelination in vitro (Copelman et a l , 2000; Honegger & Matthieu,1990). 
Aggregates develop axon-like processes with which myelin associates, synaptic 
contacts and the full repetoir of CNS cell types, organised in a 3D fashion mimicking 
the brain. The system allows for complex treatment regimens and repeated sampling. A 
flask with 4xl04 cells can be maintained in rotational culture for 21 days and split 
immediately prior to treatment, giving rise to two identical cultures that can be 
differentially treated. This increases the ‘n’ numbers for statistical analyses providing 
more reliable results with more robust internal controls.
The three-dimensional morphology of the aggregates allows studies on the 
myelin sheath and neuronal processes to be carried out. Several demyelinative agents 
have been used in conjunction with the aggregate cell culture, including complement- 
dependent and -independent antibodies and the cytokines IFN-y and TNF-a (Kruger et 
al., 1999). Addition of an agent to the culture medium elicits demyelinative effects, 
without the need for additional manipulation. The agent can be easily removed by 
replacing the culture medium several times after the required demyelinative period. Use 
of a single cytokine has advantages over the use of demyelination-inducing antibodies 
which typically require complement activation, as it requires less control cultures.
For these studies, IFN-y was used as the demyelinative agent, as it was found to
be more effective in bringing about demyelination than TNF-a, and at lower
concentrations. IFN-y levels are elevated in the CNS during EAE (Begolka et al., 1998),
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and the cytokine has been used effectively in previous studies of demyelination using 
this cell culture system.
5.2. Results 
5.2.1. Development of aggregates from knockout tissue
N-numbers used for statistical analysis in Section 5.2 were at least n=18 flasks. 
Aggregates set up using telencephalon tissue from CBiR knockout mice do not appear 
to differ morphologically over the normal time course of in vitro development than their 
wildtype counterparts. There is no discemable difference between the 04  and NG-2 
markers for early oligodendrocyte progenitors (Figures 5-1 and 5-2). Staining for the 
CBi receptor shows restricted co-localisation with NF, while as expected in knockout 
cultures, only background staining was evident (Figure 5-3). When measured by 
ELISA, there were no significant differences in NF levels between wildtype cultures 
and cultures from heterozygous and homozygous knockout animals (Figure 5-4). MBP 
levels were also consistent, until DIV 42, by which point homozygous knockout 
cultures appear to have accumulated more myelin. These results show that, in vitro, the 
CBi receptor has few significant effects on normal myelination and NF production.
5.2.2. Demyelination in aggregates from knockout cultures
In order to mimic demyelination in vitro, a subgroup of flasks was supplemented
with IFN-y for four days from DIV 21 to DIV 25. During this time, the cytokine caused 
significant (pO.OOl) loss of myelin basic protein in the aggregates. This loss was found 
to induce differentiation of some oligodendrocyte progenitors into pre-myelinating 
oligodendrocytes, as shown by dual staining for GalC and incorporated BrdU (Figure 5- 
5). The number of double labelled cells in both wildtype and knockout cultures
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appeared to increase following IFN-y treatment, and persist to DIV 42. Figure 5-6 
shows the development of myelinated fibres over the first 21 days in vitro, and the 
effects of demyelination at 25 days. Yellow double staining for myelinated fibres is 
much reduced in culture from wildtype and knockout animals treated with IFN-y. After 
a period of recovery, double staining had reappeared, albeit not to the same degree seen 
in control cultures. When measured by ELISA, developmental MBP levels in untreated 
cultures were comparable between wildtype and knockout cultures at each time point 
(Figure. 5-7). Cultures from both wildtypes and knockouts that were treated with IFN-y 
lost a highly significant (p<0.001) amount of MBP directly following treatment before 
levels recovered to normal by DIV 42.
5.2.3. Loss of neurofilament in aggregates from knockout tissue
NF levels in untreated control cultures were not significantly different between 
wildtype and knockout controls. Interferon-y treatment had no effect on the NF levels in 
wildtype cultures. However, significantly reduced levels of NF were observed in 
cytokine-treated cultures from knockout animals. NF levels in all culture flasks returned 
to that of control by DIV 42.
5.2.4. Increased NFHSMI'32:NFHSMI’35 in aggregates from knockout 
tissue
NFsmi'32 was more evident in immunostaining (Figure 5-8) following 
demyelination, and persisted until DIV 42. When measured by ELISA and expressed as 
a ratio with SMI-35, NFSMI'32 did not change over the course of the culture period in 
control cultures. However, levels were higher initially in knockout cultures, and 
remained higher at each time point. In wildtype IFN-y treated cultures, NFSMI'32 levels
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* V*jd .
Figure 5-1: Confocal staining of 0 4  antigen, a  marker for oligodendrocyte progenitors and precursors, over developm ent 
of the aggregates. The top panel show s aggregates taken from CB,-R KO animals, the bottom panel wildtype. 0 4 -  
positive cells are  less abundant in the first instance, peaking at around DiV 14, and persisting to DiV 21.
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Figure 5-2: Confocal staining of NG2 proteoglycan, a m arker for early oligodendrocyte progenitors, over developm ent of the 
aggregates. The top panel show s agg reg ates taken from CBr R KO animals, the bottom panel wildtype. NG2-positive cells 
ap p ear to peak in density a t around day 14 in vitro, with a  low num ber of cells persisting to DiV 21 and further (data not shown).
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Figure 5-3: Confocal microscopy of NfH (green) and CE^R (red) in C B^R KO (upper 
panel) and wildtype (lower panel) cultures. Som e non-specific staining is observed in 
knockout aggregates, but the receptor can be seen  co-localised with neurofilament in 
wildtype aggregates.
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Myelination in aggregates using tissue from wildtype and CB1-R knockout animals
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Figure 5-4: Myelination (A) and neurofilam ent accum ulation (B) in 
ag g reg a tes  from wildtype ABH, hom ozygous C B ^  knockout ABH mice 
and heterozygous C B ^  knockout ABH mice p ro ceed s in a m anner akin 
to the in vivo situation, and at a com parable ra te /ex ten t to previously 
ch arac te rised  rat ag g reg a te  cultures, there is no significant difference 
betw een wildtype ABH, hetero- or hom ozygous knockout anim als.
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F ig u re  5-5: G a la c to c e re b ro c id e  (red ) a n d  in co rp o ra ted  BrdU (G reen ), ind icating  in c re a s e d  pro liferation  of o lig o d e n d ro c y te s  following 
d em y elin a tio n , w hich p e r s is ts  until th e  e n d  of th e  cu ltu re  period . T h e  BrdU p u lse  w a s  ap p lied  for 4  h o u rs  prior to  fixation a n d  
im m unolabelling .
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Figure 5-6: Confocal staining for myelin basic protein (red) and neurofilament (green) during developm ent of the aggregates. 
The top panel show s agg reg ates from CBr R KO animals, the bottom wildtypes. Demyelination w as induced using interferon 
gam m a on DiV 21-25.
sC
A Demyelination using IFN-y in cultures from wildtype andCB1-R knockout animals
^  5-5n
a5 5.0- 
o
ql 4.5-
ro
4 —»O
D)
E
4.0-
3.5-
3.0-
2.5-
2 . 0-
1.5-
1. 0-  c
sL 0.5-
a>
4—»O
i_
CL
o(0(U
_o
0 . 0-
Demyelinative treatment
DiV 21-25 M-------------------------- ►
MBP
1 I
s
i
1
*
1
1
1
1
21 25
Time (days in vitro)
42
B
Neurofilament levels in dem yelinated cultures from wildtype and 
CB1-R knockout anim als
1 6 1
3  15 o
3  14 o
O)
E
O)a
13-
X  12-
11 -
o
^  10 - 0)
NF
Demyelinative treatment 
DiV 21-25 
M-------------------------- ►
I
i
I
21 25
Time (days in vitro)
42
Figure 5-7: Cytokine-induced dem yelination (A) and  neurofilam ent loss 
(B) in the ag g reg a te  cell culture. Demyelination induced by an  acu te  
IFN-y insult significantly red u ces neurofilam ent levels in cultures from 
CB-, R KO anim als only. This indicates that the CB1R plays a
neuroprotective role in dem yelination. Levels of both MBP and NfH 
recover to that of controls by DIV 42.
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Figure 5-8: Confocal staining for MBP (green) and SMI-32 (red - a m arker of com prom ised dephosphorylated neurofilament), 
indicating an increase in SMI-32 reactivity following demyelination, which persists after recovery.
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Figure 5-9: Absolute levels of NfHSMI'32 ex p ressed  a s  a proportion of total
protein(A ). NfH
NfHSMI-32 to NfH
SMI-35
SMI-35
ex p ressed  a s  a proportion of total protein (B). Ratio of
(C) in foetal agg regate  cell cultures. NfHSMI32is
expressed  a s  a ratio with NfHSMI35 due to the lack of a reliable s tandard  for 
dephosphorylated  neurofilam ent. Ratio values from KO or WT controls do not 
ch an g e  significantly over the co u rse  of the culture. The ratio in ag g reg a tes  
from both WT and KO anim als in c reases  following dem yelination, with the 
larger increase  being evident in cultures from knockout anim als.
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Figure 5-10: Two representative W estern blots showing c a s p a s e  3 
expression in (A) wildtype and (B) knockout ag g reg a te  cultures over 
time. B ands at around 20kDa and below rep resen t active c a s p a s e  3.
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Figure 5-11: G raph of c a s p a s e  3 in ag g reg a te  cell cu ltures from (A) 
Wildtype and (B) CB1R-KO overtim e. In wildtype anim als (A), total c a sp a se  
3 is upregulated following dem yelination, but activation of the p ro c asp ase  to 
the proteolytic form rem ains at a constan t low level. In CB tR KO cultures
(B), both total and active c a sp a se  3 are  increased  following IFN-y treatm ent. 
This indicates that p re sen ce  of the CB tR dow nregulates c a s p a s e  activation 
but not expression .
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Figure 5-12: W estern Blots for C asp ase  3 comparing knockout and  wildtype aggregate  
cultures (n=3) a t (A) DiV 21; (B) DiV 25; (C) DiV 42. Active c a sp a se  3 is rep resen ted  by 
the bands at 20kDa and below.
165
C aspase 3 in tissue from knockout and wildtype 
animals in vitro - prior to cytokine treatment
I I Wildtype
total active
B
<D
E o 
-*—*(/)c0)Q
1500
1000-
Caspase 3 in tissue from knockout and wildtype 
animals in vitro following cytokine treatment
total active
Caspase 3 in tissue from knockout and wildtype 
animals in vitro following recovery
=E 500
Qj 200
Total Active
Figure 5-13: C om parison of active and total c a s p a s e  3 levels betw een  
knockout and wildtype cultures (A) prior to dem yelination, (B) following 
dem yelination and (C) following recovery. Total c a s p a s e  3 is not 
significantly different until the recovery ph ase , w here wildtype cultures 
retain a higher level. Active c a sp a se  3 is higher in knockout cultures 
following demyelination, and rem ains so  into the recovery ph ase .
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rose following treatment, and persisted until DIV 42. This pattern was replicated in 
knockout cultures, but cultures lacking the CBi receptor accumulated significantly more 
N F SMi'32 (Figure 5-9). Analysis of caspase 3 by Western blotting (Figure 5-10 and 5-11), 
showed that in the wildtype cultures, cytokine insult significantly increased levels of 
total caspase 3, which were still significantly elevated at DIV 42. Active caspase 3 was 
not significantly affected. Figure 10B shows a similar pattern in knockout animals, but 
with significantly increased levels of active caspase 3 at both post-treatment time points.
5.2.5. Caspase 3 in aggregates from knockout tissue
Comparing caspase 3 levels in wildtype and knockout cultures at each time point 
(Figures 5-12 and 5-13) shows that total caspase 3 did not differ significantly between 
culture types at DIV 21 or 25. Only at DIV 42 did levels rise to be significantly higher 
in wildtype mice. Conversely, active caspase 3 levels were comparable between 
wildtype and knockout at DIV 21, but significantly higher in knockout cultures between 
DIV 25 and 42 (p<0.001 on DIV 25; p<0.05 on DIV 42). This indicates higher total 
caspase 3 in wildtype cultures, but higher levels of the active molecule in knockout 
cultures.
5.3. Discussion
In cultures derived from CBjR knockout telencephalon, the emergence, persistence and
morphology of progenitors did not differ from that in wildtype culture, as assessed by
confocal microscopy. MBP, as quantified by ELISA, did not differ significantly
between culture types. Neither did NF levels differ between cultures from wildtype and
knockout animals, indicating that the CBi receptor does not play an inherent role in NF
construction, degradation or expression. Although this could be contradictory to
previous findings (see chapter 4), where NF levels were reduced in spinal cords from
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control knockout animals compared with control wildtypes. Spinal cords were taken 
from mice where disease had been induced at 6-8 weeks of age; these animals were 
terminated at anything up to remission 4, at around 16 weeks of age. This time frame is 
significantly larger than the 42-day culture period. Experimental myelination and 
remyelination has been shown to be significantly affected by the age of the animal used.
The discrepancies may also be due to a compensatory molecule in the culture 
system. It has been demonstrated that cannabinoids can inhibit thyroid function in vivo, 
reducing serum levels of thyroid hormone (Porcella et a l , 2002). The lack of 
endogenous cannabinoid stimulation in CBiR KO mice could lead to an elevated level 
of thyroid hormone, which in turn would promote NF assembly (Stein et a l, 1991). 
However, there are supra-physiological levels of hormone in the culture medium, ruling 
this out as a putative explanation. The culture medium also contains supra-physiological 
levels of insulin (800nM). Insulin has been known to interact with both growth factor 
receptors and integrin receptors (Van Obberghen et a l , 2001), two triggers for NF 
phosphorylation via the microtubule-associate protein kinase cascade hypothesis 
(Figure 4-11). Furthermore, CBiR agonism causes a rise in insulin production in vivo 
(Li et a l , 2001), implying that the lack of endogenous CBjR activation, as in CBiR 
knockout mice, would lead to a reduction in insulin. Therefore, high levels of insulin in 
knockout cultures but low levels in knockout animals may explain the discrepancy 
between models. The effects of insulin are multipotent, so this explanation is just one 
hypothetical mechanism by which altered NF levels could be explained. Likewise, 
cannabinoids can regulate many other neuroendocrine systems that could affect 
development and influence nerve growth in vivo (Murphy et a l , 1998; Romero et a l , 
2002).
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Treatment of the cultures with IFN-y caused significant loss of MBP, followed 
by full recovery over time. IFN-y-induced demyelination can occur through a variety of 
routes. Activation of microglia and macrophages may lead to NO (Merrill et al., 1993) 
and TNF-a (Selmaj et a l, 1991) production, and direct phagocytosis of myelin, 
possibly linked to Fc receptor upregulation (de Andres et al., 1994). Upregulation of 
this receptor may cause super-oxide production and release of pro-inflammatory 
cytokines and mediators, exacerbating the effect (Roberts et a l, 1990). Induction of the 
normally-absent MHC class I expression in oligodendrocytes (Suzumura et a l, 1986) 
may cause a ‘traffic jam’ effect in the endoplasmic reticulum (E.R.), leading to release 
of Ca2+ from this organelle (Baerwald et a l, 2000). This calcium release from the E.R., 
one of the biggest intracellular calcium stores may in turn lead to production of reactive 
oxygen species (Pahl & Baeuerle, 1997). Due to its lipid constitution, myelin is 
particularly sensitive to oxidative damage (Smith et al., 1999). Upregulation of protease 
molecules has been demonstrated following IFN-y treatment (Rivett et al., 2001), and 
this could also contribute to the damaging environment.
Demyelination induces division of late oligodendrocyte precursors and 
remyelinating oligodendrocytes, as assessed by BrdU incorporation and confocal 
microscopy. This is a well-documented event following demyelinative episode, and has 
been shown to occur in MS (Reynolds et al., 2002) and in a variety of models (Arenella 
& Hemdon, 1984; Ludwin, 1984; Sato et a l, 1997). It is hypothesised that the 
stimulation of oligodendrocyte and precursor division is an attempt to repopulate and 
remyelinate areas of myelin damage. Oligodendrocyte cell division is much reduced by 
DIV 42, and levels of MBP as assessed by ELISA have risen to those of control cultures
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by this time point, indicating myelin recovery. It is likely, though not proven in this 
study, that the dividing cells are responsible for remyelination.
Treatment with IFN-y induced MBP loss in all treated cultures. However, this 
was accompanied by loss of NF in cultures from CBi receptor knockout animals only. 
This finding presents in vitro data for neuroprotection by cannabinoids, supporting data 
from mouse CREAE presented in Chapter 4. The vulnerability of neuronal processes in 
vitro shows that damage is not entirely dependent on the adaptive autoimmune response 
seen in EAE animals. In EAE, a wide variety of damaging responses contribute to 
neuronal injury . In the aggregate model, IFN-y alone is used to elicit demyelination. 
While this is designed to mimic the in vivo pathology, it is essentially missing many of 
the adaptive immune effectors seen in EAE. It has been found that IFN-y can induce 
apoptosis via cell surface receptor activation, causing upregulation of upstream caspases 
and cell death receptors (Ossina et al., 1997; Takahashi et al., 1999). It has also been 
demonstrated that pathology akin to apoptosis can occur in transected or damaged 
axons (Coleman & Perry, 2002; Peterson et al., 2001). Cannabinoids have been shown 
to reduce excitotoxic and oxidative damage to neurons through CBi activation 
(Hampson & Grimaldi, 2001; Howlett, 2002). As the data here suggest, the lack of the 
CBi receptor may confer increased vulnerability to damage by these IFN-y mediated 
pathways.
Levels of NFHSM1‘32 rose following cytokine treatment, lending support to the 
notion that IFN-y treatment conferred vulnerability to neurons. This effect was 
markedly greater in CBj receptor knockout cultures, in agreement with the hypothesis 
that endogenous CBiR activation protects neurons from damage via a modification of 
the NF phosphorylation pathways mentioned previously in Chapter 4. Treatment with
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IFN-y induced a rise in the level of caspase 3 precursor (procaspase 3) but not of the 
active form in wildtype culture and a rise in both pro- and active caspase 3 in cultures 
from knockout mice. This indicates that caspase 3 plays a role in the pathology of IFN- 
y-induced demyelination and neuronal damage. The induction of caspase 3 precursor 
protein (procaspase 3) expression following demyelination may be due to the activation 
of cell death receptors and the caspase cascade. IFN-y may induce microglial cells to 
produced TNF-a (Hu et a l, 1997) which could bind to cell death receptors causing 
processing of procaspase 8. This in turn, and possibly in tandem with calcium-induced 
caspase 9 complex formation (Adams & Cory, 2002), would lead to the activation of 
caspase 3 and to apoptosis by death effector pathways.
When comparing caspase 3 between wildtype and knockout cultures, levels of 
active caspase 3 were found to be higher in knockout cultures, while the total was 
higher in wildtype cultures. This reflects the level of caspase 3 processing following 
expression. As upregulation of procaspase 3 expression is similar in wildtype and 
knockout cultures, the activation of procaspase 3 in knockout cultures would appear to 
be enhanced. This could be due to higher levels of upstream caspases, e.g. caspase 8, 
which could be caused by greater death receptor agonism or expression. Alternatively, 
greater mitochondrial compromise, possibly caused by DNA damage and regulated by 
the Bel protein family, could cause increased induction of the caspase-9 based 
apoptosome. This would also lead to release of the proapoptotic proteins from 
mitochondria, increasing caspase 3 cleavage.
Both myelin and neuronal processes recover by the last culture time-point, 
suggesting that at least some of the effects of damage are transient and not terminal to 
cells. The recovery following damage to axonal processes suggests that neuronal cell
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death, for instance via apoptosis, is not occurring, but rather that localised axonal 
degradation accounts for the drop in NF levels observed. Increased caspase 3 levels in 
the cultures suggest otherwise. It is possible that demyelination is partially due to 
oligodendrocyte cell death via caspase 3-mediated apoptosis. Due to the morphology of 
the myelinated axon, oligodendrocytes are exposed to higher levels of IFN-y for longer 
than axons, prior to demyelination and axonal exposure. They are also highly vulnerable 
to oxidative stress. This may tip the balance between transient damage and apoptosis 
induction. In this case, oligodendroglial recovery would be due at least in part to 
precursor maturation, pre-myelinating oligodendrocyte proliferation and consequently 
de novo myelination. Confocal evidence showing the increase in dividing 
oligodendrocytes following demyelination supports this. Confocal evidence for 
regeneration in nerves, however, is inconclusive, so it is unclear whether this represents 
full axonal recovery and remyelination of new neuronal outgrowth or remyelination of 
repaired axonal processes in the absence of neuronal regeneration.
The demyelinative insult applied in this study is a short-term exposure to IFN-y 
akin to an acute lesion formation in multiple sclerosis. It has been demonstrated using 
magnetic resonance spectroscopy for N-acetyl aspartate, an axonal marker, that axonal 
recovery occurs following an acute MS episode (Davie et a l , 1994). Neuronal/axonal 
recovery may be due to sprouting of replacement processes or proliferation of neuronal 
progenitors, both of which have been shown to occur following acute attack in EAE 
(Bambakidis et a l, 2003; Picard-Riera et a l , 2002; Sandyk, 1999).
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6 . Conclusions and Future Studies
6.1. Conclusions
IFN-y is one of a number of proinflammatory cytokines which are upregulated in 
autoimmune disease. The source of IFN-y in vivo is thought to be invading Thl and 
natural killer cells (Weber, 1988). By supplementing cultures with exogenous 
recombinant cytokine, it was possible to observe the effects of a single factor in vitro. 
IFN-y treatment resulted in a loss of MBP in the aggregate cell cultures, accompanied 
by a loss of NfH in CB1R-KO cultures only. Associated increases in dephosphorylated 
neurofilament and caspase 3 activation were observed. In EAE, IFN-y is an important 
pathological mediator, and is upregulated in disease. This discussion will first focus on 
the deleterious effects of IFN-y and potential routes by which they could occur, and then 
at mechanisms for cannabinoid-mediated neuroprotection inferred from this work.
6.1.1. Mechanisms for interferon gamma mediated cell damage
Macrophages -  Macrophages are thought to be responsible for, or causative of, many 
of the deleterious effects observed in CNS inflammatory disease (Cuzner et a l , 1994). 
Activated macrophages, attracted by chemokines and facilitated by the upregulation of 
endothelial cell adhesion molecules, cross the blood brain barrier at sites of damage to 
form part of the inflammatory response (Brown, 2001). In the aggregate cell culture 
model, there is no blood brain barrier analogue, so the response can be examined as if 
looking at an isolated lesion. It has been shown that the cell culture system using rat 
tissue has a resident macrophage population, albeit limited in number (Copelman et a l , 
2001). IFN-y addition in vitro could induce macrophages to assume a phagocytotic 
phenotype, a process which may involve compliment receptor 3 (van der Laan et a l,
174
1996). Phagocytosis of myelin has been shown to upregulate macrophage production of 
TNF-a and NO, both of which damage oligodendrocytes and could contribute to 
demyelination (van der Laan et a l, 1996). TNF-a receptor activation can cause 
proximity activation of caspase 8 in oligodendrocytes and neurons, triggering the 
apoptotic cascade.
Nitric oxide and mitochondria - IFN-y has been shown to induce NO production from 
astrocytes (Chao et al., 1996) and macrophages (Misko et a l , 1995) in the CNS. As 
TNF-a is also produced by macrophages, there is potential for a feed-forward 
mechanism where NO levels are dramatically increased in disease (Nelson et a l , 2003). 
The damaging effects of NO are dualistic. Firstly, NO expression coupled with the 
super-oxide anion leads to formation of peroxynitrite, a potent oxidative effector 
(Lipton et a l , 1993). Increased levels of the reactive species can lead to demyelination 
via oxidation of lipids (Bongarzone et a l , 1995). Due to the high latent level of 
oxidative metabolism in the CNS, there is a relatively high level of super-oxide 
production in mitochondria. Oligodendrocytes are relatively poorly equipped to deal 
with oxidative insults, with low levels of antioxidant defences, high iron levels and a 
large membrane surface area (Smith et a l , 1999). The myelin membrane itself has a 
high lipid to protein ratio, making it a preferential target for reactive oxygen species 
(Verstraeten et al., 1997).
Secondly, a role for NO in neuronal damage has been proposed by the disruption 
of mitochondrial function. As mentioned, cytokines including IFN-y can stimulate 
astrocytic production of NO, leading to disruption of the mitochondrial respiratory 
chain (Moss & Bates, 2001). This is not terminal to astrocytes, as they can maintain
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ATP production by glycolysis (Almeida et a l , 2001). Accumulated NO therefore has 
the opportunity to diffuse to adjacent cells, notably neurons. It has been demonstrated 
that NO can trigger synaptic glutamate release, leading to excitotoxic activation of 
NMDA receptors. The resulting increase in intracellular calcium levels would lead to 
neuronal nitric oxide synthase-related production of further NO species (Leist et al.,
1997). The increased calcium levels could also activate protease molecules, and trigger 
the apoptotic pathway. NO and peroxynitrite radicals could lead to mitochondrial 
damage and ATP depletion. Neurons do not generally have the ability to survive under 
glycolysis alone, so ATP depletion could lead to cell death by apoptosis. In addition to 
this, it has been shown that depletion of ATP by this route causes dysfunction of the 
sodium/potassium ATPase pump, leading to a reverse in the sodium/calcium exchanger 
due to increasing intracellular sodium concentrations (Kapoor et a l , 2003). The 
resulting calcium influx may add to the pro-apoptotic environment.Mitochondrial 
dysfunction is also associated with mitochondrial membrane disruption and the release 
of cytochrome c and free radicals, contributing to the pool of toxic cytoplasmic 
molecules. Cytochrome c has been shown to be necessary for apoptosome formation 
with procaspase 9, part of the apoptotic cascade (Schild et a l, 2001).
MHC Expression - IFN-y is able to induce MHC expression on oligodendrocytes in die 
CNS giving these cells an antigen-presenting role, causing myelin perturbation (Tumley 
et a l , 1991). Oligodendrocytes are constantly replacing lipoprotein membrane 
constituents in their extensive membranes, putting a high workload on the Golgi 
apparatus and endoplasmic reticulum (ER) (Smith, 1968). When induced to express 
MHC II, it is likely that the oligodendrocyte is unable to transport histocompatibility 
complex proteins from the ER due to the absence of accessory molecules which
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Figure 6.1: Diagram illustrating the putative 
deleterious effects of interferon-gamma 
(IFN-y) on aggregated cells in vitro.
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oligodendrocytes do not constitutively express (Baerwald et a l, 2000). There is 
however low-level expression on the cell surface membrane. It has been shown that 
accumulation of protein in the ER results in calcium ion release (Pahl & Baeuerle, 
1996). This could trigger apoptosis as outlined above. Alternatively, disruption of the 
ability to process myelin proteins may result in demyelination and impaired 
remyelination.
IFN-y can induce MHC class I expression in neurons (Neumann et a l, 1997), 
allowing for antigen presentation and subsequent recognition by cytotoxic CD4+ T- 
cells, opening up the cell to damage by cytotoxic mediators.
6.1.2. Mechanisms for endogenous cannabinoid-mediated neuroprotection
It has been shown in this thesis that lack of the CB1 receptor can lead to increased 
detrimental effects in neurons following an inflammatory insult both in vivo and in 
vitro. It can be conferred from this that increased activation of CB1R could be 
neuroprotective in these pathological states, and that this may be achieved by 
modulation of the endogenous cannabinoid signalling system. Putative pathways for 
neuroprotection via CB1, especially combating the effects of IFN-y outlined previously, 
will be postulated.
Cytokines -  Cytokine expression has been shown to be affected by treatment with
cannabinoids in a range of models (Croxford & Miller, 2003; Facchinetti et al., 2003;
Gruol et a l, 1998; Molina-Holgado et a l, 1997). Cytokines are a vital control
mechanism in disorders such as EAE, initiating and upregulating the immune response
following disease induction and providing key effectors in almost all aspects of disease
(Willenborg & Staykova, 2003). The effects of IFN-y have been discussed previously.
178
With regards to IL-1 activity, one study using rat microglia in vitro indicated that THC 
administration elicits a reduction in the cytokine (Puffenbarger et al., 2000). IL-1 has 
also been shown to be modulated by the cytokine IL-1 receptor antagonist (IL- 
lra(Molina-Holgado et al., 2003). In vitro application of various cannabinoid molecules 
can induce expression of IL-lra. In vivo, mice injected with various cannabinoid 
agonists can induce expression of IL-lra. In vivo, mice injected with lipopolysaccharide 
(LPS) to initiate an immune reaction were subsequently treated with a cannabinoid 
agonist or antagonist. The agonist induced and increase in IL-lra, while the antagonist 
produced the opposite effect. Neuroprotection by the cannabinoid agonist HU210 in 
vivo following excitotoxic insult was abolished when applied to IL-lra knockout mice, 
as was the inhibition of NO production, indicating that IL-1 plays a role in these effects.
LPS-mediated inflammation in vitro following administration of the cannabinoid 
agonists WIN55,212-2 and HU210 resulted in an reduction of TNF-a and IL-12 
expression, and an increase in IL-10, producing an anti-inflammatory effect (Smith et 
al., 2000a). The authors postulate that the effect may have been due to CB1R activation 
on immune cells. However, the agonists used, while being selective for CB1R, have 
lesser efficacy at CB2. The possibility of non-receptor mediated effects was illustrated 
in vitro when WIN55,212-2 applied to blood mononuclear cells elicited a reduction in 
TNF-a (Germain et a l , 2002). This was however not significantly reduced by 
antagonists at the CB1R or CB2R. In addition, a high concentration of agonist was 
required to elicit the effect.
It has been hypothesised that CB1R activation may elicit effects on cytokines 
via the hypothalamic-pituitary adrenal axis, leading to reduced TH1 activity via 
corticosterone modulation (Gallily et a l, 1997). Given that agonists do not appear to be
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specifically efficacious at one receptor subtype, perhaps more likely is the direct effect 
of cytokine modulation via CB2 activation on immune cells. This could control the 
relative differentiation of Thl and Th2 cell types, thus controlling cytokine production.
MHC expression, cAMP and kinase regulation -  It has been reported that the CB1 
agonist CP55,940 can block IFN-y-induced MHC II expression in a mouse microglial 
cell line in vitro (Gongora et a l , 2004). It was found that the CB1R effected MCH 
expression changes through the MHC II transactivator (CIITA) following a modest dose 
of the CB1-preferential agonist. CIITA has also been found to bring about a wide range 
of gene expression changes, identified by DNA microarray to include genes responsible 
for antigen processing, signalling and cell proliferation, and may play a larger role in the 
physiology of antigen presenting cells.
One route of modulation of CIITA gene expression, and potentially transcription 
of other genes, is the negative coupling of CB1R to adenylate cyclase (Davis et a l , 
2003). Activation of the receptor has been shown to inhibit the conversion of ATP to 
cAMP through a pertussis toxin-sensitive GTPa inhibitory protein. This reduces cAMP 
levels, one effect of which is to increase the cytosolic levels of microtubule-associated 
protein kinase (MAPK) molecules. These kinases have diverse effects on cell 
proliferation, differentiation and synaptic plasticity (Bozyczko-Coyne et al.t 2002; 
Waltereit & Weller, 2003). Such a large range of potential gene regulation triggered by 
CB1R could elicit changes supportive of neurodegeneration (Barone et a l , 2001). 
Signalling via various MAPK molecules (including FAK and ERK) has been shown to 
result in changes in expression of the proinflammatory cytokines IL6 and IL8, and plays 
a role in TNFa-mediated cytokine production via the transcription factor NF-kB. TGF-
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P mediated neuroprotection in rodent hippocampal cell cultures has been shown to be 
elicited via NF-kB, and to be dependant on ERK (Zhu et al., 2004). It is worth 
remembering that there are also studies illustrating regulation of NF-kB by CB2 
receptors (Ouyang et al., 1998), putative as yet uncharacterised cannabinoid receptors 
(Herring & Kaminski, 1999), and by receptor-independent mechanisms (Sancho et a l, 
2003). Therefore, CB1 activation may not be wholly responsible for observed effects.
Excitotoxic inhibition, ion channels and apoptosis -  Endocannabinoid signalling in the 
CNS plays a major role in the control of excitatory neurotransmitter release (Wilson & 
Nicoll, 2001). The arrival of an action potential at the terminus of the presynaptic cell 
triggers opening of calcium channels and the influx of the ion. This results in vesicle 
fusion with the presynaptic membrane and the release of neurotransmitter contents 
which cross the synaptic cleft to activate post-synaptic receptors and elicit a further 
action potential, involving again the influx of calcium ions. Prolonged synaptic presence 
or excessive release of glutamate could result in excitotoxicity, whereby intracellular 
calcium ion concentration is elevated, causing protease activation and leading to 
apoptosis (Arundine & Tymianski, 2003). However, glutamate binding to postsynaptic 
metabotropic glutamate receptor 1 stimulates phospholipase D to produce the 
endocannabinoid anandamide from NAPE, it’s precursor (Hansen et a l, 1999). The 
endocannabinoid crosses the synapse in a retrograde direction and activates CB1R, 
closing associated calcium channels, causing membrane repolarisation and halting 
neurotransmitter release, thereby preventing excitotoxicity (Kreitzer & Regehr, 2002). 
This endogenous protective pathway is a strong candidate for the neuroprotective effect
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presented here. Lack of the CB1 receptor in the knockout mouse would abolish this 
pathway, potentially leading to increased excitotoxic effects.
Nitric Oxide -  As discussed previously, NO could act as a potent mediator of neuronal 
damage. Several studies have reported modulation of NO synthesis by CB1R activation. 
Inhibition of NO production by CB1R agonist A9-THC from mouse peritoneal 
macrophages has been demonstrated following activation with LPS and IFN-y (Coffey 
et al., 1996), but the high concentrations of agonist required to elicit this effect may 
have promoted non-receptor mediated events. Cannabinoid treatment in the Thelier’s 
virus model of inflammatory disease is also associated with NO production; 
anandamide treatment of virally infected astrocytes suppressed NO production in a dose 
dependant manner (Molina-Holgado et al., 1997). Inhibition of potassium chloride 
induced activation of neuronal nitric oxide synthase was observed in an in vitro 
cerebellar granule neuron cell culture preparation following treatment with WIN55,212- 
2 (Hillard et al., 1999). The CB1R antagonist SR141716A potentiated NO synthase 
activation, suggesting that tonic endocannabinoid activity at CB1R may be limiting 
NOS activity. In CNS resident microglia, NO production was inhibited by CP55940, 
with CB1 antagonists again reversing the effect, indicating functional linkage between 
CB1 and NO production (Waksman et al., 1999). However, again the high levels of 
agonist used may indicate activation of receptor independent pathways. One study 
outlined differential roles for the nitric oxide pathway on cannabinoid CNS effects 
mediated by A9-THC, suggesting that nitric oxide is involved in cannabinoid control of 
body temperature and locomotor activity, but not in nociceptive effects (Azad et al., 
2001).
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The oxidative stress mediated by NO depends at least partially on the presence 
of elevated super-oxide radical levels, as discussed previously. In human blood 
mononuclear cells in vitro, WIN55,212-2 was found to reduce reactive oxygen species 
generation in LPS-primed cells (Germain et al., 2002). However, any antioxidant effect 
may have been non-receptor mediated due to the high concentration of agonist required 
to elicit a response.
6.2. Future work
The work presented here is a step towards elucidating a therapeutic role for 
cannabinoids. Further experimental studies are needed to clarify the role of these 
compounds in protecting axonal processes.
Electron microscopical studies are required to confirm that, as in the rat-derived 
aggregate culture, myelin compaction occurs, and noR are present.
A fundamental question in neurodegenerative demyelinating disease is one of 
primary pathology -  does demyelination lead to axonal damage, or is neurodegeneration 
a result of primary inflammatory attack? Although the two are not necessarily mutually 
exclusive, this could be investigated by transverse cutting, immunostaining for myelin 
and neuronal markers, and counting/characterising of neurons and myelin from EAE 
spinal cords. A larger number of time-points in the disease course could be used to 
elucidate the primary event. The use of an assay to quantify active caspase 3 at these 
time points would illustrate the role of this pathway in cell death.
The quantification of oligodendrocyte precursor proliferation and neuronal 
sprouting following demyelination would provide insight into the remyelinative 
capacity of cells in either system. Antibodies against markers for oligodendrocyte
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precursors (e.g. NG2, 04, PDGFa receptor) and neuronal precursors (e.g. nestin), dual 
stained with a marker for proliferating cells (e.g. cyclin B l) would provide an insight 
into the proliferation of precursors. Neuronal sprouting could be identified by staining 
for a marker of growth cone extension or synapse formation (e.g. GAP-43 or 
synaptophysin), and the extent of this analysed by dual staining for 
a neuronal marker (e.g. NF) and cell counting. In this way, a ratio of total cells to dual­
stained cells will give a measure of the extent of de novo neuronal outgrowth. Also, the 
concurrent analysis of growth factor expression such as through gene microarrays may 
shed light on the microenvironment needed to provide the optimum conditions for 
remyelination. Analysis of whole spinal cords may not be an effective method by which 
to do this, as any changes would be confined to lesion sites, and thus diluted in the 
whole cord. Ideally, the microarray approach would provide sensitive and wide-ranging 
quantification of growth factors and cytokines; however, this approach may be 
prohibited by cost. Therefore, longitudinal spinal cord sectioning and antibody- 
mediated staining would provide a sensitive and cost-effective method of analysis.
Investigations into the mechanisms of cell-death independent damage to myelin 
and axons following demyelination or conductance block are required. 
Immunocytochemical and confocal analysis of apoptotic nuclei (using the Hoescht or 
TUNEL stains) paired with cell-type markers will show which cell types are undergoing 
apoptosis. Use of an antibody against caspase 3 as well as staining for cell-type markers 
may give a better idea of sub-cellular localisation of proteolytic activity.
In vitro, both NF and MBP levels recover completely by the final culture day. It 
is unlikely that this recovery represents replacement of apoptotic cells by increased 
proliferation and migration of precursors. At least in part, it is likely to be that damaged
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distal structures, such as myelin or axons, are replaced or repaired by a surviving soma. 
Apoptosis-independent mechanisms of cell damage are a potential research and 
therapeutic target, including analysis of proteinases such as the metalloproteinases, and 
examination of calcium-dependent proteolytic pathways.
Exogenous cannabinoids have been shown to effectively ameliorate EAE, at 
least with respect to control of some clinical signs. Therapeutics involving cannabinoid 
compounds have reached Phase III clinical trials for pain, spasticity and other 
disseminated symptoms of multiple sclerosis. Some have shown encouraging results, 
but none have provided an easily dosed, side effect free treatment profile. Smoking 
cannabis, as recreational users often do, is not an acceptable route of administration, as 
even tobacco-free cannabis smoke contains potent carcinogens (Roth et al., 2001). Oral 
administration leads to problems of dosing, as the first pass metabolism of active 
cannabinoid compounds can be as high as 80%. In addition, cannabinoids are taken up 
into dietary fat, being released slowly, making accurate dosing difficult. Cannabinoids 
are also currently associated with psychotropic side effects which could be debilitating 
or prevent normal activities at effective doses.
Modulation of the endogenous pathway is perhaps the most promising target for 
therapeutic intervention which may reduce the side effects and possibly administration 
problems. Up regulation of endogenous cannabinoid production or down-regulation of 
degradation would increase cannabinoids in the CNS. Experimentally, this could be 
investigated by generating transgenic mice over-expressing endogenous CBi agonists, 
such as anandamide or 2-AG, by enhancing activity of enzymes involved in 
endocannabinoid agonist production (Sugiura et a l , 2002) or by disrupting genes
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producing degradative proteins, such as fatty-acid amide hydrogenase (Cravatt et al., 
2001) or monoglycerol lipase (Dinh et al., 2002).
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